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Background: Despite the extensive research into the pathophysiology of 
osteoarthritis (OA), pain still represents a significant unmet clinical need. 
Current treatments for OA target symptomatic relief, but pharmacological 
analgesia is often not sustained. Pathological characteristics associated with 
OA pain include chondropathy, synovitis, subchondral bone marrow lesions 
and osteophytes. Concurrent with the development of OA, sensitisation of 
nociceptive pathways augments pain. Pain in OA therefore depends on a 
combination of pathology within the joint, peripheral and central neuronal 
sensitisation. 
Objectives: This thesis explores the effects of a tropomyosin related kinase A 
receptor (TrkA) inhibitor and an anti-nerve growth factor (NGF) antibody as 
interventions to modify inflammation, structural pathology and pain behaviour 
in rat models of OA. It also describes methods development and validation for 
assessing joint pathology in these rat models. 
Hypothesis: Pain behaviour and structural pathology are features of OA 
models that are mediated by NGF-TrkA signalling. NGF may mediate OA pain 
by joint function and structure, including neuronal sensitisation, inflammation 
and subchondral osteoclast activation. 
Methods: Rat models of inflammation and OA (carrageenan, monosodium 
iodoacetate - MIA and medial meniscal transection ± MNX) were assessed for 
pain behaviour, inflammation and structural pathology. In the MIA model, two 
doses were investigated. A lower 0.1mg dose representing milder OA and a 
standard 1mg dose representing more severe OA. Scoring of knee joint 
pathology macroscopically was developed and applied. Reliability, 
reproducibility and validity of both macroscopic and microscopic (histological) 
scoring systems for knee joint pathology were determined. Effect of 
interventions on pain behaviour (weight bearing asymmetry and paw 
withdrawal thresholds) and structural pathology (macroscopic and microscopic 
scoring of articular surfaces) to include inflammation were assessed using 
inhibitors of the NGF-TrkA pathway. Pain Data were analysed longitudinally 
using area under the curve or independently with Kruskal Wallis test followed 
by Dunns post hoc. Other data were analysed with Kruskal Wallis test followed 
by Dunns post hoc. Data are presented as mean (95% confidence interval). 
Results: The carrageenan, MIA and MNX models all exhibited inflammation 
and pain behaviour. The MIA and MNX models displayed both macroscopic 
and microscopic pathology. The pain phenotypes (weight bearing asymmetry 
and hind paw withdrawal threshold) observed in the MIA model were 
dependent on the MIA dose. The 0.1mg MIA injected rats displayed reduced 
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paw withdrawal threshold (0.1mg MIA v saline; day 20 = 187 [115-259] v 282 
[265±298] *p<0.05) but not weight bearing asymmetry (0.1mg MIA v saline; 
day 20 = 52.8 [4.79-101] v 49.8 [14±85.5]) whereas the 1mg MIA injected rats 
displayed both (paw withdrawal threshold; 1mg MIA v saline; day 20 = 187 
[160-215] v 282 [265±298] **p<0.01 and weight bearing asymmetry; 1mg 
MIA v saline; day 20 = 189 [118-261] v 49.8 [14±85.5] *p<0.05).   
The Guingamp method of macroscopic scoring permitted discrimination 
between OA disease group and normal controls. This method of scoring had a 
higher reliability and reproducibility than other macroscopic scoring methods. 
The Janusz and modified OARSI histopathology scoring systems for cartilage 
damage were reliable and reproducible with similar variability and had strong 
correlations to each other. 
Following preventive or therapeutic treatment with the tropomyosin receptor 
kinase (Trk) A inhibitor AR786, pain behaviour was inhibited in both MIA 
(MIA + Vehicle v MIA + drug; day 21 = 27 [21-23] v 3.7 [-1.4 ± 8.8] 
**p<0.01) and MNX (MNX + Vehicle v MNX + drug; day 21 = 27 [21-32] v 
4.8 [1.1-8.6] **p<0.01) models. Synovitis was attenuated only in the MIA 
model (MIA + Vehicle v MIA + drug; day21 = 2.3 [2-2.6] v 1.2 [0.32-2.1] 
*p<0.05). Analgesia was sustained for up to 10 days in the MNX model 
following AR786 treatment discontinuation. AR786 administration reduced the 
numbers of tartrate resistant acid phosphatase (TRAP) positive multinucleated 
osteoclast cells in the MIA model (MIA + Vehicle v MIA + drug; day 21 = 68 
[59-76] v 51 [46-56] **p<0.01) but not the MNX model. AR786 did not 
significantly alter macroscopic measures of structural pathology in either 
model. Preventive and therapeutic treatment with the anti±NGF monoclonal 
antibody M911 did not alter changes to cartilage pathology.  
Conclusions: Manifestation of pain, inflammation and alterations in knee joint 
structure are characteristic features of OA models and these alterations in joint 
structure can be measured reliably and reproducibly by both macroscopic 
visualization and assessment of histological sections. NGF might contribute to 
OA pain through the NGF-TrkA pathway. This contribution might be as a 
result of facilitating nociception, inflammation, and activation of osteoclasts. 
Further investigation into the mechanisms by which NGF contributes to OA 
pain through the TrkA receptor might increase therapeutic potential for OA 
chronic pain relief.  
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CHAPTER 1; INTRODUCTION 
Arthritis is a disease characterised by inflammation and pain to one or more 
joints. There are many different types of arthritis, with the most common form 
being osteoarthritis, which is degenerative but also inflammatory.  
1.1 OSTEOARTHRITIS  
Osteoarthritis (OA) is a painful chronic disease that affects the whole joint; 
subchondral bone, cartilage, synovium, synovial fluid, tendon, ligaments, 
menisci and joint capsule (Fig.1.1) (Little and Smith, 2008). OA is caused by 
progressive joint degeneration which includes loss of articular cartilage surface 
integrity, subchondral bone remodelling and sclerosis with osteophyte 




Figure 1.1 Normal and osteoarthritic knee. The OA knee is characterised by 
subchondral bone cyst formation, synovitis, cartilage fibrillation, subchondral bone 





In OA, joint degeneration represents the disease while symptoms of aching, 
discomfort, pain, and stiffness for which patients seek medical care represent 
the illness (Hochberg, 2013). Although the pathophysiology of joint 
degeneration in OA is extensively studied, there is still a gap in our knowledge 
of how it leads to the clinical syndrome of OA and as a result, efforts to 
prevent the disease or slow its progression are hampered. Even more complex 
are the mechanisms by which the OA joint becomes painful. The available 
therapeutic treatments do not prevent or cure OA and symptomatic treatments 
do not offer effective pain relief in everyone. OA therefore becomes a 
substantial economic burden for sufferers (as it reduces their quality of life), 
health care systems and countries (Reginster, 2002, Leigh et al., 2001, 
Buckwalter and Martin, 2006). Finding better treatments for the prevention and 
cure of OA would require more research into the modification of structural 
pathology and pain in order to slow down disease progression and reduce joint 
pain and dysfunction. 
1.1.1 Epidemiology 
OA may develop in any joint but most commonly occurs in the knee, hip, hand, 
spine and foot. It is a major cause of disability and morbidity in people aged 45 
and above in developed countries (Helmick et al., 2008). The incidence of 
hand, hip and knee OA increases with age, with women having higher rates 
than men (Cooper et al., 2013). In England and Wales approximately 1.3 ± 1.75 
million people are affected by symptomatic OA, while in France about 6 
million people are newly diagnosed each year (KO and CO, 2008, Reginster, 
2002).  Knee OA occurs less frequently than hand OA, although as previously 
mentioned, it occurs more frequently in females with female to male ratios 
varying between 1.5:1 and 4:1. US population studies on prevalence rates 
report that severe radiographic changes affect around 1% of people aged 
between 25 and 34 years and that this figure increases to nearly 50% in those 
aged 75years and above (Jordan et al., 2007).  
1.1.1.1 Risk factors 
Primary OA is OA in the absence of a known cause. Variations occur in the 
proportions of individuals with primary OA within a particular OA population. 
3 
 
The risk of developing OA is largely driven by systemic or local factors. 
Systemic factors may increase the likelihood of injury to the joint by direct 
damage to joint tissues or by preventing the repair process in damaged joint 
tissues. The most obvious of the systemic factors is age as the likelihood of 
primary OA increases exponentially with age (Cicuttini and Spector, 1997). 
Other systemic factors include sex, being more prevalent in women than men. 
For example in the Aboriginal community in Queensland, Australia, 88% of 
women were found to have primary OA, whereas 82% of men had secondary 
OA (Cooper et al., 2013). Reports from twin studies and family clustering 
provide strong evidence that OA has a genetic component (Valdes et al., 2006, 
Spector and MacGregor, 2004). For example genetic and/or life style factors 
was reported to contribute to the racial and ethnic differences in the occurrence 
of OA. The prevalence of hip and knee OA was found to be higher in African 
Americans compared to Caucasians, whereas the Chinese had a lower 
prevalence of hand and hip OA (Jordan, 2012).  Other systemic factors include 
obesity, diet and malnutrition, metabolic diseases, osteoporosis. 
Local factors such as joint overload, joint deformity, sarcopenia, malnutrition, 
joint trauma and injury etc. tend to be biomechanical in nature and adversely 
affect forces applied to the joint. OA risk factors can be grouped into two; 
those that show an increased likelihood of developing OA (predisposition) and 





















Figure 1.2 Risk factors for OA. The major risk factors that may lead to the increased 




The process of OA development involves the whole joint and redefines the 
definition of OA being a degenerative joint disease exclusively characterised 
by wear and tear but rather involves the remodelling of joint tissues which may 
be driven by a host of inflammatory mediators within the affected joint. OA 
may initially arise from changes within the cartilage or the underlying 
subchondral bone and subchondral bone pathology may drive cartilage 
pathology (Burr, 2004). The reason for the above statement is due to the 
speculation of the close relationship between the articular cartilage and 
subcondral bone, which relates to the intimate contact that exists between the 
two (Goldring and Goldring, 2010a). A controversy still exists on whether 
bone pathology precedes cartilage pathology or if it further occurs during the 
development of the disease, but there have been reports of bone remodelling 
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detected in early OA in animal models  (Pastoureau et al., 1999, Hayami et al., 
2006a) and humans (Hochberg et al., 1995, Day et al., 2001). 
1.1.2.1 Articular cartilage 
The articular cartilage is the protective connective tissue that lines the ends of 
long bones. It acts as a shock absorber and reduces friction during movement. 
It is made up of four layers (Fig. 1.3). Each layer is differentiated by 
chondrocyte shape, proteoglycan content and arrangement of collagen fibres; 
the superficial tangenital, middle (transitional), deep (radial) and calcified 
layers (Fig.1.3). The first three layers make up the non-calcified cartilage and 
are separated from the calcified cartilage by a tidemark (Fig.1.3). 
Cartilage pathology also known as chondropathy may be characterised by 
fibrillations, fissuring, diminished cartilage thickness or erosions. Progressive 
loss of the articular cartilage eventually leads to exposure of the underlying 
subchondral bone. The medial compartment of the knee is reported as the 
commonest site observed to manifest overall tibiofemoral OA possibly due to 
heavier loading on the medial than lateral compartment (Wise et al., 2012). 
Most research studies including animal studies focus on the medial 
compartment especially the medial tibial plateau (Stoppiello et al., 2014, Mapp 
et al., 2013).   
 
Figure 1.3 The articular cartilage. Chondrocyte (a) and collagen fiber organisation 
(b). Superficial tangenital zone (STZ). Figure taken from (Steward et al., 2011). 
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In the resting state of normal adult cartilage, chondrocytes are inactive and 
there is little cartilage matrix turnover. In OA, these cells become activated and 
exhibit proliferation and cloning, increased production of matrix proteins and 
degradation enzymes are also released (Goldring and Marcu, 2009). This 
change in state of chondrocytes may be viewed as an injury response that may 
eventually lead to matrix remodelling, abnormal hypertrophy of chondrocytes 
and calcification of the cartilage (Goldring and Marcu, 2009). The cartilage 
matrix consists of water and ground substance (proteoglycan and collagen). 
The breakdown of cartilage matrix is complex and may involve interplay of 
genetic, environmental, mechanical and biochemical input. One of the 
biochemical factors proposed to be involved are the degradative enzymes 
known as matrix metalloproteinases (MMPs) which break down collagen and 
proteoglycans. Of this family, aggrecanases (ADAMTS4, -5 and  -10), 
collagenases (MMP1, -8 and -13), stromelysins (MMP3) and gelatinases 
(MMP2) have been identified and reported to be elevated in OA (Hassanali and 
Oyoo, 2011, Loeser et al., 2012, Murphy and Nagase, 2008). The aggrecanase 
(A Disintegration and Metalloproteinase with Thrombospondin-like Motifs) ±
ADAMTS5 and MMP3 which degrade aggrecan followed by MMP13 which 
degrades type II collagen may be responsible for matrix breakdown in early 
OA (Loeser et al., 2012). Once the collagen matrix degenerates, a non-
reversible state may be reached. Chondrocytes express receptors for 
extracellular matrix components. Mechanical stimulation of these receptors 
contributes to the synthesis and release of matrix-degrading proteinases, 
inflammatory cytokines and chemokines. These chemokines or cytokines 
involved in cartilage homeostasis may be produced by the synovium. During 
cartilage break down MMPs increase and their inhibitors are decreased by 
interleukins (IL) -1, 17, 18 and tumour necrosis factor (TNF)-Į (Martel-
Pelletier, 2004). Tissue inhibitors of metalloproteinases (TIMPS) are 
responsible for controlling the activity of MMPs. TIMP1 which is found in 
normal cartilage inhibits MMP1 while TIMP3 inhibits ADAMTS4 and -5 
(Davidson et al., 2006, Kashiwagi et al., 2001). An imbalance in the regulation 
of MMPs and TIMPS may lead to increased chondropathy (Franses et al., 
2010).   
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The pathological process of chondropathy in OA can be divided into 3 stages 
(Martinek, 2003). The first stage, matrix degradation occurs initially at the 
molecular level with the water content increasing and aggrecan decreasing and 
as a result the cartilage network becomes damaged and results in reduced 
stiffness. In the second stage, chondrocytes try to repair the damage by 
proliferating and increasing their metabolic activity, as a result chondrocytes 
clusters (cloning) with newly synthesised matrix molecules are formed. This 
state can remain for several years. In the last stage, the chondrocytes cannot 
compensate for the matrix breakdown, thus complete loss of cartilage occurs as 
a result (Lorenz and Richter, 2006).  
1.1.2.2 Subchondral bone 
Bone underlying the cartilage is made up of the cortical plate, trabecular bone 
and subarticular bone. Each region may contribute to cartilage pathology. 
There is active bone formation at joint margins which may lead to osteophyte 
formation in primary and secondary OA or bone erosion in inflammatory 
arthritis (Roman-Blas and Herrero-Beaumont, 2013). The close relationship 
between the articular cartilage and bone both in location and mechanism makes 
them a functional unit that contributes greatly to normal joint function. An 
imbalance in the mechanical or biological state of the subchondral bone may 
alter changes in the articular cartilage and vice versa (Goldring and Goldring, 
2010b). In the course of OA, the architecture and properties of the cortical and 
trabecular bone may enter a cell mediated state of remodelling. This process is 
initiated by the quiescent bone surfaces and bone resorption mediated by 
osteoclasts. This resorption process is followed by bone formation mediated by 
osteoblasts. In physiological conditions, there is a balance between bone 
resorption and bone formation (Goldring and Goldring, 2010a).  
Subchondral bone changes in OA include; thickening of the bone plate, 
trabecular bone remodelling, osteophytes, and development of subchondral 
bone sclerosis or cysts. There is also evidence of tidemark (line that separates 
the non-calcified and calcified cartilage) duplication which occurs as a result of 
vascular invasion of the calcified cartilage from the subchondral bone (Walsh 
et al., 2007). These bone changes may result in increased alterations in the 
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contour of adjacent articulating surfaces which can lead to changes in the joint 
that can further contribute to an adverse biomechanical environment (Radin 
and Rose, 1986, Burr, 2004, Bullough, 2004). The subchondral bone may be a 
source of pain in OA as it is richly innervated by sensory nerves. Innervation 
by sensory nerves which express the neuropeptide calcitonin gene related 
peptide (CGRP) was found co-localised with nerve growth factor (NGF) 
alongside blood vessels in vascular channels associated with osteocondral 
angiogenesis (Walsh et al., 2007, Walsh et al., 2010). Recent reports also point 
to the involvement of the bone resorbing cells osteoclasts in their contribution 
to chondropathy and pain as their inhibition prevented cartilage pathology and 
pain behaviour in a rat model of OA (Strassle et al., 2010, Sagar et al., 2014). 
1.1.2.3 Synovium 
The synovium is an important component of the knee and plays a key role in 
cartilage degeneration (Scanzello and Goldring, 2012). Other of its roles 
includes regulating immune function, phagocytosis, lubrication and cartilage 
nutrition. This thesis will focus on the role of the synovium in OA pathology. 
Synovial inflammation will be referred to here as synovitis. Evidence show that 
inflammation is an integral component of OA progression contributing to its 
development and symptoms (Bonnet and Walsh, 2005) and reports from 
histological studies account the occurrence of synovitis in early OA (Benito et 
al., 2005)  and after joint injuries (Pessler et al., 2008, Scanzello et al., 2011). 
Specific characteristic features of synovitis e.g. infiltration by macrophages 
may be higher in early OA (Benito et al., 2005) but the prevalence of synovitis 
increases with advancing OA (Krasnokutsky et al., 2011, Scanzello et al., 
2011). Other characteristic features of synovitis in addition to macrophage 
infiltration include lymphocyte infiltration (Pearle et al., 2007), lining and 
villous hyperplasia, fibrosis, cartilage/bone detritus and increased vascularity 
which may be a therapeutic target (Ashraf et al., 2011b). Soluble mediators of 
inflammation such as chemokines and cytokines (IL-1, -6 and TNF-ĮZKLFK
promote synovitis are increased in OA and in post injury joint tissues. 
Inflammation may result from the phagocytosis of shed cartilage debris by 
synovial cells. Released cytokines can inhibit matrix synthesis and promote 
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cartilage break down (Goldring and Marcu, 2009). Synovitis is discussed 
further in section 1.2. 
Alterations in the cartilage, subchondral bone and synovium are interconnected 
and are essential in understanding the pathogenesis of progressive joint 
destruction in OA (Fig. 1.4). Although, whether events in cartilage precede 
those in bone and synovium or vice versa or they actually occur around the 
same time in the development of OA are all topics of interest and may have 
valuable therapeutic implications in the setting of OA. 
 
Figure 1.4 The pathology of osteoarthritis. Cartilage breakdown, bone remodelling 
and synovitis lead to weakening of joint protectors. The release of cytokines and 
degradative enzymes lead to further cartilage breakdown, producing a vicious cycle 




1.1.3 Diagnosis, detection and treatment of OA 
Imaging for assessment of all the structures of the joint using conventional 
radiography is still the most widely used technique for evaluation of a patient 
with a known or suspected diagnosis of OA. However, recent magnetic 
resonance imaging (MRI) based knee OA studies have begun to reveal the 
limitations of radiography. The ability of MRI to image the entire knee as a 
whole organ (cartilage, meniscus, subarticular bone marrow, and synovium) 
and to directly and three-dimensionally assess cartilage morphology and 
composition plays an important role in understanding the natural history of the 
disease and in the search for new treatments (Guermazi et al., 2013). This 
approach has detected abnormalities to the cartilage, menisci, bone (bone 
marrow lesions and osteophytes), synovium and ligaments in OA patients who 
show no radiographic changes (Conaghan et al., 2006). 
Radiography which is the simplest and least expensive imaging technique is 
used by physicians to frequently diagnose OA together with patient reported 
symptoms, particularly pain and stiffness (Gignac et al., 2006). Although the 
radiographic changes observed confirm the diagnosis of OA, there is often poor 
correlations between clinical symptoms and these changes, as some people 
with severe radiographic changes have minimal symptoms, whereas others 
with minimal radiographic changes have severe symptoms (McAlindon et al., 
1992). Examples of radiographic changes associated with OA are; joint space  
narrowing (JSN), osteophytes, subchondral bone sclerosis, subchondral bone 
cysts (Altman and Gold, 2007). Another disadvantage to the use of radiography 
is that it is insensitive in detecting early stage OA. Other imaging techniques 
other than MRI which can be useful in evaluating early OA are; ultrasound, 
computed tomography (CT), arthroscopy, but are rarely used for diagnosis. 
Ultrasound enables multiplanar and real time imaging at a relatively low cost, 
without radiation exposure. It is able to image soft tissue and thus is used to 
detect synovial pathology. The ability to detect synovial pathology may be a 
major advantage over radiography in regards to early changes in OA. A 
disadvantage is that that the physical properties of sound hinder its application 
to deeper articular structures and the subchondral bone (Guermazi et al., 2013). 
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CT is a valuable tool for the characterization of OA, for the imaging of bone 
changes. Cortical bone and soft tissue calcifications are better depicted than on 
MRI. CT has an established clinical role in assessing facet joint OA of the 
spine (Hechelhammer et al., 2007). A major limitation is the relatively high 
dose of radiation it delivers.   
Arthroscopy can reveal cartilage changes before bone changes, however it is an 
invasive technique and so rarely used for OA diagnosis (Ayral et al., 1996, 
Dougados et al., 1994). 
The American College of Rheumatologists (ACR) developed classification 
systems for hand (Altman et al., 1990), knee (Altman et al., 1986) and hip 
(Altman et al., 1991) OA with the aim of differentiating OA from other forms 
of arthritis. The clinical classification for knee OA was based on knee pain in 
addition to 3 of the following 6 criteria: > 50 years of age, < 30 minutes of 
morning stiffness, crepitus, bony tenderness, bony enlargement and an absence 
of palpable warmth (Altman et al., 1986). A similar criterion for diagnosing 
knee OA to those developed in 1986 by ACR were recommended in 2009 by 
the European League against Rheumatism (EULAR). The recommendations 
were that when the following 3 symptoms (persistent knee pain, limited 
morning stiffness and reduced function) and 3 signs (crepitus, restricted 
movement and bony enlargement) were detected, it was sufficient to correctly 
diagnose 99% of knee OA (Zhang et al., 2010a). 
1.1.3.1 Current treatments for OA 
OA has no cure as of yet, and although structure-modifying treatments remains 
a significant unmet need in OA, several symptomatic treatments are available. 
These treatments are directed at modifying the signs and symptoms of the 
disease especially pain and inflammation, to improve quality of life, joint 
function and mobility and if possible, delay disease progression (Altman, 
2010).  There is not a single therapy adequate enough for OA; therefore, the 
recommended therapy includes both non-pharmacological and pharmacological 
treatments (Table 1.1).  
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The non-pharmacological treatments include patient education, exercise 
programs, injury prevention, weight loss, orthortic devices (special foot wear, 
knee bracing, canes etc.), all of which in combination to pharmacological 
treatments aid in managing OA (Roubille et al., 2013) (Table 1.1). Alternative 
strategies such as acupuncture (Zhang et al., 2010b) and transcutaneous 
electrical stimulation (Zhang et al., 2008) have been reported to show some 
short term pain relief efficacy. 
Pharmacological treatments include analgesics (paracetamol, opioids, 
duloxetine, and capsaicin), anti-inflammatory agents with analgesic properties 
(non-selective non-steroidal anti-inflammatory drugs -NSAIDs, 
cyclooxygenase -COX-2 inhibitors, topical NSAIDs and intra-articular 
corticosteroids) (Michael et al., 2010, Vad and Dysart, 2012). These treatments 
are prescribed with care due to their adverse effects and unfavourable safety 
profiles (Table 1.1). Paracetamol and/or topical NSAIDS are considered as the 
first-line of treatment for mild to moderate pain (Zhang et al., 2010b) before 
oral NSAIDS (NICE). NSAIDs are among the most widely used medications 
and are prescribed to non-responders of paracetamol (Zhang et al., 2008). COX 
inhibitors were developed to decrease GI toxicity and used for pain relief in 
place of non-selective NSAIDs (McKenna et al., 2001), but pose a potential 
cardiovascular risk as do non-selective NSAIDs (Trelle et al., 2011). Tramadol 
and stronger opioids are recommended for the management of moderate to 
severe OA pain in patients intolerant to NSAIDs or unresponsive to NSAIDS 
and paracetamol (Zhang et al., 2008). Intra-articular injection of corticosteroids 
is effective for symptomatic treatment of OA patients with synovitis (Pasquali 
Ronchetti et al., 2001), but there is no evidence to support disease-modifying 
activity for these agents (McGarry and Daruwalla, 2011) 
The available drug treatments for OA have limited success, in that although 
they may reduce pain in some patients, others may often eventually end up 
with joint replacement. This is in part due to the complex nature of OA and our 
incomplete knowledge of the association of joint pathology with pain 
experience in OA. Pain in OA is discussed further in section 1.3.




Table 1.1 Osteoarthritis management involving non-pharmacological, pharmacological, and surgical treatment options; adverse 
effects/safety profiles for the different pharmacological treatment options 
Treatment type Component Adverse effects/safety profile 
Non-
pharmacological 





Oral Paracetamol Hepatotoxicity 
NSAIDS (co-therapy with proton pump 
inhibitor), COX-2 inhibitors 
GI ulcer/bleeding, cardiovascular events, renal toxicity, worsening 
asthma 
Opioids Constipation, vomiting, somnolence, increased risk of fracture, 
morbidity and mortality in the elderly, possible addiction 
Duloxetine Constipation, nauseas, hyperhidrosis, dry mouth, fatigue 
Topical Topical NSAIDS Skin reactions, GI events 
Capsaicin Skin burning sensation, long term skin desensitization? 
Injectable Intra-articular corticosteroids Local infection, systemic effects, chondrodegeneration 
Intra-articular hyaluronic acid or 
viscosupplementation 
Local reactions at the site of injection, swelling, flares of pain 
Surgical Cartilage repair, osteotomy with axis correction, arthroplasty 
(UKA, TKR, THR) 
Postoperative pain, infection, deep vein thrombosis, death 
  
Abbreviations: GI, gastrointestinal; NSAID, nonsteroidal anti-inflammatory drug, THR, total hip replacement; TKR, total knee replacement; UKA, 
unicondylar knee arthroplasty. Table adapted from (Roubille et al., 2013) 
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1.2 INFLAMMATION; ROLE OF INFLAMMATION 
IN OA PATHOGENESIS 
Inflammation is implicated in the pathogenesis of OA (Scanzello and Goldring, 
2012, Sohn et al., 2012). A study by Soren and colleagues showed synovial 
inflammation in so-FDOOHG µSRVW-WUDXPDWLF¶ V\QRYLWLV (Soren et al., 1976) and 
later, reports of similar histological synovial changes among at least a subset of 
patients with primary OA were published (Myers et al., 1990, Ayral et al., 
2005). Given that synovitis is now widely appreciated in OA patients (Table 
1.2), it does not imply that the pathogenesis of OA is related to only the 
synovium. Rather synovitis might be a secondary process initiated by the 
activation of the innate immune system following chondropathy that creates a 
critical link in the cycle of development and progression of OA.  
Synovitis is defined as inflammation of the synovial membrane. Synovitis can 
be diagnosed by imaging and histology (Table 1.2). The normal human 
synovium is made up of 1-4 cell layers at the surface with a loosely arranged 
zone of fibrocollagenous tissue consisting of adipocytes, fibroblasts, mast cells 
and macrophages (Wenham and Conaghan, 2010). There is an abundant 
vascular supply also containing nerves spread throughout the sublining of the 
fibrocollagenous tissue (Walsh et al., 2007). Synovial biopsies from knee pain 
and joint replacement patients demonstrate characteristic changes in the 
synovium (Stoppiello et al., 2014). These changes are present both in early and 
late stage OA where they become more pronounced (Loeuille et al., 2005). 
They include; proliferation and thickening of the lining layer, increase in the 
number of vascular channels and dense inflammatory cell infiltration 
composed largely of lymphocytes and monocytes (Haraoui et al., 1991). 
Surface fibrin deposition and fibrosis are present in late stage OA (Loeuille et 
al., 2005). Joint swelling is another clinical feature of OA caused by 
inflammation (Table 1.2). Joint swelling may reflect synovitis as a result of 
thickening of the synovial lining layer or effusion. Joint effusion which is the 
presence of increased intra-articular fluid may occur in parallel with OA flares 




Synovitis precedes structural change 
Although OA is considered a condition manifest by significant cartilage loss 
and joint space narrowing (JSN) or osteophytes, it is now clear that 
inflammation occurs well in advance before radiographic changes in OA. The 
combination of imaging and arthroscopy suggest the presence of inflammation 
in OA even before the occurrence of visible cartilage degeneration (Sokolove 
and Lepus, 2013). One study reported a clear association between the presence 
of synovitis and the future development of medial cartilage loss by arthroscopy 
(Ayral et al., 2005). Another study reported increased mononuclear cell 
infiltration and over expression of inflammatory mediators in early compared 
to late OA (Benito et al., 2005). Other studies using MRI report associations 
between synovitis and OA progression (Krasnokutsky et al., 2011, Roemer et 
al., 2011).  
1.2.1 Innate immunity in OA 
Unlike rheumatoid arthritis (RA), changes in the adaptive immune system in 
OA are less robust but the activation of this system is central to both diseases. 
Innate immunity is activated by pattern-recognition receptors (PRRs) in 
response to invading pathogens such as bacteria, viruses and fungi (Kawai and 
Akira, 2010). PRRs are composed of family members of cells surface, 
endosomal and cytosolic receptors e.g. toll-like receptors (TLRs) (Kawai and 
Akira, 2010). PR5V DOVR UHFRJQLVH HQGRJHQRXV µGDQJHU VLJQDOV¶ DULVLQJ IURP
damaged tissues. Pathogen-associated molecular patterns (PAMPs) and danger 
(damage) associated molecular patterns (DAMPs) are members of PRRs that 
signal to the immune system and thus initiates a protective response to fight 
infection or initiate repair (Sokolove and Lepus, 2013). In addition to DAMPs, 
PAMPs and TLRs, other molecules have been implicated in the initiation of the 
innate immune system in response to joint damage, thus potentially 
contributing to chronic inflammation in OA. Examples are; extracellular matrix 
(ECM) break down products including fibronectin (Okamura et al., 2001), 
hyaluronan (Termeer et al., 2002), and known (S100 proteins) and novel 
plasma DAMPs (Sohn et al., 2012, van Lent et al., 2012).  
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1.2.2 Inflammatory cells and cytokines in OA 
More than a decade ago, Benito and co reported the infiltration into the 
synovium by activated B and T cells and the increased expression of pro-
inflammatory mediators in both early and late stage OA (Benito et al., 2005). 
Another study reported B cell infiltration in the synovium of OA patients who 
fulfilled the ACR criteria for knee OA and presented with knee pain and/or 
joint swelling (Da et al., 2007). Following on from then, there have been other 
reports of the involvement of mononuclear cells including macrophages and 
the production and release of pro inflammatory mediators in OA synovium 
(Table 1.2). Interestingly, work by Benito et al (2005) reported that 
mononuclear cell infiltration in the synovium and expression of inflammatory 
mediators such as IL-1, TNF-Įvascular endothelial growth factor (VEGF) and 
intercellular adhesion molecules were higher in early OA than late OA (Benito 
et al., 2005) thus contributing to the evidence of the  involvement of 
inflammation in early OA. IL-1 and TNF-ĮPD\SURPRWHLQIODPPDWLRQLQ2$
as well as promoting the initiation and progression of cartilage degeneration in 
OA (Goldring, 2001). These mediators may stimulate chondrocytes to produce 
matrix and collagen breakdown proteins (MMPs). The further production of 
IL-1 by chondrocytes in turn further stimulates MMP production. IL-1 and 
TNF-Į DUH UHSRUWHG WR DOVR FRQWULEXWH WR WKH LQFUHDVHG H[SUHVVLRQ RI RWKHU
catabolic enzymes and markers including prostaglandins, nitric oxide etc. 
(Goldring, 2001, Malemud, 2010). VEGF was reported to be involved in 
regulating angiogenesis in the synovium. Angiogenesis has been suggested to 
contribute to chronic synovitis and may occur at all stages (Haywood et al., 
2003). Angiogenesis and inflammation are intercorrelated process that may 
facilitate disease progression and contribute to pain in OA (Walsh et al., 2007, 
Ashraf and Walsh, 2008). 
1.2.2.1 Role of synovial macrophages in 
inflammation and OA 
Synovial macrophages may contribute to synovitis and OA pathology. 
Histological studies have reported that synovial macrophages exhibit an 
activated phenotype in OA. These activated macrophages were observed to 
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contribute to the increased production of proinflammatory cytokines and 
VEGF (Haywood et al., 2003, Benito et al., 2005). In-vivo studies where 
synovial lining macrophages were depleted showed that, macrophage depletion 
was linked to fibrosis and osteophyte formation (Van Lent et al., 2004).  In-
vitro studies of depleted synovial macrophages demonstrated a reduction in the 
amount of macrophage derived- cytokines (IL-1, TNF-Į DV ZHOO DV WKRVH
produced by fibroblasts (IL-6 and 8) and the down regulation of matrix 
enzymes (MMP-1, -3) (Bondeson et al., 2006). These findings show the 
contribution of synovial macrophages in perpetuating the production and 
release of proinflammatory cytokines and destructive enzymes (Bondeson et 
al., 2010). In addition a clinical study by Kraus and co which used imaging by 
99mTc-Etarfolatide (folate receptor-targeted companion diagnostic imaging) 
reported the involvement of activated macrophages in OA. Activated 
macrophages were reported to be detected in 76% of OA patients and that these 
detected macrophages were strongly associated to JSN, osteophyte severity 
pain and stiffness (Byers Kraus et al., 2013). Soluble macrophage markers 
(CD14 and CD163)  were also reported to be positively associated with JSN, 
osteophyte, pain and osteophyte progression (Daghestani et al., 2015). All of 
these findings support the idea (or hypothesis) that macrophages may 
contribute to joint degeneration and is a likely promoting factor of OA 
pathogenesis and pain.  
In conclusion, the synovium in OA joints is abnormal, even from the earliest 
clinical stages. This abnormality is reflected by the (1) activation of innate 
immunity by TLRs, DAMPs, PAMPs, (2) production of inflammatory 
cytokines IL-1, IL-6, TNF-a and VEGF, (3) infiltration of mononuclear cells 
and (4) thickening of the synovial lining layer and fibrosis. Thus, the targeting 
of the inflamed synovium would be beneficial in OA. Early targeting should 
potentially delay or prevent the breakdown of cartilage and osteophyte 
formation, especially in early OA. 
1.2.3 Anti-inflammation therapy 
NSAIDS were reported to be efficacious in reducing OA pain in randomized 
clinical trials. This analgesic efficacy is thought to be due to effect on 
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inflammation or the inflamed synovium (Zhang et al., 2008). Other reports of 
NSAIDs have demonstrated their efficacy in reducing joint effusion and pain 
(Brandt et al., 2006) and cartilage and synovial turnover markers (Gineyts et 
al., 2004). Intra-articular corticosteroids  are commonly used in OA (Bellamy 
et al., 2006, Arden et al., 2008) for pain relief with the presumption that the 
effect is via effect on the synovium (Jones and Doherty, 1996).  Steroidal and 
non-steroidal anti-inflammatory treatment however have their limitations as 
periodical use can result in unwanted effects such as peptic ulcers, 
hypertension, myopathy, oedema etc. Other potential anti-inflammatory 
therapies include biologic molecules such as anti-TNF agents, anti-NGF 
antibodies, anti-proteases (anti-MMPs and ADAMTS) and bradykinin blocking 










Table 1.2 Evidence of the role of synovitis in OA 
Level of evidence Observation 
Clinical Effusion, joint swelling or palpable synovitis. Localised inflammation. Increased pain especially at night and morning stiffness 
Imaging  Gadolinium-enhanced synovium and increased synovial volume by MRI detection. Correlation between MRI and histological 
observations. Synovitis observed in symptomatic joints by ultrasonography. Association between synovitis detected by 
ultrasound and clinical symptoms of synovitis. Macroscopic synovial changes present in half of knee OA patients detected by 
arthroscopy. Associations between arthroscopic synovitis and OA knee progression. 
Histological  Synovial hypertrophy and hyperplasia. Infiltration by monocytes, macrophages, activated B and T cells. Adaptive immune T 
and B cell responses to extracellular matrix fragments. Increased angiogenesis. Synovitis localised to degenerative cartilage. 
Molecular  Production and/or release of proinflammatory cytokines (TNF, IL̻ȕ,/̻6, IL̻8, IL̻15, IL̻17, IL̻21) 
Increased production of Prostaglandin (PG) E2 and nitric oxide. Increased expression of adhesion molecules (ICAM̻1, 
VCAM-1) in the synovium. Increased activity of MMPs (MMP̻1, MMP̻3, MMP̻9, and MMP̻13) and ADAMTS.  
Production of adipokines (visfatin, leptin, adiponectin). Release of EGF and VEGF. Involvement of macrophages in 
osteophyte formation via BMPs. Insufficient release of anti̻inflammatory cytokines (IL̻4, IL̻10, IL̻13, IL̻1Ra). Release of 








Biological markers Elevated levels of CRP (detected by ultrasensitive assay). Elevated levels of MMP-3 and MMP-9 in synovial cells of patients 
with rapidly destructive hip arthropathy. Potential surrogate biomarkers of inflammation; CGP-39 and fragments of type II 
collagen and aggrecan. 
Abbreviations: ADAMTS, a disintegrin and metalloproteinase with thrombospondin motifs; BMP, bone morphogenetic protein; CGP̻39, cartilage glycoprotein̻39 (also 
known as chitinase̻3̻like protein 1 and YKL̻40); CRP, C̻reactive protein; EGF, endothelial growth factor; ICAM̻1, intercellular adhesion molecule 1; IL, interleukin; 
IL̻1Ra, interleukin 1 receptor antagonist; MMP, matrix metalloproteinase; NGF, nerve growth factor; PGE2, prostaglandin E2; TNF, tumour necrosis factor; VCAM̻1, 
vascular cell adhesion molecule 1; VEGF, vascular endothelial growth factor.  
Table adapted from (Sellam and Berenbaum, 2010, Sokolove and Lepus, 2013), see references to evidence in the referenced reviews.
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1.3 PAIN AND OA  
Pain is the major symptom suffered by arthritic patients and the reason why 
they seek medical help. This may be caused by the presence of nerves that have 
undergone peripheral sensitization, and increase in the release of inflammatory 
mediators of pain, for example NGF (Suri et al., 2007, Konttinen et al., 2006, 
Iannone et al., 2002).  
3DLQ DVGHILQHGE\ WKH ,QWHUQDWLRQDO$VVRFLDWLRQ IRU WKH6WXG\RI3DLQ ³LV DQ
unpleasant sensory and emotional experience associated with actual or 
SRWHQWLDO WLVVXHGDPDJHRUGHVFULEHG LQ WHUPVRIVXFKGDPDJH´ (Merskey and 
Bogduk, 1994). This definition emphasises the perception rather than sensation 
RI SDLQ DQG WKDW WKH SURFHVV RI SDLQ SHUFHSWLRQ LV QRW D VLPSOH µKDUG-ZLUHG¶
V\VWHP ZLWK D VLQJOH µVWLPXOXV-UHVSRQVH¶ UHODWLRQVKLS EXW LQYROYHV FRPSOH[
interactions between sensory, emotional and behavioural factors (Hudspith et 
al., 2006).  
One of the important functions of the nervous system is to provide information 
about the occurrence of a potential threat or injury. This information is 
provided by small-diameter sensory afferent fibres called nociceptors. 
1RFLFHSWLRQZKLFKLVGHULYHGIURPWKH/DWLQZRUGµnocere¶PHDQLQJWRKDUP
is the intermediate sensory process between a noxious stimulus and pain 
response. It is an afferent activity produced by a stimulus that can be 
potentially damaging. Nociceptors can respond to chemical, thermal and 
mechanical changes above their normal threshold. The nociceptive signal is 
passed via the spinal cord to the brain (McMahon et al., 2013). The perception 
of acute pain begins suddenly and is usually sharp in quality and nociceptive 
fibres respond accordingly depending on the noxious stimuli. In acute pain, 
potentiation of pain would encourage rest and thus prevent further tissue injury 
(Woolf, 1991). On the other hand chronic pain commonly persists long after 
healing of an injury (Ready and Edwards, 1992, Woolf, 2011). Chronic pain is 
often idiopathic and lacks the physiological protective role of pain. It therefore 
becomes a pathological condition that is not only useless but also greatly 
distressing (Neogi et al., 2013).   
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Chronic pain may arise from the sensitization of peripheral nerves and spinal 
neurones (Ji et al., 2014). Peripheral nerve endings become more sensitive to 
noxious stimuli through tissue damage, action of local hormones e.g. 
prostaglandins, histamine, serotonin and bradykinin, and also by direct nerve 
damage. This process is known as peripheral sensitization and is usually 
associated with localised pain from the damaged tissue. The changes in key 
proteins and ion channels (transduction proteins) determine the excitability of 
peripheral nerve endings. Two processes occur during peripheral sensitization;  
post-translational processing; this involves changes to the existing nociceptor 
proteins, and altered gene expression of new nociceptor proteins (Woolf) 
(further discussed in section 1.3.4.3). 
Central sensitization represents an increase in the function of neurones and 
circuits in nociceptive pathways of the central nervous system (CNS) (Woolf, 
2011, Latremoliere and Woolf, 2009). Central sensitization plays a role in 
many acute and chronic pain states and is responsible for the temporal, spatial 
and threshold changes in pain mechanisms and thus highlights the fundamental 
contribution of the CNS in the generation of pain (McMahon et al., 2013). 
Central sensitization has been implicated to occur in two stages; an immediate 
but shorter phase and a gradual onset but longer lasting phase. The earlier 
phase reflects changes to synaptic transmissions within the spinal cord and 
involves neurotransmitters e.g. glutamate, neuropeptides e.g. substance P and 
CGRP and synaptic modulators e.g. brain derived neurotrophic factor (BDNF) 
(Woolf). These transmitters or modulators act on specific receptors found on 
spinal neurones thereby activating intracellular signalling pathways that further 
OHDGWRWKHSKRVSKRU\ODWLRQRIPHPEUDQHUHFHSWRUVHJĮ-amino-3-hydroxy-5-
methyl-4-isoxazolepropionic acid (AMPA) and N-Methyl-D-aspartate 
(NMDA) which bind the excitatory neurotransmitter glutamate. These changes 
lower the activation thresholds of the above receptors thus leading to the 
excitation of neurones. The later phase involves increased levels of protein 
production (Woolf). Example proteins are dynorphin; an endogenous opioid 
that augments neuronal excitability, COX2; an enzyme that leads to the 
production of prostaglandin (PG) E2. In addition to the involvement of PGE2 
in mediating peripheral sensitization, it also contributes to central sensitization 
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(Woolf). The overall effect of the above changes results in the activation of 
neurones by stimuli which would otherwise not activate neurones in the normal 
healthy state. In this case, pain sensibility is drastically altered. 
Pain can arise spontaneously in many chronic pain states and can be grouped 
into; those that are elicited by a normally non-painful stimuli (allodynia), those 
that are enhanced in response to a painful stimuli (hyperalgesia), and finally 
those that spread beyond the site of tissue injury (secondary hyperalgesia) 
(Latremoliere and Woolf, 2009, Woolf, 2011).  
Chronic pain continues to be the commonest cause of disability as it limits joint 
use in OA patients and impairs their quality of life. More specifically, OA and 
RA patients together were reported to make up 42% of all chronic pain 
sufferers (Breivik et al., 2006). Although sensitisation may trigger a transition 
from acute to chronic pain (Basbaum et al., 2009), understanding this transition 
is still a crucial challenge yet to be overcome in pain research in order to allow 
for the improvement of targeted treatment to the long lasting debilitating 
condition known as chronic pain. 
1.3.1 Innervation of the normal and the arthritic knee 
joint and its link to pain 
Joints are innervated by both the afferent sensory and efferent sympathetic 
branches of the nervous system as evidenced by early studies in animals (Buma 
et al., 2000, Heppelmann, 1997, Samuel, 1952, Hukkanen et al., 1991, Freeman 
and Wyke, 1967). The knee joint of the cat proved a useful model for studying 
joint innervations in both the normal and inflamed joint (Freeman and Wyke, 
1967, Heppelmann, 1997). The normal knee joint receives its supply from two 
articular nerves. These nerves may be grouped into primary nerves (posterior, 
medial and lateral) and accessory nerves (branches of intra muscular nerves) 
(Mapp, 1995, Freeman and Wyke, 1967).  
1.3.2 The normal joint 
The parts of the normal healthy adult knee that are richly innervated by nerves 
are the muscle, synovium, articular capsule, tendons, ligaments and 
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subchondral bone (but not the hyaline cartilage nor the inner two thirds of the 
meniscus) and may be sources of pain in OA (Hunter et al., 2008). The pattern 
of innervation is made up of four groups (I ± IV) of sensory afferents (~60%) 
and sympathetic fibres and arises from several locations on the spinal cord 
(Heppelmann, 1997, Schaible and Straub, 2014). The sympathetic fibres which 
are postganglionic help to regulate vascular tone in the joint, since blood flow 
was observed to be increased after elimination of the sympathetic innervation 
and was decreased during electrical stimulation of joint nerves (Schaible and 
Straub, 2014). Sensory nerves which also have afferent vasoregulatory 
functions are responsible for detecting and transmitting mechanical information 
and also chemical information during inflammation between the joint and the 
central nervous system (CNS) (McDougall, 2006).  
Groups I and II DUH WKH ODUJHGLDPHWHU PP\HOLQDWHGILEUHV$ĮDQG$ȕ
fibres. These fibres are proprioceptive (they can be activated by innocuous 
light pressure and stretch) with a conduction velocity of 20-100 m/s. These 
nerve fibres have their nerve endings terminating in the fat pad, capsule, 
ligaments, menisci, and periosteum (Hunter et al., 2008, McMahon et al., 
2013).  
Group III $įILEUHVDUHVPDOOGLDPHWHU-3µm) myelinated fibres that have 
their myelin sheaths terminating in the terminal region to become free nerve 
HQGLQJV7KHVHILEUHVKDYHDFRQGXFWLRQYHORFLW\RIPV6RPHRIWKH$į
fibres are low mechanical threshold fibres thus they tend to respond to passive 
joint movements as compared to the high mechanical threshold fibres which 
respond more to extreme noxious stimuli (Hunter et al., 2008).  
Lastly the group IV fibres are the thinly unmyelinated C fibres. These fibres 
have a conduction velocity of <1 m/s (Hunter et al., 2008, McMahon et al., 
2013) 
Some $įDQG&KLJKWKUHVKROGILEUHVDUHnociceptive in nature because they 
are responsible for carrying nociceptive information. Most nociceptors are 
polymodal i.e. they may respond to painful mechanical stimuli (intense 
pressure or stretch), painful thermal stimuli (hot or cold) or to chemical stimuli 
(Schaible et al., 2006) %RWK WKH QRFLFHSWLYH $į DQG & ILEUHV VXSSO\ WKH
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capsule, ligaments, menisci, periosteum and mineralized bone (mostly areas of 
high mechanical load) (Hunter et al., 2008), whereas only C fibres innervate 
the synovial membrane (Loeser et al., 2012, Heppelmann, 1997). It has been 
estimated that of the total number of nerves that supply the joints, ~80% are C 
fibres and that sympathetic efferent C fibres make up half of this 80% as they 
disappear after surgical sympathectomy (Hassanali and Oyoo, 2011, Loeser et 
al., 2012).  
C fibres are responsible for the slow burning, throbbing pain experienced by 
OA sufferers. Nociceptors can be categorized based on their expression of 
molecular and neurochemical markers. For example C fibres have been sub-
grouped as either peptidergic or non-peptidergic. Peptidergic fibres are defined 
by their expression of the neuropeptides; substance P (SP), calcitonin gene 
related peptide (CGRP), NGF receptor (tropomyosin-related kinase A; TrkA). 
Non-peptidergic fibres are classed as those that express the growth factor 
receptor c-Ret and bind to lectin IB4 (Canetta, 2010, Miller et al., 2015). 
1.3.3 Mechanisms involved in the development of joint 
pain  
Joint nociceptors are usually localized to specific articular structures while 
having their receptive field in the joint, but during inflammation this receptive 
field may expand to include other adjacent areas such as the surrounding 
muscle. An example of this case is a spinal neurone with its receptive field in 
the joint responding to physical stimulation of the surrounding muscle of the 
joint (Hunter et al., 2008). Pain in arthritis may originate from the innervated 
areas of the joints such as the synovium, periosteum, subchondral bone, 
ligament and muscle (Hunter et al., 2008). The cartilage is normally without 
innervations, but in diseased conditions such as in knee OA, the normally 
aneural cartilage may be innervated by peptidergic nerve fibres which contain 
the neuropeptides SP and CGRP (Suri et al., 2007, Hunter et al., 2008). A study 
which investigated neurovascular invasion in knee joint confirmed the 
localisation of sympathetic and sensory nerves to the cartilage, this may 
suggest that nerve innervation in the aneural tissue in the knee joint may be a 
potential source of pain for OA patients (Suri et al., 2007). The neuropeptides 
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SP and CGRP can lead to neurogenic inflammation which is inflammation that 
arises as a result of the local release of inflammatory mediators from sensory 
fibres and immune cells e.g. mast cells and macrophages (Tore and Tuncel, 
2009). Release of SP and CGRP can result in vasodilatation, plasma 
extravasation, leukocyte chemotaxis and phagocytosis (Zegarska et al., 2006). 
The process of neurogenic inflammation plays an important role in the 
pathogenesis of numerous diseases including OA (Saito, 2003). 
Joint nociceptors may become activated by responding to noxious mechanical 
stimuli such as when the normal joint is hit, over rotated or over stretched, 
although there are a few nociceptors that do not respond at all to noxious 
mechanical stimuli of the normal joint (Hassanali and Oyoo, 2011, Schaible et 
al., 2006)7KHVHQHUYH ILEUHV DUH FDOOHG µVLOHQW QRFLFHSWRUV¶EHFDXVH WKH\DUH
dormant in normal healthy joint, but become active and begin to send 
nociceptive inputs to the CNS following tissue injury or inflammation. This 
supplementary input by silent nociceptors accounts for one of the factors that 
contribute to the generation of arthritis pain as it contributes to the increased 
afferent inflow (recruitment) into the spinal cord during inflammation 
(McDougall, 2006, Schaible et al., 2002).  
1.3.4 Inflammatory mediators and modulators of pain 
Numerous inflammatory mediators contribute to both the degradative and 
nociceptive pathways associated with OA progression. During inflammation, a 
cascade of events occurs which includes the release of cytokines by 
chondrocytes or synovium; as a result, a complex biochemical and mechanical 
interplay with other biological mediators leads to the induction of OA and pain 
(Dray and Read, 2007, Schaible et al., 2011). Some particular mediators are 
known to stimulate hyperalgesia by a number of direct and indirect 
mechanisms of actions, including the sensitization of primary afferent fibres 
following mechanical stimuli. Examples include pro-inflammatory mediators; 
interleukins (IL-1, IL-6, and IL-17), tumour necrosis factor-Į (TNF-Į DQG
prostaglandin E2 (PGE2). Other mediators include SP, VEGF, nerve growth 
factor (NGF) etc. (Lee et al., 2013a). The focus of this thesis was on NGF as an 
inflammatory mediator of pain through TrkA. 
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1.3.4.1 Nerve growth factor  
NGF is a member to a family of molecules known as neurotrophins. These 
neurotrophins are 12.5-kd proteins that are usually associated as homodimers 
and are responsible for controlling the survival, development and function of 
subsets of sensory and sympathetic neurones; in general they play roles in the 
maintenance or regeneration of the nervous system (Mantyh et al., 2011, 
Anand, 1995). The other members of the neurotrophin family are BDNF, 
neurotrophin-3 and neurotrophin-4/5 (Mantyh et al., 2011). NGF is synthesised 
as pro-NGF and cleaved by endoproteases e.g. MMP-7 (Le and Friedman, 
2012), tryptase (Spinnler et al., 2011) into the mature form of NGF 
(Fahnestock et al., 2004). NGF is made up of an ĮDQGȕFKDLQZLWKWKH1*)ȕ
chain being responsible for its neurotrophic effects (Freemont et al., 2002). 
NGF has two receptors which it binds to; the high affinity receptor TrkA which 
binds only to NGF and the low affinity receptor (p75 receptor) which binds all 
members of the neurotrophin family (Mantyh et al., 2011). In addition to the 
p75 receptor, the other neurotrophins bind the other two Trk receptors B and C 
(Fig.1.3). NGF binds to the extracellular region of the TrkA receptor. This 
region comprises of three leucine and two cysteine rich motifs, followed by 
two immunoglobulin like domains (Ig-like) (HoldenPaul et al., 1997, 
Robertson et al., 2001). On release of NGF by cells in target organs such as 
skin, blood vessels and bladder, NGF is taken up by sympathetic and small 
sensory nerve fibres by binding to TrkA. This is achieved by the formation of 
NGF-TrkA complex which is then internalised and transported in a retrograde 
fashion i.e. from peripheral terminals to sensory cell bodies in the dorsal root 




Figure 1.5 Neurotrophins and their preferred Trk receptors. NGF binds TrkA, 
BDNF and NT4/5 bind TrkB and NT3 binds TrkC but can bind other Trk receptors 
albeit with different potencies. All neurotrophins bind p75 with equal affinity. 
1.3.4.2 General roles of NGF 
NGF IN NEURONAL GROWTH AND DEVELOPMENT 
It has been more than 60 years since the discovery of the role of NGF in 
neuronal development. This role which it plays in the development of the 
peripheral nervous system (PNS) is to support the growth and survival of some 
neural-crest derived cells in developing embryos especially those of the 
sympathetic and sensory neurones (Levi-Montalcini and Hamburger, 1951, 
Mantyh et al., 2011). A study was published in 1996 regarding the importance 
of NGF in developing neurones (Indo et al., 1996). Congenital insensitivity to 
pain with anhidrosis (CIPA) was witnessed in a single family who had a 
mutation in the gene encoding the TrkA receptor that resulted in structural 
neuropathy of unmyelinated peripheral nerve fibres. This mutation was seen to 
disrupt the normal signalling functions of NGF. The patients who had this 
condition had normal proprioception and normal sensitivity to innocuous 
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pressure but abnormal sensitivity to thermal stimuli (McMahon and Bevan, 
2005, Indo et al., 1996).  
Other cases of this congenital insensitivity to pain have also been seen in 
genetically altered mice that either have mutations to NGF or its high affinity 
receptor TrkA (Mardy et al., 2001). These 3-day-old genetically modified mice 
that are either lacking NGF or TrkA were born without the neural crest-derived 
small diameter sensory neurones because all of them undergo cell death. 
Therefore these animals were seen to be highly unresponsive to painful stimuli 
as the above neurones are mostly nociceptive in nature or that the nociceptors 
that express TrkA fall into this group (Brown and Podosin, 1966, Crowley et 
al., 1994, Smeyne et al., 1994, Mantyh et al., 2011, Pezet and McMahon, 
2006).  
Apart from its role in neuronal development and survival, NGF has other roles 
which it plays, an example is its involvement in the phenotypic expression of 
peptidergic primary afferent neurones soon after birth (early postnatal period). 
+HUH $į KLJK WKUHVKROG PHFKDQRUHFHSWRUV ZHUH DEVHQW LQ DQLPDOV WKDW ZHUH
deprived of NGF in the critical postnatal period. The animals were deprived of 
NGF by immunizing them with neutralizing antibodies (anti-NGF) against 
NGF. This revealed that neurones in the DRG could survive without NGF 
shortly after birth but that within 10 days of birth the high threshold 
mechanoreceptors that were seen in non-deprived animals were switched to 
sensitive mechanoreceptors in deprived animals. Other changes that occurred 
were to the C-fibres which were seen to lose their heat sensitivity (McMahon 
and Bevan, 2005, Mantyh et al., 2011, Rueff and Mendell, 1996).  
NGF AS A NOCICEPTIVE AGENT (ADULT) 
NGF is a sensitizer and modulator of the expression of a variety of components 
such as neurotransmitters, ion channels and receptors expressed by adult 
nociceptors (Mantyh et al., 2011). Evidence for NGF being a sensitizing agent 
has being demonstrated in acute, short-lived nociceptive responses and in 
longer term, chronic pain (Aloe and Levi-Montalcini, 1977, Taiwo et al., 1991, 
Mantyh et al., 2011). NGF becomes involved in sensitization of nerves only 
after sensory neurones are no longer dependent on it for survival. This involves 
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the NGF-TrkA pathway. This pathway plays an important role in the early, 
intermediate and long-term generation and maintenance of a variety of acute 
and chronic pain states (Zhu et al., 2004, Mantyh et al., 2011).   
1.3.4.3 Actions of NGF  
NGF sensitizes nerves, thus an increase in NGF expression in OA may lead to 
increased activity of the nerves in the subchondral bone. As a result of this, 
pain is increased both structurally (increased and abnormal innervations at the 
osteochondral junction), and through peripheral sensitization (Walsh et al., 
2010). Blood vessels and nerve growth may be induced by other growth factors 
such as VEGF. NGF produced by vascular cells may contribute to the growth 
of nerves along newly formed vessels (Walsh et al., 2010, Nico et al., 2008). 
Recent clinical trials using the monoclonal antibody; Tanezumab which blocks 
NGF, demonstrated the ability to inhibit OA knee pain thus confirming the 
involvement of NGF in arthritis (Lane et al., 2010), although the drug¶s rapid 
analgesic effect may have been due to an action on sensitization rather than 
nerve growth (Ashraf et al., 2011b, Cattaneo, 2010). The occurrence of adverse 
effects (rapidly progressive OA ± RPOA; osteonecrosis) with this NGF 
antibody (Brown et al., 2012) once led to their being put on hold by the federal 
drug administration (FDA). 
NGF receptors have been detected on murine CD4 T cells, human B 
lymphocytes, human keratinocytes, fibroblasts etc. In respect to the above, 
NGF may be a possible mediator of cross-talk between the nervous and 
immune systems (Iannone et al., 2002). This may enable it to maintain and 
exacerbate inflammatory disease (Iannone et al., 2002, Raychaudhuri et al., 
2011). Levels of NGF have been observed to increase in some immune 
diseases such as systemic sclerosis and chronic arthritides (Iannone et al., 
2002). Raised levels of NGF in the synovium may contribute to joint 
inflammation by activating inflammatory cells (Halliday et al., 1998). 
Finally endogenously produced NGF can lead to increased destruction of 
normal joint tissue by enabling the inward movement and degranulation of 
neutrophils thus raising elastase levels leading to overall joint destruction and 
ultimately pain (Raychaudhuri et al., 2011). Evidence suggest the involvement 
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of NGF in inducing RANKL-independent osteoclastogenesis and its potential 
contribution to normal and pathological subchondral bone remodelling 
(Hemingway et al., 2011). 
MECHANISM OF ACTION; NGF-TRKA SIGNALLING (PROTEIN 
PHOSPHORYLATION AND ALTERATIONS IN GENE 
EXPRESSION) 
The binding of released NGF to TrkA expressed on sensory neurones after 
tissue injury leads to the occurrence of early transcriptional changes in the 
sensory signalling pathway. NGF principally signals via retrograde transport of 
the internalized NGF-TrkA complex, so there is thus a delay (from hours to 
GD\VEHIRUHWKHHIIHFWRI1*)¶VFRQWULEXWLRQWRK\SHUVHQVLWLYLW\LVVHHQ$IWHU
retrograde transport of the NGF-TrkA complex to the dorsal root ganglia 
(DRG), changes in sensory phenotypes occur through the switching on (and 
off) of gene promoters (Fig. 1.4), which leads to the  increased synthesis of 
peptides (e.g. SP, CGRP, and BDNF), and of nociceptor-specific ion channels 
(NaV 1.8, CaV 3.2, -3.3) at the DRG (Kerr et al., 2001). For example it was 
observed that exposing sensory neurones expressing TrkA to NGF led to an 
increase in the synthesis and expression of acid sensing ion channel (ASIC) 3 
through the control of the promoter region of its gene (Mamet et al., 2002). 
Also NGF-induced altered gene expression can result in the phenotypic switch 
of non-peptidergic neurones to peptidergic neurones (Woolf and Costigan, 
1999). These peptidergic fibres express increased levels of SP, CGRP and 
BDNF. Stimulation of peptidergic fibres may lead to an enhanced 
inflammatory response and further sensitisation of nociceptors by SP and 
CGRP (Donnerer et al., 1992).  
Downstream signalling of NGF can lead to central sensitization. The 
involvement of NGF in mediating central sensitization can occur as a result of 
the indirect effect of NGF on synaptic transmission between nociceptors and 
second-order cells in laminae I and II of the spinal cord via its effect on the 
release of peptides such as BDNF (Fig. 1.4) (Garraway et al., 2003). Released 
BDNF acts as a central modulator via post synaptic TrkB (Thompson et al., 
1999). BDNF-TrkB binding on second-order neurones can lead to the 
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activation of intracellular protein kinases. These protein kinases can mediate 
the phosphorylation of glutamate AMPA receptors. Phosphorylation of AMPA 
receptors was observed to contribute to central sensitization at the dorsal horn 
synapse, particularly in combination with SP and CGRP acting on postsynaptic 
receptors (Fig. 1.4) (Mantyh et al., 2011). BDNF upregulation after peripheral 
inflammation was observed to be NGF-dependent as upregulation was 
inhibited by NGF antibody (Obata et al., 2003). Involvement of BDNF in 
mediating central sensitization was reported after it was observed that  
inhibition of central BDNF led to the attenuation of second (delayed) phase of 
hyperalgesia (Kerr et al., 1999). The delayed hyperalgesia was induced by 
formalin and thermal hyperalgesia in carrageenan rats in an NGF-dependent 
manner (Kerr et al., 1999). The involvement of NGF in mediating nociception 
either by peripheral or central sensitization or both, points to the fundamental 
difference between the role of NGF during neuronal embryonic growth and 
differentiation, and its role in the adult sensory system.  
NGF modulation of TRPV1: TrkA-expressing sensory neurones are known to 
also express transient receptor potential vanilloid 1 (TRPV1) (Ramsey et al., 
2006). TRPVI is a non-selective ligand-gated cation channel that plays a role in 
pain transmission and modulation (Szolcsányi and Sándor, 2012, Kelly et al., 
2013a). There is evidence of its involvement in contributing to inflammatory 
pain in arthritis (Brain, 2011). TRPV1 may be activated by exogenous and 
endogenous mechanical, thermal and chemical (i.e. acid, lipids) stimuli. 
Stimulus-induced opening of TRPV1 results in the influx of calcium ions and 
the generation of an action potential (i.e. thus transmission of pain signals) by 
the nociceptive neuron (Ramsey et al., 2006). The binding of NGF to TrkA 
during injury or inflammation leads to the activation of the phospholipid 
cleaving enzyme phospholipase C (PLC). Activation of PLC leads to TRPV1 
sensitization by decreasing the threshold at which it opens. Furthermore NGF 
upregulates the expression of TRPV1 on plasma membranes of neurones. NGF 
action on TRPV1 activation and expression results in a decrease in threshold 
for action potential generation in nociceptive neurons (McKelvey et al., 2013). 
Effect of NGF on mast cells: NGF contributes to pain facilitation indirectly by 
biding to TrkA-expressing mast cells. This results in the release of pain 
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mediators such as histamine, prostaglandins, and including NGF which may 
contribute to inflammation or create a positive feedback loop that sensitizes 
adjacent nociceptive neurones (Kawamoto et al., 2002) (Fig. 1.4). The 
prominent role which NGF plays in contributing to driving nociception creates 
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Figure 1.6 NGF-TrkA signalling. Neurotransmitters, receptors and ion channels are 
modulated and up-regulated by NGF binding to TrkA-expressing sensory neurones. 
TrkA-positive nerve fibres have their cell body in the dorsal root ganglia (DRG) and 
transmit sensory information from the periphery to the spinal cord and brain. During 
inflammation, injury, or certain diseases, inflammatory, immune, or Schwann cells 
release NGF. Released NGF binds to TrkA, which in turns directly activates and/or 
sensitizes nociceptors (A). The formed NGF-TrkA complex is transported retrogradely 
to the DRG, resulting in increased synthesis of neuropeptides (e.g., substance P [SP], 
brain-derived neurotrophic factor [BDNF], calcitonin gene-related peptide [CGRP]), 
receptors, ion channels, and anterograde transport of certain neurotransmitters, 
receptors, and ion channels from the DRG to the periphery tissue and spinal cord. 
Alternatively NGF may be released from mast cells but also from other recruited 
inflammatory cells (B). Indirect action of NGF in mediating sensitization occurs by 
NGF-TrkA binding on mast cells. This results in the release of inflammatory 
mediators; histamine, serotonin (5HT), and protons (H+), hyaluronan (HA), adenosine 
triphosphate (ATP) as well as NGF. NGF-TrkA binding on TrkA expressing fibre 
terminals activates intracellular signalling pathways. This results in the increased 
expression and/or modulation of a number of receptors, e.g. bradykinin (BK) receptors 
(B2R); ion channels, e.g. transient receptor potential vanilloid 1 (TRPV1); acid-
sensing ion channels (ASIC) 2/3 at the membrane surface of the fibre terminal. These 
rapid changes (minutes to hours) in tKHDIIHUHQW WHUPLQDOPRGLI\ WKH VHQVRU\ ILEUH¶V
response to sensory stimuli and the propagation of sensory impulses to the dorsal horn 
of the spinal cord. Figure adapted from (Mantyh et al., 2011).  
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1.3.4.4 Current strategies for targeting NGF-TrkA 
signalling 
Analgesic efficacies of NGF blockers continue to make the targeting of NGF 
attractive for OA chronic pain relief (Lane et al., 2010, Sanga et al., 2013, 
Tiseo et al., 2014). There are four major strategies currently being pursued for 
targeting NGF/TrkA (Fig. 1.5) and each one has its pros and cons (Hansel et 
al., 2010, Opar, 2010). For example, while monoclonal antibodies (mAbs) are 
very specific in their targeting, there are reports of immune reactions such as 
acute anaphylaxis, serum sickness and the generation of antibodies against the 
therapeutic agent from their use. In contrast, small molecule inhibitors of 
kinase activity do not require intravenous or intramuscular administration, 
might be more cost effective to produce than mAbs and allow greater 
flexibility in dosing as they are mostly administered orally, but are generally 
less selective than mAbs (Opar, 2010, Ghilardi et al., 2010, Ghilardi et al., 
2011). With the lack of selectivity being said, this thesis provides results using 
a very selective TrkA (AR786) inhibitor (chapter 6). It also investigates the 
effects of a mAb (Mumab911) - chapter 6. Mumab 911 reported by Shelton et 
al (2005) completely reversed established pain in auto-immune arthritic rats 





Figure 1.7 Therapeutic strategies for targeting NGF/TrkA for OA pain relief.  
Available therapeutic targeting of NGF or its cognate receptor TrkA include; 
monoclonal antibodies or peptibodies that sequester NGF (1), monoclonal antibodies 
that target TrkA and prevent NGF from binding to TrkA (2), small molecule TrkA 
antagonist therapy (3) and small molecule kinase inhibitors of TrkA (4). The anti-NGF 
used in this thesis is Mumab 911 while the TrkA inhibitor is AR786. Figure adapted 
from (Ghilardi et al., 2010). 
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1.4 PRECLINICAL ANIMAL MODELS  
The use of animal models has increased our understanding of the basic 
mechanisms of joint disease. There are variations that occur within the 
different models, and also because arthritis is induced by different stimuli. 
These include; autoimmunity production to cartilage components, nonspecific 
targeting of autoimmunity with adjuvants, and stimulating effects with 
exogenous noxious agents such as bacteria, viruses and mono-iodoacetate, 
including inducing post trauma by surgery. In addition, the recent use of 
focused manipulation of transgenics has introduced novel variants (Berg, 
2009).  
There is not one animal model of arthritis that truly portrays the human disease, 
but each one models a different aspect and thus can be useful tools to 
comprehend particular pathways (Berg, 2009). This includes their use in drug 
testing of anti-arthritis agents in the pharmaceutical industry. The important 
criteria in the selection of an ideal animal model are; (a) efficiency for 
therapeutic prediction in humans, i.e. what is effective in the animal should be 
effective in the patient, (b) similarity to human disease in all tissues of the 
articulating joint, (c) mammalian species that is inexpensive, easy to use and 
house, (d) reproducible disease that occurs in a suitable time frame to allow for 
high through put studies and also for reproducibility of data and, (e) reasonable 
test duration period, thus allowing for the study of early, mid and late  
pathophysiology and treatment  effects (Bendele et al., 1999, Little and Smith, 
2008). 
 A number of animal models have been developed for the different types of 
arthritis; examples of the models for OA include; naturally occurring Dunkin 
Hartley Guinea pigs, surgically-induced rat medial meniscal tear (MNX), 
anterior cruciate ligament transection (ACLT) in rats and dogs, less surgically 
invasive destabilization of the medial meniscus (DMM) in mice and 
chemically-induced intra-articular monosodium-iodoacetate (MIA) model etc. 
(Bendele, 2001, Malfait et al., 2010).  
It is widely accepted that the naturally occurring (spontaneous) OA models 
may mimic the causes, histopathological features, and slow progression of 
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human disease better than surgical or chemical models (Poole et al., 2010). 
However like in humans, there is a high degree of variability in the onset and 
the rate and extent of structural progression between animals in spontaneous 
models. This thus leads to a heterogeneous population and the need for larger 
experimental group sizes. In addition, appropriate age-matched, non-arthritic 
controls from which meaningful and ultimately translatable comparisons can 
be made are not always possible to achieve, therefore, experimenter-induced 
models of OA pain which share similar pathological features of human OA 
especially when fully established can be used instead (Sagar et al., 2013).   
1.4.1 Monosodium iodoacetate (MIA) model of OA 
MIA is an inhibitor of the enzyme glyceraldehyde-3-phosphate dehydrogenase 
hence it inhibits glycolysis, thus it kills chondrocytes. Intra-articular injection 
of MIA leads to the destruction of cartilage and can be induced in any species 
(rat, mouse, guinea pig). Different degrees of chondrocyte killing and thus 
cartilage destruction can be achieved depending on the concentration and 
frequency used. Two intra-articular injections of MIA (0.1ml of 3mg/ml) at 24 
hour intervals were reported to result in death of all chrondrocytes in the tibial 
plateaux and femoral condyles (Williams and Brandt, 1985, Bendele, 2001). 
Chondrophytes / osteophytes are also formed. Other characteristic occurrences 
in the joint are; progressive proteoglycan loss (evidence seen as a reduction in 
toluidine blue or Safranin-O matrix staining), and atrophy of the remaining 
collagenous matrix. Fibrillation occurs at a later stage as well as collagen 
matrix resorption and subchondral bone degradation. This model is useful for 
the evaluation of agents that inhibit matrix breakdown and induction of repair 
(Bendele, 2001). Another advantage to this model is that it reduces hind-paw 
withdrawal thresholds within a week of induction, so it is useful in studying 
pain related behaviours (Fernihough et al., 2004, Anemaet, 2008). A 
disadvantage is that this model does not fully mimic the OA process (Little and 
Smith, 2008). 
1.4.2 Medial meniscal transection (MNX) model of OA   
The MNX is a model that results in the rapid degeneration of cartilage 
characterized by loss of chondrocytes and proteoglycans, formation of 
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osteophytes, fibrillation and chondrocyte cloning in rats that have had their 
medial collateral ligament and meniscus transected and removed. These 
degenerative cartilage changes are seen to occur within 3 - 6 weeks post-
surgery. Tibial cartilage degeneration may be severe compared to the 
surrounding matrix. An advantage to using this particular model is that it 
produces rapid, reproducible changes, and can be used to investigate disease 
modifying OA drugs, as well as studying the induction and inhibition of 
osteophyte formation as osteophyte formation is a prominent feature (Bendele, 
2001). A disadvantage of this model is that cartilage degeneration progresses 
rapidly compared to the human OA progression which is slow (Anemaet, 2008, 
Bendele, 2001). Rats are also known to have very little spontaneous knee joint 
degeneration, thus the observed lesions are assumed to be as a result of surgical 
manipulation only. (Bendele, 2001). 
 
Despite there being a variety of animal models of OA that mimic different 
aspects of the disease, there is not yet an ideal model that would truly represent 
the human disease because of its complexity. Each model and disease onset 
and pathology has its own advantages and disadvantages, and there are still 
gaps in our knowledge of the disease and its pathogenesis. With that been said, 
animal models are still required because of the ethical limitations to the use of 
humans, lack of readily available human samples and also because the 
available human samples are obtained from patients with advanced disease at 
total knee replacement (tkr) surgery or post mortem in the case of OA. This 
thus limits our knowledge into the mechanisms that contribute to the 




1.5 PAIN BEHAVIOURAL MEASUREMENTS 
Pain is a major symptom of OA, therefore assessment and quantification of 
pain in experimental animal models would be useful in investigating OA 
mechanisms and assessing effect of anti-arthritic medication for the 
development of effective analgesics for OA pain treatment. A number of 
behavioural tests have been developed for pain assessment in rodent models of 
arthritis. These include; weight bearing by the affected foot, foot position and 
gait analysis, paw elevation time, heat sensitivity of the paw (secondary 
hyperalgesia), locomotor activity scoring either subjectively or by computer, 
and paw withdrawal threshold to punctuate stimulation indicative of distal 
mechanical allodynia (Yu et al., 2002, Min et al., 2001, Tonussi and Ferreira, 
1992, Malfait et al., 2013).  
 
Weight bearing asymmetry, an indicator of standing pain is brought about by 
the tendency to lean away or put less weight on the affected joint in OA 
(Christiansen and Stevens-Lapsley, 2010). This phenomenon does occur in 
animals with unilateral joint injury and can be measured (Bove et al., 2003). 
On the other hand, mechanical thresholds which indicate widespread or 
referred pain for example in the affected and non-affected limb (Arendt-
Nielsen et al., 2010) can also be measured in animals (Sagar et al., 2010). 
Weight bearing and paw withdrawal threshold were the pain measurements of 
choice in this thesis as they broadly represent nociceptive, peripheral and 
central sensitisation pain mechanisms and also because they generate robust 
and reproducible measures of joint pain and secondary allodynia respectively. 
(Andruski et al., 2008, Suokas et al., 2012). Weight bearing is both peripherally 




1.6 HYPOTHESIS AND OBJECTIVES OF THESIS 
1.6.1 Hypothesis 
Pain behaviour and structural pathology are features of OA models that are 
mediated by nerve growth factor (NGF). NGF may mediate OA pain by 
altering joint function and structure, including neuronal sensitisation, 
inflammation and subchondral osteoclast activation. 
1.6.2 Objectives 
To investigate the relationship between structural pathology including 
inflammation and associated pain in models of OA. 
To explore the effects of a TrkA inhibitor and an anti-NGF antibody on 
inflammation, structural pathology and pain behaviour in models of OA.  
The thesis has been structured as follows; 
x Chapter 2; describes in detail all the methodology used in this thesis 
and why they were selected for use.  
x Chapter 3; Investigates the characteristic features of the carrageenan 
model as a model of inflammatory arthritis. These features include pain 
behaviour and acute inflammation observed as joint swelling, synovitis 
and synovial macrophage infiltration. Three macrophage markers are 
explored in this chapter and they provide the rationale for the use of the 
selected macrophage marker in the subsequent chapters. 
x Chapter 4; Describes in detail the methodology development of 
assessing joint pathology macroscopically in the MIA and MNX 
models of OA. Determines the reliability, reproducibility and validity 
of the selected macroscopic scoring system and provides an additional 
method of assessing pathology in OA. The selected macroscopic 
scoring system was applied in the subsequent chapters. 
x Chapter 5; Investigates the characteristic features of symptomatic 
(structural pathology, inflammation and pain behaviour) OA in two 
MIA models (0.1mg and 1mg). Determines the reliability and validity 
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of histopathological scoring systems. Validated scoring system was 
applied in the next chapter.  
x Chapter 6; Evaluates the effect of inhibitors of NGF (Mumab 911) and 
its cognate receptor TrkA (AR786) in modifying pain behaviour, 
inflammation and structural joint damage in the MIA and MNX models 
of OA. It also explores the duration of sustained analgesia following 
discontinued treatment with AR786. 
x Chapter 7; General discussion of the results, relevance of the studies to 
the existing literature and how the current work of preclinical research 
may impact on clinical research. This chapter concludes with the 
limitations met in this thesis and an outline of possible research arising 
from this thesis. 
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CHAPTER 2; MATERIALS AND METHODS  
2.1 INTRODUCTION 
This chapter outlines all the methods carried out in this thesis, with 
descriptions of the sources of rats, tissues, consumables and equipment. All 
studies including pilot experiments were carried out on rats in line with the 
5¶VUHGXFWLRQUefinement and replacement).   
2.2 ANIMALS 
Male Sprague-Dawley rats obtained from Charles River U.K were used. Rats 
weighed between 200-400g at the start of the experiments. Rats were housed in 
groups of 4 per cage and habituated in the animal holding room for at least 5 
days after delivery. All procedures carried out on the rats including housing, 
handling and testing were conducted within the Guidelines for the Ethical use 
of animals in experimental pain (Zimmermann, 1983) and with accordance to 
the UK Home Office regulations, and were in line with the Animals Scientific 
Procedures Act (ASPA) 1986. Body weights of rats were measured before, 
during and after each experiment. All experiments were carried out in a 
randomised and blinded fashion; the experimenter was blind to arthritic and 
non-arthritic rats, treated and untreated groups. Rats were randomised 
following baseline pain behaviour measurements. Experiment start dates were 
staggered to permit pain assessment and tissue collection, ensuring balanced 
representation of each of the experimental and control groups in each cohort of 
rats.  
2.3 ANIMAL MODELS 
2.3.1 Anaesthesia 
Anaesthesia was thought traditionally as an all or nothing binary phenomenon 
(Pandit, 2014). This view was put forward in an editorial by Prys-Roberts 
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where he wrote, ³There cannot be degrees of anaesthesia nor for that matter 
can there be variable depths of anaesthesia´ (Prys-Roberts, 1987). This 
statement although not supported by other references, became a sentiment 
widely repeated in standard texts (Miller, 2010). Anaesthesia has now been 
redefined as the state of the brain in complete mental oblivion with no recall in 
memory, thoughts or experience of sensory perception (Pandit, 2014). In 
reality, however, µDQDHVWKHVLD¶ LV DQ\ GUXJ-induced mental state that makes 
surgery acceptable at the time, and later, whether or not that includes some 
awareness and recall of events (Pandit, 2014). 
General anaesthesia by inhalation was administered to rats undergoing 
recovery procedures (intra-articular administration of compounds or surgery) 
or an overdose by injection in non-recovery experiments (as recommended in 
the schedule 2.4 of the Animals Scientific Procedures Act 1986 (ASPA) 
(Wolfensohn and Lloyd, 2003). Isoflurane (halogenated ether), the inhalant 
anaesthetic of choice is a volatile compound delivered in conjunction with 
oxygen (O2). Isoflurane induces and maintains general anaesthesia by 
depression of the central nervous system (CNS). It is less soluble in blood so it 
has a high rate of rapid induction and recovery of anaesthesia. Its circulatory 
margin of safety is the largest compared to all other potent halogenated agents 
as it produces the least myocardial depression at a given minimum alveolar 
concentration (MAC) multiple (Eger, 1984). Each rat was placed in a chamber 
and anaesthetised with isoflurane mixture (2% in 1L/min of O2) until areflexic. 
Areflexia was confirmed by pinching of the fore and hind paws.  
2.3.2 Intra-articular injections 
Each rat was anaesthetised with isoflurane mixture (2% in O2) (section 2.3.1). 
The rat was then placed in a supine position and the skin directly above and 
around the joint of the left leg was shaved and swabbed with chlorhexidine 
(Animal care Ltd, Dunning ton, York). The white tendon below the skin of the 
knee joint was identified. Injection of 50µl was then given into the left joint of 
the rats using a 27-gauge 12.7-mm needle inserted through the suprapatellar 
ligament with the joint held in 90° flexion (Mapp et al., 1996, Walsh et al., 
1998a, Seegers et al., 2003). Administered compounds were dissolved in sterile 
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0.9% normal saline (pH 7.4). After injection, the injected area was then 
massaged to allow proper dispersion of the drug. Un-injected and saline-
injected knee joints were used as controls.  
   
Figure 2.1 Intra-articular injections into rat knees  
Anaesthetised rat in an areflexic state, judged by pinching of the fore and hind paws 
(A). Skin above knee joint is shaved and swabbed with chlorhexidine ready for 
injection (B). Compound administered using a 27G, 12.7mm needle inserted through 
the suprapetallar ligament or inserted straight in the joint space through the infra-
patella ligament with the joint held in 90° flexion (C). Picture taken from (Ashraf, 
2011). 
2.3.3 Intra-peritoneal injections 
Each rat was restrained by the scruff in the non-dominant hand or by another 
person in cases where the rat was too big to be restrained by the same person 
administering the injection. The rat was positioned with the head angled toward 
the floor or on its back. This allowed intestines to move away from injection 
site, with the position maintained throughout procedure. In the case of a rat, a 
23-25 g, 0.5 to 1 inch needle, volume limit 10ml/kg was used. The syringe was 
held in the dominant hand (thumb, bevel & measurement lines up). The needle 
was then inserted to the hub into the lower abdominal quadrant between the 
midline and leg at a 45° angle. Aspiration was done gently to ensure that the 
needle was not inserted into a blood vessel, urinary bladder or intestine. If this 
was the case, the needle was removed and with a different needle, a new 
A B C 
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solution was injected with as little movement as possible, after which the 
needle was carefully removed (AWHLA, 2005-2014). This procedure was used 
at the end of the studies for termination by an overdose of pentobarbital 
anaesthetic (5ml/kg). 
 
Figure 2.2 Administration of compounds intra-peritoneally 
Procedure carried out by two people, one holding the rat in the correct position and the 
other doing the injecting in the lower abdominal quadrant with needle placed at a 45° 
angle. Picture taken from (AWHLA, 2005-2014). 
2.3.4 Oral gavage 
Gavage or stomach catheters are used to introduce liquids directly into the 
stomach of animals. They are stainless steel needles with a protective rounded 
tip or soft flexible plastic tubes to prevent any internal damage to the animal 
during oral dosing. The maximum volume that could be administered to a rat 
was calculated based on the Home Office guidance (20ml/kg up to three times 
daily). For a 200-350g rat, a 14G-3inch and 4mm ball diameter needle is used. 
The rat was restrained by scruffing with its neck extended, so that the head was 
well controlled and the forelimbs immobilised (Wolfensohn and Lloyd, 2003). 
Distance from the oral cavity to the end of the xyphoid process (caudal point of 
the sternum) was measured outside of the restrained rat with the feeding needle 
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to ensure that the needle to be used was of appropriate size and at the same 
time giving an idea of how far the needle was to be inserted when dosing. 
Inappropriate sized needles could lead to damage of the oesophagus or the 
stomach of the rat as well as resulting in the drug being delivered to a site other 
than the stomach. The needle attached to a 1ml syringe containing the 
appropriate drug in a 500ȝOYROXPHZDVSDVVHGJHQWO\GRZQDORQJWKHURRIRI
the rat¶VRUDOFDYLW\RQWKHOHIWVLGHWKXVHQDEOLQJWKHQHHGOHWRVOLGHGRZQWKH
oesophagus with ease. The needle was rotated slightly to enable smooth 
passage throughout the sphincter of the epiglottis and into the oesophagus. 
Once the needle was at the premeasured distance, the contents of the syringe 
were slowly administered to prevent reflux of the fluid. The needle was then 
gently removed in the opposite direction from insertion and the rat returned to 
its cage and observed for potential complications such as gasping and frothing 
at the mouth or nose.  
  
Figure 2.3 Compound administration by oral gavage 
Rat is restrained with the non-dominant hand or by another person, and the dosing 
needle measured from the oral cavity to the stomach to see if the needle was the right 
size and what distance the needle should be inserted (A). Dosing needle carefully 
inserted through the oral cavity (B). When the correct distance was reached, the 
compound was then administered slowly (C). Picture taken from (Jones, 2012). 
A B C 
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2.3.5 Medial meniscal transection  
OA was induced on day 0 by surgical transection of the medial meniscus as 
previously described (Janusz et al., 2002, Ashraf, 2011).  
Briefly, prior to surgery, each rat was anaesthetized (section 2.3.1); the left leg 
was shaved and swabbed with chlorhexidine, so as to provide a sterile area to 
operate on. The rat was appropriately positioned over a heat blanket to keep it 
warm during surgery. A nose cone was used to deliver the anaesthetic and keep 
the rat anaesthetised during surgery. A sterile op-cover (Kruuse Ltd, Sherburn 
in Elmet, North Yorkshire) was placed over the leg to be operated on, covering 
all but the area to be operated on, thus minimising the risk of sterile items 
becoming non-sterile due to contact with areas close to the surgical field. All 
instruments were autoclaved a day before the surgery and re-autoclaved 
between rats during surgery.  
A section of skin medial to the joint was lifted using straight forceps 
(InterFocus Ltd, Linton, Cambridge, 11370-40) and a single cut made 
underneath the joint cavity with straight iris scissors (InterFocus Ltd, Linton, 
Cambridge, 14558-11). The medial collateral ligament (MCL) could be seen as 
a white shadow buried under the muscle layers following the cut. Any 
haemorrhage from the skin edge was stopped by firmly applying pressure with 
a sterile swab. Connective tissue (CT) directly above the MCL was grasped 
with straight forceps and cauterized using small vessel cauteriser (InterFocus 
Ltd, Linton, Cambridge, 18000-00) edged in a straight line from one corner of 
the cut to the other so as to easily access the MCL. The muscle layers were 
held before being cauterized in the same way as the CT. If any bleeding 
occurred during this process, it was arrested by cauterizing the bleeding vessel. 
When the MCL was clearly visible, the distal end was grasped with rat teeth 
forceps (InterFocus Ltd, Linton, Cambridge, 11084-07) and cut using a straight 
spring scissors (InterFocus Ltd, Linton, Cambridge, 15000-00) held flat to the 
joint.  The MCL was lifted until the meniscus was clearly seen and then cut and 
partly removed (3mm) to uncover the meniscus.  
The procedure was stopped and the wound sutured if SHAM surgery was being 
performed. Otherwise the procedure was continued and the meniscus was freed 
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from its surrounding tissues by making two cuts on either side, anterior and 
posterior of the meniscus, at the top and two cuts at the bottom using straight 
spring scissors. The ankle of the rat was twisted gently to clearly visualize the 
joint space and the meniscus was then held with rat teeth forceps before being 
cut through its full thickness at its narrowest point (middle) using straight 
spring scissors. The procedure was done with care so as to ensure that the 
underlying articular cartilage did not suffer any forced damage whilst the 
meniscus was being cut during the surgery. Following the transection of the 
meniscus, the bone ends were inspected thoroughly under the microscope to 
ensure no damage was sustained. The site was also flushed with saline and 
dabbed using sterile swabs to remove any blood. Sutures were made using a 
micro needle holder with cutter (InterFocus Ltd, Linton, Cambridge, 12075-14) 
and suture tying forceps (InterFocus Ltd, Linton, Cambridge, 18025-10) to 
pass curved needles through tissues and to tie knots after suturing. The CT 
layer was closed with interrupted stitches using Ethicon coated vicryl 8/0 
sutures (NHS supply chain). The skin was closed using wound clips (Harvard 
Apparatus) to appose the tissue margins and allow healing (Figure 2.4). 





Figure 2.4 Transection of the medial meniscus of the knee 
Exposed medial collateral ligament (MCL) was cut and partly removed for easy access 
to the meniscus (A). Meniscus (M) transected through its full thickness at its 
narrowest point, femur (F) and tibia (T) are seen and can freely move (B), after which 
the connective tissue was closed (C), then followed by the skin (D). Picture taken 
from (Ashraf, 2011).  
 
2.4 ACUTE INFLAMMATION 
2.4.1 Joint swelling 
OA is a disease of the joint and the procedures carried out on the rats were 








contralateral-non operated or control) was measured using a digital electronic 
calliper (Miyutoyo UK Ltd., Andover, UK) at set time points as differences in 
knee diameters (mm) representing acute or chronic inflammation. 
 
 
Figure 2.5 Measurement of knee joint swelling  
Procedure was carried out by two people, one to restrain the rat in the correct position 
and the other doing the measurement with a digital electronic calliper. Picture taken 
from (Ashraf, 2011). 
 
2.5 PAIN BEHAVIOUR MEASUREMENTS 
Pain behaviour was measured indirectly as a percentage difference in hind-limb 
weight bearing asymmetry (peripheral sensitisation) and distal allodynia-hind 
paw withdrawal threshold (central sensitisation) (Neugebauer et al., 2007). 
These methods are used in research studies in humans for pain assessments in 
arthritic patients. Reduced weight bearing is comparable to weight bearing 
asymmetry. Paw withdrawal threshold (PWT) indicates reduced pain 
thresholds to mechanical stimuli distal to the affected joint. Similar 
observations have been made by quantitative sensory testing in man (Hassan 





2.5.1 Weight bearing 
This technique compares the difference between the weights placed on the 
ipsilateral limb and contralateral limb of an animal. Rats were first habituated 
in a Perspex box prior to start of the study where the baseline measurements 
would be taken thereafter at the start of each study. This enabled the rats to get 
used to their surroundings and aimed to reduce a rise in stress levels. Stress 
may confound pain behaviour measurements. Weight bearing asymmetry was 
measured at different set time-points using an Incapacitance Meter (Linton 
Instruments, Norfolk, UK). Each rat was placed in a Perspex box such that 
each paw rests on a separate transducer pad that records the rat¶V ZHLJKW
distribution over a period of 3 seconds. After 3 consecutive readings an 
average was taken and expressed as a difference in percentage of force between 
the hind limbs (Mapp et al., 2010, Bove et al., 2003). Results are presented as 
calculated by the following equation, so as to take into account the weights of 
the rats: (Contralateral ± Ipsilateral / Contralateral + Ipsilateral) x 100 
 
 
Figure 2.6 Incapacitance meter used for recording weight bearing  
The incapacitance meter consists of a Perspex box to hold the rats, transducer pads 








2.5.2 Distal (static) allodynia 
Hind paw withdrawal threshold (PWT) which indicates distal mechanical 
allodynia was measured. Rats were habituated by placing them singly into 
Plexiglas mesh bottom test cages 15-20 minutes prior to the assessment of 
allodynia. Measurement was done via the Dixon up-down method using 
calibrated Semmes-Weinstein monofilaments ranging in strength from 1g, 1.4g 
2g, 4g, 6g, 8g, 10g and 15g as previously described (Chaplan et al., 1994, 
Sagar et al., 2010, Sagar et al., 2011). Firstly the ipsilateral paw was stimulated 
with the 2g filament and held for 3 seconds. In the case of a pain response, seen 
as a rapid lifting of the affected paw and flinching, the next lower filament was 
used.  In the case of a no pain response, the next upper filament was used. 
After the first threshold response was observed, i.e. a response followed by no 
response or vice versa, the lowest monofilament that elicited a response was 
then noted as the PWT. A repeat of the above was then carried out on the 
contralateral side.  
 
 
Figure 2.7 Wire bottom test cages for measuring allodynia  
Each rat was placed in Plexiglas mesh bottom test cage and paw withdrawal threshold 
measured by stimulation with von Frey hairs. 
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2.6 TISSUE COLLECTION AND PROCESSING 
2.6.1 Euthanasia (overdose by CO2 or anaesthetic-
pentobarbital) 
At the end of each in-vivo study in this thesis, each rat was killed either by a 
rising concentration of carbon dioxide (CO2) in the case of fresh tissue 
collection or by an overdose of the anaesthetic pentobarbital for perfusion fixed 
tissue collection. These methods of sacrifice are in line with the recommended 
schedule 1 method (appropriate methods of humane killing) of the Animals 
Scientific Procedures Act 1986 (ASPA). The following refers only to CO2 use; 
each rat was placed in an empty chamber with a transparent lid. Flow of CO2 
was turned on to 2 L/min for a 200-500g rat, gradually introducing 100% CO2 
to result in the replacement of 20% of a small chamber volume per minute 
while for a big chamber flow of CO2 was 6 L/min (for two or more rats) 
(Hewett et al., 1993). The narcotic effect of CO2 to depress awareness causes 
the rats to lose consciousness with increasing concentration and then they 
eventually die from hypoxia (Mackay, 1947). The flow of CO2 was turned off 
after 6 minutes and the chamber inverted each time in order to tip out all of the 
residual CO2 which would have otherwise sunk to the bottom of the chamber 
as CO2 has a higher density than O2 thus making it heavier than O2 (Smith and 
Harrap, 1997). The danger of not performing the above action would result in 
the respiratory distress and struggling of the next rat put into the chamber as 
the procedure requires the gradual introduction of CO2 (Danneman et al., 
1997). Death was always confirmed by dislocation of the neck. 
2.6.2 Systemic transcardiac perfusion fixation 
Each rat was fully anaesthetised 15 minutes prior to the fixation procedure with 
intraperitoneal injection (section 2.1.3) of 2ml sodium pentobarbital (Euthatal). 
The rat was left until there were no corneal and hind paw withdrawal reflexes 
but not left too long that the heart was no longer beating, as maintained 
circulation was needed for the procedure. The rat was restrained on a perfusion 
tray with needles so that the fixative would easily access the joint tissues, and 
the skin directly above the rib cage was cut exposing the muscle underneath. 
 56 
 
The cartilage below the sternum was held with a forceps and the ribcage cut 
through gently to expose the heart without damaging the lungs. The auricle 
above the heart was excised to allow for the clear visibility of the ascending 
aorta. The heart was then grasped gently with forceps and a small incision 
made in the left ventricle and a cannula was then passed through it into the 
ascending aorta. A small incision was made in the right atrium to allow 
drainage of returning blood (in the case blood collection was needed) and fluid 
from the systemic circulation. 300ml phosphate buffered saline (PBS) was 
pumped through the cannula to wash out any remaining traces of blood in the 
rat. $IWHU WKH IOXLG UDQ FOHDU PO =DPERQL¶V IL[DWLYH was then pumped 
through the rat to fix the tibiofemoral knee joints (Hukkanen et al., 1992, 
Honore and Mantyh, 2000). Tibiofemoral joints were promptly excised by 
cutting mid-femur and tibia with a bone cutter and post fixed in the same 
perfusion fixative solution, ready for the decalcification process (section 2.6.4) 
(Imai et al., 1997). 
2.6.3 Harvesting and mounting of rat synovia 
Each rat was killed by a rising concentration of CO2 (section 2.6.1). The skin 
above the knee was removed for each rat and the synovia with patellae from 
right and left knees were dissected free from bone. The skin above the patella 
was sliced using a scalpel. The patella was held using a rat teeth forceps and 
the skin on either side was sliced to expose the fat pad below the patella that 
houses the synovium. The synovium was then held by the patella end and 
embedded perpendicularly on its side in Tissue Tek Optimum Cutting 
Temperature (OCT®) mounting medium (Raymond Lamb, Eastbourne, UK) 
onto cork blocks before being snap frozen in melting isopentane and stored at -
80°C until use (Ashraf, 2011, Walsh et al., 1993). 
For Zamboni-fixed synovia, samples were transferred to 15% [w/v] sucrose in 
PBS/Sucrose-azide solution at 4°C for 5 days. The PBS/Sucrose solution was 
changed daily until the yellow appearance of the solution cleared. Once 
cleared, the PBS/Sucrose-azide was replaced with 1:1 mixture of PBS/Sucrose-
azide and OCT® mounting medium for 2 days and then into 100% OCT® for 
another two days after which it was embedded in OCT onto cork blocks and 
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snap frozen in melting isopentane and stored at -80°C until use. The samples 
were placed in PBS/Sucrose-azide, to cryoprotect the tissue and also prevent 
any bacteria growth with sodium azide. The synovium were put in OCT before 
being embedded so that the OCT would coat the cells and prevent the section 
from drying out and will also prevent ice crystal from forming during 
embedding. 
 
Figure 2.8 Harvested synovia  
Rat knee with removed skin to expose tendon directly above joint (A). Dissected 
synovium with patella (B). Picture adapted from (Ashraf, 2011). Supra-patellar 
ligament (SPL), patella (P), infra-patellar fat pad (IPFP). 
 
2.6.4 Harvesting and mounting of rat tibiofemoral joints 
Tibiofemoral joints were excised by cutting mid-femur and tibia with a bone 
cutter and excess skeletal muscle dissected off. Joints taken fresh were 
immersed in neutral buffered formalin containing 4% formaldehyde at room 
WHPSHUDWXUHIRUKZKLOHSHUIXVLRQIL[HGMRLQWVZHUHSRVWIL[HGLQ=DPERQL¶V
fixative (4% paraformaldehyde, 15% (v/v) saturated (1.3% picric acid), 0.1M 
phosphate buffer, pH 7.3) for 48h at 4°C (Imai et al., 1997), ready for the 
decalcification process. The joints were placed on a roller mixer and 








agitation is thought to hasten the decalcification process (Russell, 1963) and 
also to prevent the formation of artefact crystals due to stagnation (Mepham, 
1991). 
Decalcification is the process by which heavily mineralised tissues are softened 
in order to obtain satisfactory thin sections for histological purposes. This 
process is usually carried out by treatment of tissues with reagents which react 
with calcium; either by use of acids (weak acids - formic acid) to produce 
soluble calcium salts or the use of chelating agents (ethylenediaminetetraacetic 
acid [EDTA]) which take up calcium salts (Mepham, 1991). The choice of 
decalcification is dependent on a few different factors; the hypothesis of the 
experiment, the staining techniques required and the urgency of the case. In 
this thesis, EDTA decalcification was mainly used because it was a less harsh 
and slower method of decalcification compared to formic acid. EDTA has less 
of an effect on many immunohistochemcial stains e.g. for detection of TRAP 
positive osteoclasts ± section 2.7.2.1. It also allows the detection of nerve 
structures. Formic acid was used only once to rapidly decalcify the 
tibiofemoral joints to be used for histological (Safranin-O fast green) stains 
(section 2.7.1.2) in order to analyse the proteoglycan content of the joint as it 
has been reported that there is increased wash out of proteoglycan with the 
slower EDTA method (Kiraly et al., 1996, Chevrier et al., 2005). 
Weak acid fixation; formic acid is the only weak acid extensively used 
primarily for decalcification. It can be used as a simple 5-10% aqueous 
solution or in addition with a buffer or formalin which has the benefit of 
simultaneous fixation and decalcification. Decalcification occurs rapidly within 
1-10days depending on the size and nature of the tissue, and the acidity of the 
solution.  
Chelating agents; EDTA is the most commonly used agent in the form of its 
disodium salt. Although an acid, it does not act as a mineral or organic acid but 
can only capture and bind ionised calcium. It acts only on the outer layer of the 
apatite crystal at the start of decalcification. As decalcification proceeds, the 
crystal becomes smaller as the layers become depleted, and thus it is a slower 
process (6-8weeks). This method of decalcification has less effects on other 
 59 
 
elements making it a better method for immunohistochemistry as some 
enzymes are still active after EDTA decalcification (Mepham, 1991).  
Formalin-fixed tibiofemoral joints were decalcified in 10% formic acid in 
neutral buffered formalin (containing 4% formaldehyde), changed twice a 
week, for 7 days at room temperature or in 10% EDTA in 10mM Tris buffer 
with 7.5% [w/v] polyvinylpyroolidene [PVP], pH 6.95). The joints were 
decalcified for approximately 6 weeks at room temperature. The decalcification 
fluid was changed twice a week. 
Zamboni-fixed tibiofemoral joints were transferred to 15% [w/v] sucrose in 
phosphate buffered saline (PBS/Sucrose) solution at 4°C for 5 days. The 
PBS/Sucrose-azide solution was changed daily until the yellow appearance of 
the solution cleared. Once cleared, the PBS/Sucrose-azide was replaced with 
decalcification fluid (10% EDTA in 10mM Tris buffer with 7.5% [w/v] 
polyvinylpyroolidene [PVP], pH 6.95). The joints were then decalcified for 
approximately 6 weeks at 4°C.  
After decalcification of the formalin fixed joints, the joints were then split in a 
frontal plane and placed in cassettes (Figure 2.9). These trimmed joint tissues 
were then processed by standard histological techniques and mounted in 
paraffin wax blocks for sectioning. Briefly, the joint samples were secured (flat 
side down) in labelled plastic cassettes. The cassettes were then placed in the 
Shandon Pathcentre enclosed tissue processor (Shandon ThermoScientific, 
/HLFHVWHUVKLUH 8. DW .LQJ¶V 0LOO +RVSLWDO E\ DQ H[SHULHQFHG ODERUDWRU\
technician (Roger Hill) to undergo a series of dehydration (in alcohol) and 
clearing (in xylene) steps. The joint tissues were impregnated with molten wax 
for the final embedding stage of setting the tissues in blocks of paraffin wax. 
For this, the tissues were left in the respective cassettes in molten wax. Metal 
moulds were placed on a hot-plate and molten wax was dispensed into them 
from a Tissue Tek ® embedding centre (model TEC5 EME2; Sakura Finetek 
Europe, The Netherlands). Tibiofemoral joint or tibia joint tissues only (in the 
case of disarticulated joints) were then placed flat side down into the centre of 
the mould using warm forceps and transferred briefly to a cold-plate to allow 
the wax to slightly solidify at the bottom of the mould and at the same time the 
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section was pressed down to enable an even flat tissue surface to be achieved 
with the wax. Labelled plastic cassettes were then placed on top of the mould, 
pressed down and more wax poured on top to evenly fill the cassettes. Moulds 
were then placed on the cold-plate for quick cooling of the wax. Once the wax 
set, the wax blocks were removed from the metal moulds, excess wax trimmed 
from the cassettes and the wax blocks were stored at room temperature until 
required for sectioning (Figure 2.9).  
After decalcification of WKH =DPERQL¶V IL[HG MRLQW, and after radiography, the 
frontal split trimmed joints were transferred to PBS/Sucrose solution for 5 days 
at 4°C, then through to 1:1 mixture of PBS/Sucrose and OCT® embedding 
matrix for 7 days, then into 100% OCT for a further 7 days at 4 °C. The 
sections were continuously agitated on a roller-mixer throughout this process 
before being mounted onto cork blocks and then snap frozen in melting 
isopentane on liquid nitrogen and stored at -80 °C until use. 
Frontal sectioning is the most commonly used method of splitting, embedding 
and sectioning of rat knees for microscopic evaluation by histology (Gerwin et 
al., 2010, Janusz et al., 2002, Hayami et al., 2006b). In this process, the joints 
were split into two equal halves, anterior and posterior, along the MCL in the 
frontal plane. The knee joint was placed in between blunt forceps on its side 
with the MCL facing up. The forceps were then squeezed to straighten the joint 
and allowing for aligning the cut through the middle of the arms of the forceps 
with a scalpel. The two resulting anterior and posterior halves were embedded 
separately in two different blocks. The resulting histological section included 
both femoral condyles, tibial plateaux and menisci (Gerwin et al., 2010) or in 
most of the cases in this thesis, it included only the tibial plateau as 
macroscopic scoring (Chapter 4) were carried out on the joints hence the joints 
were disarticulated before splitting and only the tibia embedded.  
Following the osteoarthritis research international (OARSI) histopathology 
initiative recommendations for histological assessments of osteoarthritis in the 
rat, three 5µm sections were cut from each paraffin block at approximately 
200µm levels in order to obtain 6 sections in total (3 from each anterior and 
posterior block of one rat) but that 3 of the sections from a part was scored 
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(Gerwin et al., 2010). This protocol was tested in Chapter 5 and it was found 
that in order to obtain sufficient power to demonstrate structural changes to the 
cartilage surface and chondrocyte appearance, 6 sections to include both 
anterior and posterior joints was required (detailed explanation and results in 
chapter 5). 
  
Figure 2.9 Harvested and embedded rat joints  
Knee joints split frontally into anterior and posterior halves with femur and tibia intact 
(A). Tissue samples subsequently embedded in paraffin wax blocks for storage and 








Histochemistry is the study of the identification of chemical components of 
cells and tissues using histological techniques. Histochemistry is useful in the 
evaluation of diseases that involve the bone e.g. OA.  
2.7.1 Histological stains 
The most frequently used stains are haematoxylin and eosin (H&E), Safranin-
O-Fast green, toluidine blue and alcian blue PAS. It is recommended that for a 
method of scoring, the stain used should be sensitive enough to detect the 
tidemark. In this case, the H&E stain is used, although the tidemark is more 
clearly seen in humans than rats (Gerwin et al., 2010). 
2.7.1.1 Haematoxylin and eosin (H&E) 
H&E is often used to analyse tissue morphology. The haematoxylin dye is 
basic and has a high affinity for acidic structures; examples are the cell nucleus 
which it stains blue/black. The acidic eosin dye stains more of basic structures; 
the cell cytoplasm and connective tissue fibres in different hues of pink, red or 
orange (Mepham, 1991). There are different types of the haematoxylin dye; 
(KUOLFK¶V +DUULV¶V 0D\HU¶V DQG :HLJHUW¶V haematoxylin. The Harris 
haemalum is used for fresh frozen tissue in a progressive staining method while 
WKH 0D\HU¶V KDHPDOXP LV XVHG IRU IL[HG IUR]HQ RU SDUDIILQ ZD[ HPEHGGHG
tissues in a regressive stain.  A progressive stain is when the tissue is stained 
long enough to reach the desired endpoint, while a regressive stain is when the 
tissue is over stained and then later differentiated in acid alcohol to the desired 
endpoint (King and King, 1986, Millikin, 2005). Unfixed tissues such as 
synovia cannot be stained by the regressive method as the acid alcohol step 
will damage the tissue, hence the Harris haemalum is used. 
Frozen tissue sections were cut using the cryostat and paraffin sections using 
the microtome. 5ȝm thick frozen sections were washed for 5 minutes in PBS 
and another 5 minutes in distilled water. Paraffin wax embedded tissue sections 
(5ȝP WKLFN ZHUe first dewaxed in xylene and then rehydrated in graded 
ethanol (100% and 70%) before being washed in distilled water for 5 minutes. 
1XFOHDU VWDLQLQJ ZDV WKHQ DFKLHYHG E\ LPPHUVLQJ WKH VHFWLRQV LQ 0D\HU¶V
 63 
 
haematoxylin for 10 minutes or Harris haematoxylin for 5 minutes, rinsing in 
running tap water to differentiate the staining, dipping the sections in 1% acid 
alcohol solution for 10 seconds (for wax sections) and back into tap water for 
further 3 minutes before being immersed in 1% eosin for 1 minute (fresh tissue 
step is from water to eosin) to stain all other tissue structures varying degree of 
red. Staining was then differentiated with running tap water and the sections 
were dehydrated through graded ethanol (70% and 100%) into xylene and 
mounted in DePeX and covered with cover-slips and allowed to dry. 
 
Figure 2.10 Haematoxylin and Eosin stained section of a tibia.  
 
2.7.1.2 Safranin-O fast green 
Safranin-O fast green is a widely used technique for studying cartilage and 
bone (Bulstra et al., 1993, Pedersen et al., 2013). Safranin-O is a cationic dye 
that binds specifically to sulphated glycosaminoglycans (GAGs) and 
proteoglycan. A product of the binding is the intense red stain which indicates 
the presence of proteoglycan content. Varying intensity of the red colour is 






green provides a contrasting counterstain, it stains the underlying subchondral 
bone a blue/green colour (Rosenberg, 1971). In normal cartilage, Safranin-O 
staining is known to be directly proportional to proteoglycan content and 
therefore have been used to investigate changes in articular disease. In 
cartilage, where the levels of GAGs have been severely depleted, sensitivity to 
proteoglycan content is reduced (Camplejohn and Allard, 1988). The result 
may vary in staining intensity between individuals of the same species, hence 
another proteoglycan stain could be used in parallel (Alcian blue PAS stain, 
section 2.7.1.3). As proteoglycans are usually washed out during 
decalcification, especially with prolonged methods, other quicker 
decalcification methods (Formic acid-Formalin method instead of the EDTA 
method) could be applied to preserve proteoglycan content so as to achieve 
high quality quantitative assessment results (Schmitz et al., 2010, Encfeldt and 
Hjertquist, 1967).  
Paraffin wax embedded sections were cut using the microtome. Five ȝPWKLFN
sections were first dewaxed in xylene and then rehydrated in graded ethanol 
(100% and 70%) before being washed in distilled water twice for 5 minutes. 
6HFWLRQVZHUHWKHQLPPHUVHGIRUPLQXWHVLQ:HLJHUW¶VKDHPDWR[\OLQULQVHG
for 1 minute in running tap water and submerged in acid alcohol solution for 20 
seconds. The sections rinsed again in tap water for further 3 minutes. Sections 
were subsequently immersed in Fast Green for 5 minutes, dipped in acetic acid 
solution for 1 minute and immersed in Safranin-O for 5 minutes. Staining was 
then differentiated with running tap water and the sections were dehydrated 
through graded ethanol (70% and 100%) into xylene and mounted in DePeX, 




Figure 2.11 Safranin-O Fast green stained section of a tibia. Scale bar = 50µm. 
 
2.7.1.3 Alcian blue-pas 
Toluidine blue, Safranin-O and alcian blue are cationic dyes. Alcian blue with 
the periodic acid Schiff (PAS) reaction is widely used in histological studies of 
connective tissue for both light and electron microscopy (Ippolito et al., 1983, 
McIlwraith and Van Sickle, 1981). There are extensive investigations in in-
vitro studies of the chemical interactions of GAGs with alcian blue (Scott and 
Dorling, 1965). The PAS reaction is used to indicate the presence of 
carbohydrates in tissues. The reaction occurs by oxidative cleavage of the 
carbon-to-carbon bond in 1.2-glycols or their amino or alkylamino derivatives 
by periodic acid, thus resulting in dialdehyde formations (Mepham, 1991). 
These aldehydes react with fuchsin-sulphurous acid, combining with the basic 
pararosaniline to give the magenta colour (Stoward, 1967). 
The tissue parts (non-calcified cartilage) that stain blue to bluish green in the 






that contain neutral mucins stain magenta (calcified cartilage). A mixture of the 
above stain the underlying bone bluish-purple and the nuclei appear dark blue. 
3DUDIILQ ZD[ HPEHGGHG VHFWLRQV ZHUH FXW XVLQJ WKH PLFURWRPH ȝP WKLFN
sections were first dewaxed in xylene and then rehydrated in graded ethanol 
(100%, 96% and 90%) before being washed in distilled water twice for 5 
minutes. Sections were then immersed for 5 minutes in acetic acid solution, 
and incubated in alcian blue for 1 hour. Sections were then rinsed for 5 minutes 
in running tap water and distilled water. They were then immersed in periodic 
acid solution for 10 minutes and rinsed thereafter for 5 minutes in distilled 
water. Sections were subsequently immersed in Schiff reagent for 15 minutes 
and rinsed thereafter for 5 minutes in distilled water. The sections where then 
dehydrated through graded ethanol (90%, 96% and 100%) into xylene and 
mounted in DePeX, then covered with cover-slips and allowed to dry. 
 
Figure 2.12 Tibia plateau with Alcian blue PAS stain. Scale bar = 100µm 
Acidic mucins stain 
blue (alcian blue) 











2.7.2 Enzyme histochemistry 
Enzyme histochemistry is one subclass of histochemistry. In general, enzymes 
are the proteins being studied in enzyme histochemistry and are the rate 
determining factor for most biochemical reactions. 
2.7.2.1 Tartrate resistant acid phosphatase (TRAP) 
Tartrate resistant acid phosphatase (TRAP) is a histochemical marker for 
osteoclasts, and is involved in diverse pathological conditions to include hairy 
cell leukaemia, AIDS, encephalopathy, OA etc. (Summers and Jaffe, 2011, 
Schindelmeiser et al., 1989, Sagar et al., 2014). It is also expressed by other 
mono histocytes such as macrophages. These cells express the band 5 isozyme 
of TRAP (Minkin, 1982). Expression of TRAP is associated with the activation 
and differentiation of osteoclasts. Commercially available TRAP test kits have 
been designed to detect TRAP on osteoclast. The TRAP enzyme is higher in 
GLVHDVH FRQGLWLRQV ZKHUH ERQH EUHDNGRZQ LV HQKDQFHG HJ 3DJHW¶V GLVHDVH
hyperthyroidism and OA (Lau et al., 1987, Chamberlain et al., 1995, Sagar et 
al., 2014). 
3DUDIILQ ZD[ HPEHGGHG VHFWLRQV ZHUH FXW XVLQJ WKH PLFURWRPH ȝP WKLFN
sections were first dewaxed in xylene and then rehydrated in graded ethanol 
(100% and 70%) before being washed in distilled water twice for 5 minutes. 
Sections were then incubated overnight in a mixture of 1mM CaCl2 and 1mM 
MgCl2 solution, after which they were rinsed for 5 minutes in distilled water. 
TRAP solution was applied on each individual section in a humidified box and 
incubated at 37°C for 1 hour. The TRAP substrate consisted of 2ml acetate 
solution, 2ml Napthol AS-BI phosphoric acid, 2ml Tartrate solution, contents 
of 1 capsule of Fast Garnet GBC salt, all of which were dissolved in 44ml of 
distilled water, stirred and filtered before use. Following incubation, the 
sections were rinsed in tap water and then in distilled water. Acid haematoxylin 
was used to counterstain the sections for 5 minutes and then the rinsing process 
was repeated in both tap water and distilled water before being mounted in 1:1 




The contents of the TRAP solution including Acid Haematoxylin all came 
premade in a TRAP kit (Sigma Aldrich).  
2.7.3 Immunohistochemistry (IHC) 
2.7.3.1 Introduction 
Immunohistochemistry comprises of various methods used to detect tissue 
constituents (antigens such as, amino acids and proteins, infectious agents and 
specific cell populations) when specific antibodies are employed. For example, 
in cell preparations it is known as immunocytochemistry (Matos et al., 2010, 
Coons and Kaplan, 1950).  
The IHC technique consists of two phases: (1) slide preparation and staining: 
specimen fixation, tissue processing and storage, antigen retrieval, non-specific 
site block, endogenous peroxidase block, primary antibody incubation, 
secondary antibody incubation (whether the antibody is conjugated to an 
enzyme example, a peroxidise labelled antibody or is tagged with a 
fluorophore; fluorescein example in immunofluorescence), employment of 
detection systems, counterstaining (optional) and slide mounting; (2) analysis 
and quantification of obtained expression (Matos et al., 2010, Renshaw, 2007).  
2.7.3.2 Limitations, difficulties and problems of IHC  
Although IHC is useful for scientific research and employs relatively simple 
immunostaining techniques, there are some limitations to it and the result 
outcome obtained usually depends on a variety of different factors. The 
usefulness and contribution that IHC brings to scientific research depends on 
the expertise of the experimenter carrying out the IHC technique and the 
observer who interprets the results expressed (Leong and Wright, 1987, Werner 
et al., 2000, Jaffer and Bleiweiss, 2004, Matos et al., 2010). Thus IHC may 
have simple immunostaining methods but it requires efficient execution and in 
order to prevent significant bias, the results obtained should be interpreted with 
caution (Matos et al., 2010). A review presented the different bias that can 
occur with analysing IHC reactions; they are reaction bias and interpretation 
bias (Yaziji and Barry, 2006). In reaction bias, the different conditions are;  
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x Specimen fixation (long periods of tissue fixation may cause tissues to 
lose their antigenicity or some fixations may mask some of the 
important antigens e.g. formalin fixations) 
x  Tissue processing (this may also compromise tissue antigenicity if not 
carried out properly). 
x Antigen retrieval (this helps to unmask antigens in e.g. formalin fixed 
tissues, but this may also damage the tissue structure). 
x Detection systems (the secondary antibody employed and the 
amplification system used; the avidin-biotin peroxidise complex - ABC 
method etc. is among one of the best amplifications systems because it 
is relatively low cost and more flexible).  
In interpretation bias, there are; the types of antibodies to be used, the 
sensitivity of the antibodies selected and their use in the literature 
(interpretation of the outcomes) (Yaziji and Barry, 2006, Shi et al., 2007, 
Rickert and Maliniak, 1989, Giorno, 1984, Matos et al., 2010).  
Irrespective of the limitations, difficulties and problems which may be 
encountered in IHC, the use of immunohistochemical methods in scientific 
research for the diagnosis of pathologic conditions still continues to rise as 
evidenced by the high number of scientific publications that use the IHC 
technique (Matos et al., 2010, Werner, 2005). A way in which this can be 
achieved is by standardizing the IHC methods protocol so as to minimize the 
occurrence of undesirable outcomes (Matos et al., 2010).  
2.7.3.3 Principles of IHC 
Tissues were initially harvested and processed (section 2.6.3) after each study. 
Thin sections were then cut and stained with labelled antibodies. Processing the 
tissue samples are necessary to preserve the tissue architecture and also fix the 
antigen in place so as to protect them from deteriorating or leaking out of the 
tissue during the staining procedure. In this thesis, sections used for IHC were 
cut from unfixed (fresh) frozen tissue samples. The sections were always 
immersed in acetone prior to staining. Acetone is an organic solvent that 
removes lipid molecules while dehydrating cells. It also precipitates protein 
molecules onto the cell surface in the process. There are other crosslinking 
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reagents used for fixation, examples are paraformaldehyde (PFA). Although 
PFA is better at preserving the structure of tissues and cells, it may reduce the 
antigenic properties of some of the cell components due to crosslinking, 
thereby preventing the binding of an antibody. In this case, antigen retrieval 
methods may be applied.    
The fundamental principles of IHC staining are the incubation of tissue 
samples with primary antibodies directed to preferred antigens of interest. The 
binding of these antibodies to form an antigen-antibody complex and the 
detection of said antibodies. There are several methods of visualising bound 
antibody to an antigen; a) direct method, b) indirect method, c) unlabelled 
antibody enzyme method with peroxidase-anti-peroxidase complex (PAP), d) 
immunogold method, e) Avidin biotin complex (ABC) method and f) new 
direct technique (enhanced polymer one-step staining system) (Mepham, 
1991). In this thesis we have used the indirect method with the ABC method.  
The indirect method requires the application of an unconjugated primary 
antibody which is then followed by a labelled antibody directed against the first 
antibody (Figure 2.10). This technique is more sensitive than the direct method 
and relatively cost effective. In this thesis, we used the indirect method. Here 
the labelled secondary antibodies are biotinylated and raised against the 
immunoglobulin G (IgG) of the animal species of which the primary antibodies 
were raised. This enables the reaction between both primary and secondary 
antibodies. The specific antigen-antibody complex formed due to the above 
interactions can be visualised using the ABC method (Hsu and Raine, 1981).  
The ABC method greatly depends on the affinity of the glycoprotein avidin for 
the low molecular weight vitamin, biotin. Avidin is made up of four subunits in 
a tertiary structure possessing four biotin-binding hydrophobic pockets, thus 
amplifying the antigen-antibody signal (Mepham, 1991). Biotin (Vitamin H) 
easily binds to antibodies and enzyme markers and up to 150 biotin molecules 
can bind to one antibody molecule. Labelled variants of the avidin ±biotin 
system include peroxidase and alkaline phosphatase which directly bind avidin 
or streptavidin (Guesdon et al., 1979). Alternatively, the enzymes maybe 
labelled with biotin and three-quarter of the avidin binding sites are then 
occupied by the biotinylated label to form the avidin-biotin complex (Hsu and 
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Raine, 1981). As a number of biotins attach a single antibody, it enables the 
labelled avidin molecules to bind to it. This results in increased sensitivity 
compared to the techniques previously mentioned. In other to be able to 
visualise ABC, it can be developed by incubating with diaminobenzidine 
(DAB) substrate to give a brown coloured stain. Furthermore, the DAB stain 
can be enhanced using the enzyme glucose oxidase and nickel to obtain a final 
deep purple to black colour (Shu et al., 1988). 
 


























Figure 2.13 Indirect immunohistochemistry. Indirect method, biotin labelled 
secondary antibody binds the unconjugated primary antibody (A). Avidin-biotin 
complex method, the biotinylated secondary-primary antibody complex is detected 
with the preformed avidin-biotin complexes (B). Four biotin vitamins bind with high 
affinity to one avidin glycoprotein, thus intensifying the antigen-antibody signal. 
Peroxidase (P), antigen (Ag). 
 
2.7.3.4 Staining procedures 
Unfixed fresh frozen tissues were used. All tissue samples were sectioned to 
5µm thickness in this thesis unless otherwise stated. Details of primary and 
secondary antibodies can be found in the appendix. Synovial sections were cut 
using a motorised cryostat, mounted on diagnostic microscopic slides and 
briefly air dried. Preparations were mounted in DePeX. Unfixed tissue sections 
were fixed firstly in acetone for 10 minutes at 4°C and washed twice for 5 
minutes in 0.01M PBS, pH 7.4. The sections were then incubated for 30 










as to block the effect of endogenous peroxidase and thus reducing the chances 
of false positive reactions (Streefkerk, 1972). After the blocking step, they 
were rinsed twice in 0.01M PBS for 5 minutes. 
Primary antibodies to macrophage clone ED1, ED2 or ED3, were initially 
diluted in 0.01M PBS with 5% bovine serum albumin (BSA) and 3.3% normal 
serum obtained from the species in which the secondary antibody was raised. 
These antibodies were applied onto sections and left for 1h in a humidified 
box, after which the sections were rinsed twice in 0.01M PBS for 5 minutes. 
The secondary antibody was then applied onto the sections and the sections 
placed in a humidified box for 45 minutes at room temperature. After which 
they were then rinsed twice in 0.01M PBS for 5 minutes. ABC was then 
applied in the required concentration to the sections and incubated for 30 
minutes at room temperature. ABC was made 30 minutes and left to stand at 
room temperature before use. ABC peroxidase comes in a kit containing 
solution A and B. depending on the number of sections needed to be stained, 
ABC was made appropriately. 100µl of solution A was added to 5ml 0.01M 
PBS and mixed by vortexing, the same volume of solution B was then added to 
the mixture. Following ABC incubation, the sections were rinsed in 0.01M 
PBS twice for 5 minutes. They were then incubated in 0.1M sodium acetate 
buffer solution, pH 4.6 for 5 minutes before being developed with the glucose 
oxidase/nickel DAB solution. The development process was monitored directly 
using a light microscope and the reaction time was mostly at 7 minutes 
maximum, after which the sections were rinsed in 0.01M PBS, thus stopping 
the reaction and then dehydrated in graded alcohols and mounted in DePeX.. 
The glucose oxidase/nickel DAB solution comprised of 25mg DAB in 5ml of 
distilled water, 1.25g di-ammonium nickel II sulphate, 25ml of 0.2M sodium 
acetate buffer (pH 6.0), 20mg ammonium FKORULGH PJ ȕ-D-glucose and 
0.5mg glucose oxidase. The glucose oxidase was always added last minute to 
the solution before been applied to the sections in an incubation box as the 





2.8 IMAGE ANALYSIS AND QUANTIFICATION 
All image analysis and quantification were carried out using a Zeiss Axioscop-
50 microscope (Carl Zeiss Ltd, Welwyn Garden City, UK) with the 
experimenter blinded to experimental group and sections randomised by an 
independent researcher. Images were captured using a video camera (AxioCam 
MRm ZEISS) and analysed using Axiovision image analysis software.  
2.8.1 Synovia 
2.8.1.1 Synovitis 
Using a 20x objective lens, synovitis was scored according to the thickness of 
the synovial lining layer and synovial cellularity as follows;  
Grade 0 = Lining cell layer 1±2 cells thick. Grade 1 = Lining cell layer 3±5 
cells thick. Grade 2 = Lining cell layer 6±8 cells thick and/or mild increase in 
cellularity. Grade 3 = Lining cell layer >9 cells thick and/or severe increase in 
cellularity (Mapp et al., 2008).  
2.8.1.2 Macrophage infiltration 
Using a 20x objective lens, data were obtained from four fields of view on one 
section per rat. The optimum number of fields per section and sections for each 
case had already been determined by Walsh and co (1998a).  The fields were 
chosen dependent on the areas that displayed the highest densities of 
macrophages. Colour transmitted light image of a selected area was captured 
and directly changed to a monochrome image. An outline was then made on 
the surrounding positive area and measured. The image was thresholded 
according to hue to include all positive cells and measured. Macrophage area 
was defined as a percentage of positive synovial area for the subsets of 
macrophages (ED1, ED2, or ED3) (Seegers et al., 2003, Ashraf, 2011, Walsh 
et al., 1998a). 
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2.8.2 Cartilage and subchondral bone 
2.8.2.1 Macroscopic chondropathy scoring 
The severity of loss of articular cartilage integrity for the medial and lateral 
femoral condyles,  tibial plateaus and femoral groove were determined for each 
knee joint by a single assessor blinded to both OA and treatment groups 
immediately following tissue harvesting (Guingamp et al., 1997). All five 
chondral (medial and lateral femoral condyles, tibial plateaux and femoral 
groove) surfaces were photographed using a video camera (model W30X-HD, 
30x zoom full HD (1080p) - Vet Tech solutions limited). Severity of 
chondropathy was analysed directly using a dissecting microscope and later on 
from the photographs. A graded score of 0 to 4 were given as follows: 
Grade 0 = Normal appearance. Grade 1 = Slight yellowish discolouration of the 
chrondral surface. Grade 2 = small cartilage erosions in load bearing areas. 
Grade 3 = Large cartilage erosions extending down to subchondral bone. Grade 
4 = Large cartilage erosions with large areas of subchondral bone exposure. 
The grade from each articular surface was summed to give a total maximum 
possible score of 20 for a joint, with 0 indicating no evidence of chondropathy.  
A detailed explanation of the above method can be found in Chapter 4 of this 
thesis. 
2.8.2.2 Microscopic scoring 
The modified Mankin scoring system is what is mostly used as microscopic 
scoring systems for rat OA (Gerwin et al., 2010). The Mankin scoring system 
was developed from a grading system using femoral heads removed at 
arthroplastic surgery in humans and might not be a suitable method of scoring 
in rats (Mankin et al., 1971). Although modified for use in rats, the scoring 
system restricted the evaluation of OA cartilage changes while a few included 
OA related changes in synovium and bone (Appleton et al., 2007, Yorimitsu et 
al., 2008). Even though we conclude that the Mankin score may not be ideal 
for use in rats, there are still structural features in the cartilage that require the 
use of the Mankin score. In this thesis the monosodium iodoacetate (MIA) rat 
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model which is a model that affects chondrocytes in the cartilage was used 
hence chondrocyte morphology was assessed. The level of GAGs 
(proteoglycan content) in the cartilage was also of interest. The Mankin scoring 
system delineates the grades and criteria needed to measure these features. 
Simplicity, utility, scalability, extendability and comparability are the five 
principles for an ideal cartilage histopathology scoring system. The method 
should be simple, reproducible and easily applied by different investigators. It 
should be a useful assessment of both clinical and experimental OA. It should 
be a method that would correlate easily with cartilage macroscopic appearance. 
It should be a method capable of being applied successfully by qualitative 
assessment and finally, it should be capable of being harmonized with 
histological assessment systems of other cartilage disorders to include those 
associated with cartilage repair (Pritzker et al., 2006). 
The entire lateral and medial tibial plateau (in the case of the MIA model) or 
the medial tibial plateau only (MNX model)  of frontal sections stained with 
H&E were used to assess chondropathy through a ×10 objective lens under 
transmitted light, While Safranin-O fast green or alcian blue was used to assess 
proteoglycan content.  Chondropathy was evaluated using the system of Janusz 
et al., as previously described (Janusz et al., 2002) or the modified OARSI 
osteoarthritis cartilage histopathology assessment system (Pritzker et al., 2006). 
Both scoring methods were tested and validated (detailed explanation in 
Chapter 5).  
Janusz method; cartilage pathology was scored on a scale of 0 to 5 as follows: 
Grade 0 = Cartilage of normal appearance. Grade 1 = Minimal fibrillation in 
superficial zone only. Grade 2 = Mild, extends into the upper middle zone. 
Grade 3 = Moderate, well into the middle zone. Grade 4 = Marked, into the 
deep zone but not to the tidemark. Grade 5 = Severe, full thickness 
degeneration to the tidemark 
The extent of medial tibial plateau involved in the damage was also taken into 
account; 1/3, 2/3 or 3/3. The cartilage damage score was then multiplied by 1, 
2 or 3 respectively to give an overall chondropathy score. 
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OARSI method; cartilage pathology was scored based on a scale of 0±6 as 
follows: 
Grade 0 = normal. Grade 1 = surface intact. Grade 2 = surface discontinuity. 
Grade 3 = vertical fissures (cleft). Grade 4 = erosion. Grade 5 = denudation. 
Grade 6 = deformation 
A stage score (scale of 0±4) indicating the surface extent of joint involvement 
(0 = no activity, 1 = <10%, 2 = 10±25%, 3 = >25±50%, and 4 = >50%) was 
multiplied by the grade to give an overall chondropathy score. 
Integrity of the osteochondral junction was measured as the number of 
channels crossing the osteochondral junction into the articular cartilage per 
millimetre length of the tibial plateau of an H&E stained section using a ×20 
objective lens. Channels were accepted as being in the cartilage if they had 
either entered into the cartilage or were not separated from cartilage by bone. 
To measure the length of the tibial plateau, a digital electronic calliper 
(Miyutoyo UK Ltd., Andover, UK) was used. 
Morphology of chondrocytes and proteoglycan content were scored using the 
Mankin scoring system (Mankin et al., 1971). 
Chondrocyte morphology: 
Grade 0 = Normal. Grade 1 = Hypercellularity. Grade 2 = Cloning (occurrence 
of 2 or more cells with 4 or more nuclei). Grade 3 = Hypocellularity 
Proteoglycan content: 
Grade 0 = Normal. Grade 1 = Mild loss. Grade 2 = Moderate loss. Grade 3 = 
Severe loss. Grade 4 = Complete loss 
2.8.2.3 TRAP (osteoclast) counting 
Tartrate resistant acid phosphatase (TRAP) positive osteoclast cell counting 
was developed in-house (Luting Xu). The effective area to count was from one 
end of the growth plate to the other end, underneath the cartilage and/or around 
the bone marrow cavities. In the event of cartilage break down under 
pathological conditions, cells in between the bone marrow circles were 
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counted. A positive osteoclast cell was always found in a dark purplish or 
reddish area and was counted if it had least 3 or more nuclei. The cells and area 
to count was initially visualised under a 4x objective lens but counted at x20 
magnification. In cases where 2 nuclei aggregates shared a positive stained area 
border and the cell membrane was discernible between them, this was counted 
as 2 osteoclasts. Also, in cases when the stained area was too dark to identify 
the number of nuclei, the size of the area was compared to the negative cells 
adjacent to it. If it was larger than twice of the adjacent cells, it was counted 
one positive osteoclast. Light stained area with no identifiable nuclei was never 
counted. 
2.9 STATISTICAL ANALYSIS 
Synovial inflammation, lining thickness and cellularity were scored as 
previously described, one synovial section per rat and overall grade that best 
represented the section given (Ashraf et al., 2011a). Infiltration by 
macrophages was quantified on 4 fields of view per synovial section per rat 
(Walsh et al., 1998a). Data for each experiment were presented graphically as 
mean ± SEM and analysed using Prism V.6 (GraphPad, San Diego, California, 
USA). The different groups were compared using non-parametric tests either 
Mann-Whitney U test when only comparing two groups or Kruskal Wallis tests 
with SRVWKRF'XQQ¶V WHVW  ZKHQFRmparing more than two groups). Weight 
bearing asymmetry and PWT data were firstly analysed using area under the 
curve (AUC). Numerical data were presented as mean (95% confidence 
interval - CI) or median (Interquartile Range - IQR). Associations between 
variables were analysed using Statistical package for the Social Sciences v.21 
(SPSS Inc., Chicago, Illinois, USA). Data weUH SUHVHQWHG DV 6SHDUPDQ¶V
correlation coefficients. A two-tailed P value of less than 0.05 was taken as 
significant in all cases. 
Sample Size 
A power calculation was performed to determine the minimal number of rats 
required to test for a significant difference in the data. A power of 80% was 
decided to show a difference of 10% at P value of 0.05. Pilot data was used to 
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determine mean and standard deviation. The formula used was; (u + v)2 ı12 + 
ı12   ȝ12  ȝ12), where u is the one sided percentage point of the normal 
distribution corresponding to 100% minus the power. In this case 100-80 = 
20%, so u = 0.84. V is the percentage of the normal distribution corresponding 
to the two sided significant level. In this case the significant level used was 5% 
LHS  VRY ı LV VWDQGDUGGHYLDWLRQDQGȝ LV WKHPHDQ6DPSOH
size was increased from n = 6 to n = 10 following power calculations. 
2.10 REAGENTS 
Monoclonal antibodies to macrophages (clone ED1, ED2 and ED3) were from 
Serotec (Oxford, UK). Biotinylated rat-adsorbed horse anti-mouse antibody 
(BA 2001) and avidin-biotin complexes (Vectastain Elite ABC Kits) were from 
Vector laboratories (Peterborough, UK). DePeX mounting medium, Schiff 
reagent and PBS were from VWR Ltd (Lutterworth, UK). OCT®, Mayers and 
Harris haematoxylin and eosin were from Raymond Lamb (Eastbourne, UK). 
Carrageenan, BSA, Tris, EDTA, tartrate resistant acid phosphatase (TRAP) kit, 
neutral buffered formalin, formic acid, PFA, alcian blue, periodic acid and 
other chemicals were obtained from Sigma-Aldrich (Poole, UK). AR456786-
06 and Gelucire (vehicle) compounds were kindly provided by Array 
Biopharma (Colorado, USA) for use in collaboration.  
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CHAPTER 3; THE CARRAGEENAN MODEL 
OF INFLAMMATORY ARTHRITIS 
3.1 INTRODUCTION 
Osteoarthritis (OA) is primarily thought to be a degenerative disease; however, 
more often observed through imaging and histology (Ayral et al., 2005, 
Scanzello and Goldring, 2012), inflammation is increasingly recognized as 
being a major contributor to the pathology of OA hence making it clinically 
important in OA. Synovitis is a feature of OA and is characterised by marked 
hyperplasia of the lining cells of the synovium, infiltration by inflammatory 
cells such as macrophages, a subset of B and T cells, mast cells and natural 
killer cells (Sokolove and Lepus, 2013). Synovitis can be both episodic (flares 
characterized by local warmth, tenderness and effusion) and persistent (Bonnet 
and Walsh, 2005, Mapp and Walsh, 2012). Inflammation under physiological 
conditions is needed to maintain homeostasis. It does this by controlling tissue 
damage which can occur as a result of traumatic, pathogenic and toxic insults 
or injury (Benelli et al., 2006). The initial response to cellular injury is known 
as acute inflammation. Acute inflammation occurs rapidly within minutes of 
trauma occurring and is characterised by coagulation, increased blood flow and 
vascular permeability at the affected site, which resolves with time. Chronic 
inflammation is prolonged inflammation characterised by release of 
inflammatory cells, blood vessel growth (angiogenesis), neovascularization etc. 
Development of chronic inflammation in OA is understood as a recurring 
vicious cycle of tissue damage, inflammation and repair (Dallegri and 
Ottonello, 1997, Scanzello et al., 2008).  
Carrageenan (Sigma Aldrich) is often used in research to induce tissue 
inflammation. Carrageenan is one of a family of linear sulphated 
polysaccharides obtained from red seaweed. There are three main commercial 
classes of carrageenan; kappa, iota and lambGDȜ,QWUD-DUWLFXODULQMHFWLRQRIȜ
carrageenan in rat knees induces synovitis in the rat knee and pain behaviour 
when injected into the foot (Lam and Ferrell, 1991, Lam and Ferrell, 1989, 
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Walsh et al., 1998a). Histological evidence of synovitis is represented by 
increased synovial lining thickness, macrophage infiltration and angiogenesis 
(Mapp and Walsh, 2012).  
Macrophage precursors originate in the bone marrow as monocytes, when 
monocytes are released into the peripheral blood, they circulate for a few days 
before becoming localized to different tissues, where they undergo 
differentiation into macrophages (Dijkstra et al., 1985, Gordon and Taylor, 
2005). Different subpopulations (immature resident or mature resident) of 
macrophages can be distinguished by different monoclonal antibodies (Kool et 
al., 1992, Richards et al., 1999). The monoclonal antibody ED1 identifies 
immature resident or exudate macrophages while ED2 and ED3 monoclonal 
antibodies identify mature resident macrophages. ED1 is the rat homologue of 
human CD68 a single chain glycoprotein of 90-110 kDa. CD68 
immunoreactivity is mostly found on the lysosomal membrane of myeloid 
cells. The majority of tissue macrophages express CD68. ED2 recognises 
CD163, a 175 kDa cell surface glycoprotein expressed by about 50% of 
peritoneal macrophages, which are group of macrophages found in the spleen 
and by macrophages in most other tissues. However, monocytes, alveolar 
macrophages or microglia do not express CD163. ED3 recognises CD169, a 
185 kDa molecule expressed by macrophages which are closely associated 
with T cells predominantly confined to lymphoid organs only (Dijkstra et al., 
1985, Richards et al., 1999)). Depending on the local microenvironment, 
macrophages differentiate into M1, which are the classically activated (pro-
inflammatory) form or M2 which are the alternatively activated 
(immunomodulatory and tissue remodelling) form. The M2 form can further be 
subdivided into M2a (alternative), M2b (type II) and M2c (deactivated). The 
antibody clone ED1 (CD68) is a pan macrophage marker that stains all 
phagocytic macrophages, ED2 (CD163) is an M2c macrophage marker and 
ED3 (CD169) is known to be expressed by activated macrophages in chronic 
inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, HIV etc. 
(Ito et al., 2014, Hartnell et al., 2001, van der Kuyl et al., 2007). Evidence 
suggests that the ED3 (CD169) marker is not restricted to all M1 macrophages 
but is rather a marker of interferon (IFN)-induced inflammatory M1 
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macrophages (Ohnishi et al., 2013). High expressions of CD169 in IFN-
stimulated M1-type human macrophages were observed from peripheral blood 
mononuclear cells.  
All three macrophages markers have been reported to be expressed in complete 
Freund's adjuvant (CFA) ± induced rat knees (Dijkstra et al., 1987) and the 
ED1 antigen expressed in carrageenan induced rat synovium but the ED2 and 
ED3 macrophage markers have not been reported to be expressed in the rat 
synovium in the carrageenan model. 
Synovitis is reported to play an important role in driving OA pathology 
(Bondeson et al., 2010). There is evidence from imaging studies that suggest 
the role of synovitis in structural degradation of the OA joint (Ayral et al., 
2005, Roemer et al., 2009, Atukorala et al., 2014). Synovitis contributes to OA 
pathology and has also been reported to contribute to OA pain. Imaging studies 
have reported possible associations between synovitis and pain (Torres et al., 
2006, Hill et al., 2007, Baker et al., 2010). Synovitis might contribute to pain 
by the release of pain related mediators e.g. serotonin, substance P (SP), 
prostaglandin E2 (PGE2), bradykinin, leukotriene B4 (LTB4),  nerve growth 
factor (NGF) etc. which act on pain receptors on sensory nerves, sensitizing or 
activating them. Studies have shown that the carrageenan model including the 
kaolin/carrageenan-induced model have a neurogenic component as reduced 
responses to carrageenan-induced inflammation was observed after surgical 
denervation or capsaicin pre-treatment (Lam and Ferrell, 1991, Neugebauer 
and Schaible, 1990). Neurogenic and acute inflammation caused by these 
models leads to sensitization of spinal neurons with input from the inflamed 
joint as the neurons in the joint showed altered responses to stimulation (Lam 
and Ferrell, 1989, Neugebauer and Schaible, 1990). Altered responsiveness to 
stimulation were also observed in non-inflamed regions of the leg in these 
models, showing expansion of the receptive field of these neurons (Neugebauer 
and Schaible, 1990). This allows for pain measurements of secondary allodynia 




The carrageenan model was reported to cause a reduction in weight bearing by 
the affected limb (Valenti et al., 2010a) and reduced paw withdrawal threshold 
(Lee et al., 2013b) when injected to the joint. The macrophage markers ED1, 
ED2 and ED3 have been used extensively but none of these studies have 
investigated their associations to synovitis and pain behaviour in this model or 
elsewhere.   
The hypothesis was that intra-articular injection of carrageenan into the knee 
would induce acute inflammation (seen as joint swelling, synovitis with ED1, 
ED2 and ED3 macrophage expression) and increased pain behaviour (weight 
bearing asymmetry and reduced hind paw withdrawal threshold) and that 
associations between synovitis and pain may be as a result of macrophages. 
 
3.2 AIMS 
x To characterise the effect of intra-articular injection of carrageenan on 
pain behaviour and inflammation. 
x To investigate ED1, ED2 and ED3 macrophage expression in the 
synovium of carrageenan injected rats. ED2 and ED3 markers have not 
been explored previously in the synovium of carrageenan rats. 
x To explore possible associations between pain behaviour, synovitis and 




Refer to Chapter 2 for general methodology. Experiments were carried out on 
male Sprague Dawley rats (Charles River, UK) n = 25, weighing 220-370g at 
time of carrageenan injection. This chapter consists of two studies.  
Induction of inflammatory arthritis 
25 male rats were anaesthetised with isoflurane mixture (2% in O2) and then 
given intra-articular injections of either 50µl of 2% carrageenan (Lam and 
Ferrell, 1989, Walsh et al., 1998a)  in sterile 0.9% saline or 0.9% saline into 
their left knee joints (n=22) or 0.9% normal saline into their right knee joints 
(n=6). Naïve rats (n=3) were also anesthetised but not injected. Study 1 
investigated the effect of intra-articular carrageenan for 24h while study 2 went 
up to 3 days post injection (Fig. 3.1). 
Pain measurements 
Pain behaviour was measured as hind limb weight-bearing asymmetry and 
distal allodynia to punctuate stimulation of the hind paw using von Frey 
filaments (Semmes-Weinstein monofilaments 1 - 15g). Measurements were 
taken pre-injection and also at 2h, 6h, 24h, 1, 2 and 3days post injection.  
Tissue collection 
At end of each study, rats were killed by a rising concentration of CO2. 
Synovia with patella from the rat joints were then harvested and immediately 
snap frozen in isopentane on day 3 for histology and immunohistochemistry. 
Frozen synovial tissues were stored at -80°C until when needed. The controls 
used were the saline injected right knees and naïve un-injected knees.  
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Figure 3.1 Time course of carrageenan induced inflammation and pain behaviour 
Rats were habituated to pain assessment (incapacitance meter and von Frey box) for 2 
days prior to baseline measurements. 2% carrageenan or saline was injected intra-
articular at time point 0. Knee diameter and pain behaviour measurements were taken 
prior to injection, then at 2h, 6h, day 1, day 2 and day 3 post injection. Weights of rats 
were measured at similar time points except at 2h and 6h.  Synovia harvesting was 
carried out day 1 and day 3 post injection 
  
Weight, knee diameter, weight bearing and von Frey measurements 
50ul of 2% 
Carrageenan or 





0h 2h D-2, D-1 
Groups: Carrageenan n = 14, Saline n = 14 and 








Inflammation was assessed as joint swelling, synovial histological score and 
macrophage infiltration.  
Knee diameter (joint swelling) of the right and left knee joints were measured 
at 2h, 6h, days 1, 2 and 3 post intra-articular injection. 
Synovial sections (5µm), 1 section/rat were stained with haematoxylin and 
eosin (H&E) to assess its lining thickness and cellularity (Mapp et al., 2008). 
Synovitis scoring was performed using a 20× objective lens of a Zeiss 
Axioscop-50 microscope (Carl Zeiss Ltd, Welwyn Garden City, UK).  
Macrophage infiltrations were assessed in synovial sections stained by 
immunohistochemistry. Frozen synovia sections (5ȝPWKLFNZHUHSODFHGLQ a 
trough containing cold acetone for 10 minutes to fix the sections. They were 
then washed in PBS twice for 5minutes and then endogenous peroxidase 
blocked by placing in hydrogen peroxide/methanol (1:4) solution for 30 
minutes. Mouse monoclonal primary antibodies for ED1 (1:1000), ED2 
(1:1600) and ED3 (1:400) were applied to each individual section for 1h. 
Biotinylated horse anti-mouse (1:100) was added for 45 minutes. Sections were 
then placed in ABC peroxidise solution for 30 minutes and then 0.1M sodium 
acetate solution for 5 minutes. Nickel DAB solution was made and applied 
following the sodium acetate and incubated until desired endpoint (Shu et al., 
1988). PBS washes were done at room temperature twice for 5 minutes in 
between steps except for the sodium acetate and Nickel DAB step. After PBS 
wash, staining was then differentiated with running tap water and the sections 
dehydrated through graded ethanol (70% and 100%) into xylene and mounted 
in DePeX and covered with cover-slips. ED2 and ED3 macrophages had never 
been stained in the carrageenan synovium. Normal rat spleen was reported to 
express ED2 and ED3 macrophages (Denham et al., 1990), therefore the rat 
spleen was used as a positive control in this experiment (Fig. 3.8). Negative 





Synovial inflammation, lining thickness and cellularity were scored as 
previously described, one synovial section per rat and overall grade that best 
represented the section given (Ashraf et al., 2011a). Infiltration by 
macrophages was quantified on 4 fields of view per synovial section per rat 
(Walsh et al., 1998a, Walsh et al., 1998b).  
Data for each experiment were presented graphically as mean ± SEM or 
median and analysed using Prism V.6 (GraphPad, San Diego, Carlifornia, 
USA). The different groups were compared using the non-parametric Kruskal-
:DOOLVWHVWIROORZHGE\SRVWKRF'XQQ¶VWHVWIRUHDFKSDUDPHWHU A two-tailed p 
value of less than 0.05 was taken as significant in all cases. Numerical data 
were presented as mean (95% CI) or median (IQR). 
Data for correlations between variables were obtained using scores observed at 
and after day of sacrifice for all groups of rats and analysed using Statistical 





Two studies were carried out in this chapter. Study 1 investigated the effect of 
intra-articular carrageenan for 24h while study 2 went up to 3 days post 
injection 
3.4.1 Effect of intra-articular injection of carrageenan  
3.4.1.1 Body weight 
Rats given 50µl carrageenan or saline into their left knee joint had equal 
weights (Fig. 3.2A). Those given carrageenan or saline into their left and right 
knee joints respectively had higher weights than the naïve rats. The weights of 
these rats on day 0 when the treatments were given were already higher than 
the naïve rats, and continued to increase with no loss in weight (Fig. 3.2B).  
 
Figure 3.2 Weight gain of rats 
Bar graph shows mean ± SEM of weights from carrageenan or saline injected rats (n = 
8). Line graph shows mean ± SEM of weights from carrageenan (left knee - Ŷ) and 
saline (right knee) injected rats (n = 6) and naïve rats (n = 3 - Ƒ) 
 
A B 
Study 1 Study 2 
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3.4.1.2 Pain behaviour 
Weight bearing asymmetry (%) increased from 6h after carrageenan injection 
and this was significant at 24h [7 (4.5 ± 9.4)] compared to saline injected rats 
[1.2 (0.2 to 2.1) p<0.01] (Fig. 3.3A). 
Weight bearing asymmetry (%) significantly increased at 6h following intra-
articular injection of 2% carrageenan [17 (6 to 28)] compared to naïve controls 
[-1 (-7 to 5) p<0.05]. The significant increase in weight bearing asymmetry 
was maintained at a plateau till day 3 [19 (3 to 35)] v [2 (-0.2 to 5) p<0.05] 
(Fig. 3.3B).  
Hind paw withdrawal threshold (g) was significantly reduced at day 3 post 
carrageenan injection [3 (1 to 5)] compared to saline-injected [9 (5 to 12) 




Figure 3.3 Effect of intra-articular injection of 2% carrageenan on weight 
bearing asymmetry  
Pain behaviour was measured in two separate experiments as a % difference in weight 
bearing between left and right hind limb from 0 to 24h (A) or 0 to 3 days (B) after 
carrageenan injection. Intra-articular carrageenan (Ŷ) injection induced weight bearing 
asymmetry compared to saline injected (A - ż) or naïve rats (B - Ƒ). Data are 
expressed as mean ± SEM, carrageenan (n = 8) and saline (n = 8) (A) or carrageenan 
(left knee) and saline (right knee) injected rats (n = 6) and naïve rats (n = 3) (B). 
Differences between groups were analysed using a Mann Whitney-U test. **p<0.01 
compared to saline and +p<0.05 compared to naïve controls. 





Figure 3.4 Effect of intra-articular injection of 2% carrageenan on paw 
withdrawal threshold 
Pain behaviour was measured in two separate experiments as a rapid lifting of the paw 
when von Frey filaments were applied from 0 to 24h (A) or 0 to 3 days after injection 
(B). Intra-articular carrageenan (Ŷ) injection induced paw withdrawal threshold 
compared to saline injected (B - ż) or naïve rats (B - Ƒ).  Data are expressed as mean 
± SEM, carrageenan (n = 8) and saline (n = 8) (A) or carrageenan (left knee) and 
saline (right knee) injected rats (n = 6) and naïve rats (n = 3) (B).  Differences between 
JURXSVZHUHDQDO\VHGXVLQJD.UXVNDO:DOOLV WHVWZLWK'XQQ¶VPXOWLSOHFRPSDULVRQ













3.4.1.3 Acute inflammation 
Knee joint diameter (joint swelling) increased following intra-articular 
injection of 2% carrageenan and was significantly different to saline injected 
rats within 3 to 24h of administration (Fig. 3.5A). Joint swelling was also 
increased in another group of carrageenan injected rats [0.4 (0.3 to 0.6) mm] 
and was significantly different at day 2 compared to naïve controls [-0.003 (-
0.07 to 0.06) mm, p<0.05] (Fig. 3.5B).  
Normal rat synovium lining region is 1-2 cells thick but 3 days after intra-
articular injection of 2% carrageenan, there was increased synovial lining 
thickness with intense cellular infiltration. Carrageenan induced a significant 
increase in synovial inflammation compared to naïve controls [3 (2 to 3)] v [0 
(0 to 1) p<0.05] (Fig. 3.6).  
Synovial macrophage fractional area (%) was higher for rats that received 
intra-articular carrageenan compared to normal saline and naïve controls. ED1; 
carrageenan [31 (15 to 47)] v saline [10 (6 to 15) p<0.05] v naïve [12 (5 to 19) 
p<0.05], ED2; carrageenan [33 (29 to 37)] v naïve [26 (22 to 30) p<0.05] and 
ED3; carrageenan [44 (36 to 51)] v saline [21 (14 to 28) p<0.05] v naïve [14 (9 





Figure 3.5 Effect of intra-articular injection of 2% carrageenan on joint swelling 
(Knee diameter).  
Joint swelling representing acute inflammation was measured as an increase in knee 
diameter using an electronic knee calliper from 0 to 24h (A) and 0 to 3 days (B) after 
injection. Increased joint swelling for carrageenan (Ŷ) injected rats compared to saline 
injected (A - ż) or naïve rats (B - Ƒ).  Data are expressed as mean ± SEM, carrageenan 
(n=8) and saline (n = 8) (A) or carrageenan (left knee) and saline (right knee) injected 
rats (n = 6) and naïve rats (n = 3) (B).  Differences between groups were analysed 
using a Mann Whitney-U test. * or +p < 0.05, **p<0.01, ***p<0.001 compared to 



























Figure 3.6 Histologic changes after intra-articular injection of 2% carrageenan  
Synovium from carrageenan-injected rats showing an increase in synovial lining 
thickening (red arrow), with an intense increase in cellular infiltration. Synovia from 
saline-injected and naïve rats showing normal histologic appearances with a thin 
lining region, 1-2 cells deep (black arrows) and sparse number of cells. Scale bar = 
100µm. Data are expressed as median, carrageenan (n = 6), saline (n = 5) and naïve 
synovia (n = 5).  Differences between groups were analysed using a Kruskal Wallis 




















Figure 3.7 Macrophage infiltrations after intra-articular injection of 2% 
carrageenan  
Synovium from carrageenan-injected rats showing dense infiltration by ED1-
immunoreactive macrophages (black dots). Synovia from saline-injected and naïve 
rats showing sparse infiltration by ED1-immunoreactive macrophages (black dots). 
Red arrows indicate synovial lining. Scale bar = 100µm. Data are expressed as mean ± 
SEM, carrageenan (n = 6), saline (n = 6) and naïve synovia (n = 6).  Differences 
EHWZHHQ JURXSV ZHUH DQDO\VHG XVLQJ D .UXVNDO :DOOLV WHVW ZLWK 'XQQ¶V PXOWLSOH



























Figure 3.8 ED2 and ED3-immunoreactive macrophages in normal rat spleen  
Positive staining for ED2 in red pulp (rp) of spleen and negative stain in the white 
pulp (wp). Positive staining for ED3 on the rim of the periarteriolar lymphoid sheet 
(PALS), follicle (f) and marginal zone (mz) as well as some staining of the red pulp of 





























Figure 3.9 Macrophage infiltrations after intra-articular injection of 2% 
carrageenan  
Synovium from carrageenan-injected rats showing dense infiltration by ED2-
immunoreactive macrophages (black dots). Synovia from saline-injected rats show 
similar infiltration to the carrageenan-injected rats by ED2-immunoreactive 
macrophages (black dots). Naïve synovia showing less intense ED2 infiltration. Red 
arrows indicate synovial lining. Scale bar = 100µm. Macrophage quantification from 
previous published method. Data are expressed as mean ± SEM, carrageenan (n = 6), 
saline (n = 6) and naïve synovia (n = 6). Differences between groups were analysed 
using a Kruskal Wallis test wiWK'XQQ¶VPXOWLSOHFRPSDULVRQp < 0.05 compared to 
















Figure 3.10 Macrophage infiltrations after intra-articular injection of 2% 
carrageenan  
Synovium from carrageenan-injected rats showing dense infiltration by ED3-
immunoreactive macrophages (black dots). Synovia from saline-injected and naïve 
rats showing sparse infiltration by ED3-immunoreactive macrophages (black dots). 
Red arrows indicate synovial lining; blue arrows indicate artefact and not 
macrophages. Scale bar = 100µm. Data are expressed as mean ± SEM, carrageenan (n 
= 6), saline (n = 6) and naïve synovia (n = 6).  Differences between groups were 
DQDO\VHGXVLQJD.UXVNDO:DOOLVWHVWZLWK'XQQ¶VPXOWLSOHFRPSDULVRQDQG:LOFR[RQ
signed rank (paired t-) test respectively. ++p < 0.01 compared to naïve controls, * 





3.4.2 Macrophage markers are associated with 
inflammatory pain 
Associations were observed between synovitis and weight bearing asymmetry. 
Macrophages expressing ED3 were associated with weight bearing asymmetry, 
paw withdrawal threshold and synovitis while macrophages expressing ED1 
were associated with paw withdrawal threshold only. Macrophages expressing 
ED2 were associated with weight bearing asymmetry and synovitis (Table 3.1). 
Table 3.1 Correlations between pain, synovitis and ED macrophage 
markers 
 Weight bearing 
asymmetry 
Paw withdrawal  
threshold 
Synovitis   
Synovitis 0.69* -0.37 NA 
ED1 (CD68) 0.47 -0.53* 0.31 
ED2 (CD163) 0.7* -0.28 0.57* 
ED3 (CD169) 0.82** -0.53* 0.72** 






This present study demonstrated that intra-articular injection of carrageenan 
induced acute inflammation seen as joint swelling, synovitis with macrophage 
infiltration and increased pain behaviour observed as increased weight bearing 
asymmetry and reduced paw withdrawal threshold. An interesting and novel 
finding in this chapter was that macrophages were observed to be associated to 
both synovitis and pain behaviour. 
A constant occurrence in OA is recurrent inflammatory flares (phases). The 
kaolin/carrageenan-induced knee joint arthritis model (K/C arthritis) imitates 
the acute inflammatory phase observed in OA. Injection of K/C into the knee 
causes damage to the cartilage, synovitis and synovial fluid exudates which 
develops rapidly within hours and is maintained for weeks (Neugebauer et al., 
2007). Electrophysiological studies have shown the induction of acute 
inflammation in the joint of cats within 1-3h following K/C injections 
(Neugebauer and Schaible, 1988, Neugebauer and Schaible, 1990). Intra-
articular injection of carrageenan alone is the modified version of the K/C 
monoarthritis model, here the time course of carrageenan arthritis is much 
shorter (hours to days) (Tonussi and Ferreira, 1992, Min et al., 2001, 
Neugebauer et al., 2007).  
Chronic inflammatory arthritis may be characterised by chronic synovitis and 
joint swelling. Histology is a commonly used method for diagnosing synovitis 
(Wenham and Conaghan, 2010). Histology, arthroscopy and imaging studies 
show a marked increase of synovitis in a third of symptomatic OA patients 
(Mapp and Walsh, 2012). Biopsies from these patients exhibit a variety of 
changes in the synovium, which although are more pronounced in the late 
stages of OA, are also present in the earlier stages. These changes include; 
thickening of the lining layer, increased vascularity and inflammatory cell (e.g. 
macrophage) infiltration (Wenham and Conaghan, 2010).  
Intra-articular injection of 2% carrageenan has been shown to induce joint 
swelling and synovitis in the rat knee (Lam and Ferrell, 1989, Lam and Ferrell, 
1991, Walsh et al., 1998a, Valenti et al., 2010b). Similarly in the present study, 
joint swelling and synovitis were observed following carrageenan injection. 
 100 
 
Intense cellular infiltration by macrophages which occurs 3 days after intra-
articular injection of 2% carrageenan is similar to what was previously 
published (Walsh et al., 1998a). In both Walsh et al, 1998 and Valenti et al, 
2010 publications, acute joint swelling was present within 3 days of 
carrageenan injection. This is in line with the present study which showed joint 
swelling within 24h of carrageenan injection and was present until the end of 
the study (day 3).  
A characteristic feature of synovitis is the infiltration into the synovium by 
immune cells such as macrophages. Three days after intra-articular injection of 
2% carrageenan, there was increased infiltration by ED1 immunoreactive 
macrophages. This is similar to what was reported by Walsh and colleagues 
(1998a). Using rat models of antigen-induced arthritis, ED1, ED2 and ED3 
immunoreactive macrophages were seen in the superficial layers of the 
synovium located at the joint space and articular cartilage (Dijkstra et al., 
1987). A similar dense infiltration by ED2 and ED3 immunoreactive 
macrophages at 3 days post carrageenan injection was observed in the 
synovium located at the infra patellar fat pad in the current study.   
Macrophages may be responsible for contributing to maintaining synovial 
inflammation in OA (Bondeson et al., 2010). The implication of synovial lining 
macrophages in OA progression was reported from studies that used liposome-
encapsulated clodronate injections to deplete these macrophages in a mouse 
model of OA (OA was induced by injection of collagenase) (van der Kraan et 
al., 1990, Bondeson et al., 2010). Another study reported the use of clodronate 
injections in depleting ED1, ED2 and ED3 immunoreactive macrophages in a 
rat model of antigen-induced arthritis (Richards et al., 1999). Production of 
proinflammatory cytokines and vascular endothelial growth factor (VEGF) 
show that synovial macrophages are activated in OA as shown by histological 
studies (Haywood et al., 2003, Benito et al., 2005, Bondeson et al., 2010). 
Using model cultures from the OA synovium, it was seen that macrophages 
spontaneously produce pro-inflammatory and anti-inflammatory cytokines 
such as TNF-Į ,/-ȕ ,/-10 including the major matrix metalloproteinases 
(MMPs) and tissue inhibitors of metalloproteinases (TIMPs) (Amos et al., 
2006, Bondeson et al., 2010).  
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The antibody clone ED1 is a pan macrophage marker and thus stains all 
phagocytic macrophages (Damoiseaux et al., 1994) while the clone ED2 stains 
macrophages involved in the resolution of inflammation (Fabriek et al., 2005). 
The clone ED3 stains macrophages involved in chronic inflammation (Hartnell 
et al., 2001). In regards to the above statement on the ED macrophage markers, 
it is highly likely that the ED1 and ED2 but not the ED3 macrophage markers 
would be expressed by macrophages in the carrageenan model of acute 
synovitis. In contrast, all ED macrophage markers were expressed. The 
association of the macrophages expressing ED2 and ED3 to synovitis may 
suggest the involvement of these macrophages in inflammation in this model. 
The association of all 3 markers to either pain phenotypes (weight bearing 
asymmetry or paw withdrawal threshold) may suggest the involvement of 
macrophages in contributing to pain in this model. However, the mechanisms 
by which macrophages contribute to pain behaviour needs further 
investigation. A role of CD163 (ED2) in host immunity is the regulation of 
cytokine release by macrophages (Fabriek et al., 2005). These cytokines may 
then contribute to inflammation and pain. Studies have reported the 
involvement of macrophages in contributing to the development of neuropathic 
pain following peripheral nerve injury (Myers et al., 1996) and that the 
complete or partial depletion of macrophages yield beneficial effects in 
alleviating nerve injury associated chronic pain (Liu et al., 2000, Mert et al., 
2009). 
Pro-inflammatory molecules such as WXPRXU QHFURVLV IDFWRU DOSKD 71)Į
interleukins (IL) etc. released into the joint during synovitis initiate local 
inflammatory vasodilatation and increased vascular permeability thereby 
facilitating inflammation and as a result pain molecules which sensitize or 
activate sensory nerves are in turn released. Intra-articular injection of 2% K/C 
was shown to cause a reduction in weight bearing by the affected limb and 
allodynia in the rat (Andruski et al., 2008). Similarly, intra-articular injection 
of 2% carrageenan caused a reduction in weight bearing by the affected limb 
(Zhang et al., 2004, Kissin et al., 2005, Valenti et al., 2010a). In the present 
study, intra-articular injection of 2% carrageenan induced a weight bearing 
deficit of the ipsilateral limb and a reduced nociceptive threshold to punctuate 
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stimulation of the hind paw thus confirming increased pain sensitivity in this 
rat model. The weight bearing asymmetry observed here develops early with 
significant differences seen at 6h, 1, 2 and 3 days post intra-articular injection 
compared to the paw withdrawal threshold which developed later on, with 
significant differences to saline injected control observed at day 3. This is 
different to what was reported by Lee et al, who reported weight bearing 
asymmetry and reduction in hind paw withdrawal thresholds within 3h of intra-
articular injection of 1% carrageenan (Lee et al., 2013b). The reason for the 
lack of reduced paw withdrawal threshold observed in the present study may be 
because hind paw withdrawal threshold which is driven mainly by central 
sensitization of second order neurons in the spinal cord may occur later on, i.e. 
distal allodynia requires the development and spread of spinal sensitization 
(Schaible and Grubb, 1993, Schaible et al., 2002). Weight bearing asymmetry 
on the other hand is a measure of localised joint nociceptive pain and is usually 
driven by peripheral and central sensitization, thus it may tend to occur earlier 
in this model. Pain in OA may arise from the different tissues (subchondral 
bone, ligaments, muscle etc.) within the joint that contain nociceptive fibres; 
one of such tissue is the synovium. The synovium is richly innervated and can 
be a likely source of nociception in OA (Hunter et al., 2013). Synovitis was 
found to be associated with weight bearing asymmetry. The association 
observed between synovitis and weight bearing asymmetry might be as a result 
of macrophages as the ED macrophage markers were observed to be associated 





Carrageenan induced inflammation is characterised by joint swelling, synovitis 
and infiltration by macrophages expressing ED1, ED2 and ED3 
immunoreactivities.  
Associations of macrophages expressing ED markers with synovitis, weight 
bearing asymmetry and paw withdrawal threshold may suggest the 
involvement of macrophages in contributing to inflammation which can then 
further contribute to nociception and central sensitization.  
The ED1 antibody clone is recommended for use in research studies as it labels 
all active phagocytic macrophages but if the study is specific to chronic 
inflammatory diseases, then the ED3 antibody clone is highly recommended. 
Although this model may have limited validity as a model of human disease, it 
has potential for the screening of novel interventions that aim to modify pain 
and joint inflammation in pathological processes such as arthritis.  
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CHAPTER 4; RELIABILITY, AGREEMENT 
AND VALIDITY OF THE GUINGAMP 
MACROSCOPIC CHONDROPATHY SCORING 
SYSTEM IN RAT MODELS OF OA  
4.1 INTRODUCTION 
In osteoarthritis (OA), histological grading is the gold standard for 
investigating pathological change. Mankin, Janusz and a few others have 
described methods that show sensitivity to changes caused by disease 
pathology (Mankin et al., 1971, Janusz et al., 2002, Pritzker et al., 2006, 
Ostergaard et al., 1999) and a number of ways for the measurement of 
structural changes have been reported. Structural changes to the articular 
cartilage, chondrocyte morphology and loss of matrix components are normally 
detected by histology. Although histological methods are often used in 
characterising structural changes in OA, it is limited by a few disadvantages 
(Table 4.1).  
Table 4.1 OA cartilage histopathology assessment ± pros and cons 
Pros Cons 
Assesses pathology occurring in the 
cartilage 
Requires invasive tissue sampling 
Assesses pathology occurring below the 
cartilage e.g. in the underlying 
subchondral bone 
Time consuming: length of time for tissue 
processing 
Provides insights into chemical and 
cellular changes with the joint 
Assesses one articular surface instead of 
the whole joint 
 
Always requires the use of histological 




Macroscopic chondropathy scoring allows for the gross evaluation of the 
appearance of the joint, and have been mostly developed from arthroscopic 
studies in man (Oakley and Lassere, 2003). Most macroscopic and 
KLVWRSDWKRORJ\DVVHVVPHQWV\VWHPVDUHGHULYHGIURPWKH&ROOLQV¶VFODVVLILFDWLRQ
(Collins, 1950) based on autopsy material of femoral condyles. His 
FODVVLILFDWLRQ LQFOXGHGSDWKRORJLFDOJUDGHVZKLFKURXJKO\IROORZHG)LVKHU¶V
classification (Fischer, 1929), which mainly considered cartilage destruction, 
marginal proliferation and alterations in bony contour. Of this classification 
system, Collins mentioned that his grading system was arbitrary and was in no 
way representing fixed stages of disease progression. Following on from 
Collins, macroscopic grading has since then progressed. 
The Société )UDQoDLVH'¶$UWKURVFRSLH6)$V\VWHP(Dougados et al., 1994) ± 
revised to a simpler score by Aryal et al 1994 (Ayral et al., 1996) builds on the 
Collins classification system. The SFA system is based on an overall 
assessment of severity of change to articular surfaces of the tibiofemoral joint 
in OA and is validated for use across the scale from mild to severe OA 
chondropathy (Dougados et al., 1994, Ayral et al., 1996). The SFA system 
involved reporting the observed severity score on an articular diagram (Fig. 
4.1) dependent on 3 baseline variables; localization, depth and size. 
x Localization: patella, trochlea (femoral grove), medial femoral condyle 
(MFC), lateral femoral condyle (LFC), medial tibial plateau (MTP) and 
lateral tibial plateau (LTP). 
x Depth: based on the classification by Beguin and Locker (Benguin and 
Locker, 1983) (Table 4.2). 
x Size: lesions evaluated as a % of the whole articular surface, which is 
then reported on a special form. 
The SFA score is a continuous variable between 0-100, obtained for each 
compartment and 0-400 for the total score. SFA score = size (%) of each grade 
x severity of grade. Formula is as follows = %( Grade 1 x 0.14) + % (Grade 2 x 
0.34) + % (Grade 3 x 0.65) + % (Grade 4 x 1). 
Most of the other classifications systems to include Outerbridge classification 
reported in a publication on the aetiology of chondromalacia patellae 
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(Outerbridge, 1961) and Pelletier classification (Pelletier and Martel-Pelletier, 
1989) follow the 3 baseline variables criteria. The Outerbridge and Pelletier 
classifications were not used in this thesis because they did not meet the 
criteria required for classification systems to be used in rats. Both systems 
involved measuring the fragmentation and fissuring observed in the cartilage in 
length (cm or mm). This would have not been feasible due to the size of the rat 
knee. 
Use of Indian ink; as described by Yoshioka et al (Yoshioka et al., 1996), 
assesses gross morphological changes after the application of Indian ink. The 
Indian ink method was originally carried out by Meachim on preparations 
made from patellofemoral articulations taken at necropsy done on 29 subjects  
(Meachim, 1972) (Table 4.2). He was looking for a way to indicate how 
minimal fibrillations were initiated and he assessed this using transmitted light 
microscopy. His work showed that articular surfaces with minimal fibrillations 
exhibited a variety of patterns when examined by stereomicroscopy and by 
transmission light microscopy of tangential slices. Macroscopic scoring using 
Indian ink was selected because application of Indian ink to articular surfaces 
makes areas of mild damage more readily apparent than in unstained surfaces. 
Another advantage to its use is its aid in the interpretation of histological cut 
sections after fixation and preparation of tissue. Since the Indian ink is retained 
at the site of cartilage fibrillation, it helps to distinguish between real and 
artefactual irregularities of the articular surface (Meachim, 1972).  
Finally a macroscopic scoring published by Guingamp et al (Guingamp et al., 
1997) was the last of the classification systems chosen because it fits the 
criteria when taking joint size into consideration. It follows the general theme 
of localization and depth (Table 4.2) and it was published for use in the 
monosodium iodoacetate (MIA) model of OA. This classification system is 
graded from 0-4. These grades are for the 6 chondral compartments of the 
knee: patella, femoral groove (FG), LTP, MTP, LFC and MFC, with the grades 
and 6 compartment scores summated for a maximum possible score of 24. 
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Principles of an ideal macroscopic chondropathy scoring system 
Macroscopic chondropathy scoring should be based on the following 
principles; simplicity, feasibility, scalability, validity and discrimination. 
x Simplicity; a system which is simple and reproducible and can be easily 
applied by investigators with varying levels of experience for 
macroscopic scoring.  
x Feasibility; a system that allows for the scoring of articular surfaces 
from photographic recordings by a single observer and 
contemporaneous validation by another observer irrespective of the 
duration of time (often months or years) over which the samples were 
harvested. It must also be easily modifiable based on what is required 
from it e.g. knee joint size of species taken into consideration.  
x Scalability; a system that can be correlated with cartilage 
histopathology and other disease severity. 
x Validity; a system that measures what it intends to measure and can 
show consistency and repeatability by the same observer, between 
observers and between different modes of scoring. 
x Discrimination; a system that has a high sensitivity and can distinguish 
between disease groups and healthy controls or changes over time. 
 
4.2 AIMS 
x To identify a macroscopic scoring system from the literature, that will 
be suitable for use in rat models of OA. 
x To validate this system for reproducibility, to determine inter-observer 
and intra-observer reliabilities. 
x Using this system to explore possible associations with other 




4.3 MATERIALS AND METHODS 
General methodology can be found in chapter 2. Experiments were performed 
on male SD rats (Charles River, Margate, Kent, UK). Two studies were carried 
out for this chapter, and tissues from subsequent studies are also reported here. 
Criteria for choosing the classification systems were based on the method that 
was feasible when taking the small size of the rat knee into consideration as 
compared to the size of a larger animal or human knee. 
4.3.1 Indian ink and modified SFA classification 
This study comprised of 12 Male SD rats, 6 per group (housed 4/cage) 
weighing approximately 200-250g. The rats were anaesthetised with isoflurane 
mixture (2% in O2) and then given intra-articular injections of either 50µl of 
0.1mg MIA or 1mg MIA into their left knee joints.  
Dissection and grading; Two weeks post treatment, all rats were killed by a 
rising concentration of CO2. The left knees of all the rats were dissected and 
examined for gross morphologic changes which included articular cartilage 
surface lesions. Using a dissecting microscope, patella with synovium was 
gently removed and snap frozen in isopentane as previously described. Frozen 
synovial tissues collected at day 14 for histology and immunohistochemistry 
were stored at -80°C until when needed. The controls used were the right un-
injected (contralateral) knees. With a bone cutter, the bone was cut mid femur 
and tibia far away from joint as possible. Scissors was then used to remove 
excess skeletal muscle on either side of the joint so as to see the bone properly. 
The tip of the scalpel blade was then used to cut the lateral and medial 
collateral ligaments. The anterior and posterior cruciate ligaments were also cut 
to slightly free the femur and tibia. Placing the scalpel on the side of the joint 
directly on the meniscus, the scalpel was gently pressed down, watching out for 
the cartilage on the femoral condyle and tibia plateau on the side which the 
blade was placed. The joint was then turned over to the other side and the same 
procedure was applied. When the femur and tibia became freer, the joint was 
gently twisted and sliced completely though the meniscus to disarticulate the 
femur from the tibia. Excess ligament or meniscus left on the bone or cartilage 
surface was removed with a small scissors. Both femur and corresponding tibia 
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bones were placed in PBS and then viewed individually under the microscope. 
The same procedure was applied to the other knee. 
All chondral surfaces, MTP, LTP, MFC, LFC and FG (for both knees) were 
scored using the corresponding scoring sheets i.e. Indian ink, SFA scoring 
sheet (Table 4.2). The SFA scoring system used here was modified to score the 
worst grade observed on an articular surface instead of the percentage damage 
observed for each grade multiplied by the severity of grade for all the grades 
observed on an articular surface as per the original scoring system (Fig. 4.1). 
The reason for this was because the rat knee joint is small in size so it would 
not have been feasible to do this and also scoring the worst grade reflects the 
true state of the joint at the end of the study or at the time of tissue collection. 
Indian ink preparation; The joint was rinsed in PBS and then painted with 
Indian ink diluted in saline. Excess Indian ink was removed with moistened 
cotton. The joint was then placed in a standing position to view the cartilage. 
The painted surface of the cartilage was examined visually at a magnification 
(X10) using a dissecting microscope (Olympus SZ40-SZ-STU1) with reflected 
light from table top lamps. 
After scoring, the joints were then immediately placed in 20ml vials containing 





Figure 4.1 Original SFA scoring from diagrams obtained from photographs of 
human knees.  
The SFA method requires reporting on an articular diagram the macroscopic changes 
based on their location (patella, femoral grove, MTP, LTP, MFC and LFC), depth of 
chrondropathy (from mild to severe) and the size in percentage from 0-100 of lesions 
detected. The SFA score is a continuous variable between 0-100, obtained for each 
compartment and 0-400 for the total score. SFA score = size (%) of each grade x 
severity of grade. Formula is as follows = %( Grade 1 x 0.14) + % (Grade 2 x 0.34) + 






4.3.2 Modified SFA and Guingamp classification 
Knee joint tissues from another study which can be found in chapter 5 were 
used here. 40 Male SD rats, 10 per group (housed 4/cage) and weighing 
approximately 200-250g were anaesthetised and then given intra-articular 
injections of either 50ul of 0.1mg, 1mg MIA or 0.9% saline into their left knee 
joints.  
Dissection and grading; At end of study, rats were killed by a rising 
concentration of CO2. Synovia with patella from the rat joints were then 
harvested and immediately snap frozen in isopentane on day 20 and 42 for 
histology and immunohistochemistry. Macroscopic scoring was carried out in a 
similar procedure as the above, excluding the Indian ink. The controls used 
were the saline-injected knees. After scoring the joints directly using a 
dissecting microscope, the joints were then fixed and after fixation they were 
photographed using a video camera (model W30X-HD, 30x zoom full HD 
(1080p) - Vet Tech solutions limited). The pictures were then graded using the 
modified SFA and Guingamp classifications. 
Note: The complete description of the methodology, behaviour results of the 
rats used in the second study can be found in chapter 5.  
4.3.3 Validation of the macroscopic scoring systems  
Knee joint sections stained with H&E or Safranin-O Fast green were used to 
explore associations between OA structural severity (cartilage damage, 
chondrocyte morphology, osteochondral junction integrity, matrix 
proteoglycan content) and macroscopic scores. H&E stained synovial samples 
were also explored for associations to synovitis. 
In another experiment, knee samples from an intervention study which can be 
found in chapter 6 were used to validate the Guingamp method of scoring. In 
order to evaluate the validity of using photographs for scoring articular surface 
changes, macroscopic scores were compared between direct visualisation and 




Inter and Intra-observer reliability was determined by two independent 
observers (Lilian Nwosu - scorer1 and Pongsatorn Meesawatsom - scorer2), 
who independently derived scores from photographic images of knee joints 
from MIA or saline injected, MNX or sham operated rats. Scorer2 was trained 
and then practised grading 20 photographs of pathological samples.  
 
Statistical analysis 
Statistical analysis was performed using Statistical package for the Social 
Sciences v.21 (SPSS Inc., Chicago, Illinois, USA) or Prism v.6 (Graph Pad, 
San Diego, California, USA). All data were analysed using a one sample t-test 
RUD.UXVNDO:DOOLVWHVWIROORZHGE\SRVWKRF'XQQ¶VFRPSDULVRQ 
Internal consistency for macroscopic chondropathy scoring was determined as 
&URQEDFK¶V DOSKD DQG H[SUHVVHG DV D QXPEHU EHWZHHQ  DQG  (Cronbach, 
1951, Tavakol and Dennick, 2011). The closer to 1 the &URQEDFK¶V alpha was, 
the higher the consistency. Intra observer and inter observer agreements were 
estimated using intraclass correlation coefficients (ICC): intra-rater analysis 
used a one-way random single measures and an inter-rater analysis used a two-
way mixed model, absolute agreement. The reliability was regarded as 
excellent if ICC>0.75, fair to good if 0.4<ICC<0.75, and poor if ICC<0.4 
(Fleiss, 1999, Bruton et al., 2000).  
Reliability between macroscopic scores based on direct visualisation of 
pathological samples and on photographs and between independent observers 
based on photographs was reported using Bland-Altman plots, which is a 
graphical illustration that illustrates limits of agreement and repeatability 
(Bland and Altman, 1986). To construct a Bland-Altman plot, the difference 
between scoring methods (direct and photographs), between scores by an 
observer and scores between observers was plotted on the y-axis against the 
average total between scoring methods (direct and photographs), between 
scores by an observer and scores between observers on the x-axis. Systematic 
error in terms of bias (mean difference) and random error in terms of precision 
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(Mean±2SD) were also calculated to determine agreements between scores 
(Hanneman, 2008).  
Graphs are presented as mean ± SEM or median. Correlations were presented 
DV 6SHDUPDQ¶V UDQN FRUUHODWLon coefficients. A two-tailed p<0.05 was 




Table 4.2 Outline of classification systems used for macroscopic chondropathy scoring of OA 
Grade Indian ink (Meachim, 1972) 
SFA (Dougados et al., 
1994) Guingamp (Guingamp et al., 1997) 
0 Not applicable Normal appearance Normal appearance 
1 (intact surface) surface appears normal and does not retain any ink 
Swelling and/or 
softening 
Slight yellowish discolouration of the 
chondral surface 
2 
(minimal fibrillation) site appears normal before staining, but retains ink as 
elongated specks or light grey patches Superficial fibrillations Little cartilage erosions in load bearing areas 
3 
(overt fibrillation) the cartilage is velvety in appearance and retains ink as 
intense black patches 
Deep fibrillations down 
to bone 
Large erosions extending down to 
subchondral bone 
4 (erosion) loss of cartilage exposing the underlying bone 
Exposure of subchondral 
bone 
Large erosions with large areas of 









Figure 4.2 Example pictures of the Guingamp scoring system for the medial 
femoral condyle of MNX-operated rats. 1: Slight yellowish discolouration of the 
chondral surface. 2: Little cartilage erosions in load bearing areas. 3: Large erosions 
extending down to subchondral bone. 4: Large erosions with large areas of 








4.4.1 Macroscopic chondropathy scoring on 0.1mg or 
1mg MIA injected knee joints 
Intra-articular MIA injection was followed by increased cartilage damage as 
indicated by increased macroscopic chondropathy scores. There were no 
significant differences between macroscopic scores for all the experimental 
groups using the Indian ink direct method of scoring (Fig. 4.3A). Likewise, 
there were no significant differences in macroscopic scores observed between 
the experimental groups using the modified SFA direct method of scoring (Fig. 
4.3B and C), whereas in the photographic method, only the 1mg MIA injected 
rats had significantly higher macroscopic scores compared to the saline 
injected rats (Fig. 4.4A). On the other hand, using the Guingamp photographic 
method, all groups of MIA injected rats had significantly higher macroscopic 
scores compared to the saline injected rats but without significant differences 




4.4.1.1 Direct visual scoring; 
     
 
Figure 4.3 Macroscopic changes, articular surface lesions after intra-articular 
injection of 1mg or 0.1mg MIA.  
Intra-articular MIA injections were given in rat knee joints on day 0. At end of study, 
knee joints were harvested and their articular cartilage surfaces viewed under a 
dissecting microscope. The worst grade for each chondral surface; MTP, LTP, MFC, 
LFC and FG were scored at days 14 (A and B), 20 and 42 (C) after MIA injection. 
Data are expressed as mean ± SEM n = 6 (A), n = 3 (B) and n = 10 (C) knee joints / 






4.4.1.2 Photographic scoring 
 
Figure 4.4 Macroscopic changes, articular surface lesions after intra-articular 
injection of 1mg or 0.1mg MIA.  
Intra-articular MIA injections were given in rat knee joints on day 0. At end of study, 
knee joints were harvested and fixed in formalin before being photographed. Articular 
cartilage surface changes seen in the photographs were then graded. The worst grade 
for each chondral surface; MTP, LTP, MFC, LFC and FG were scored at days 20 and 
42 after MIA injection. In the modified SFA classification, surface lesions were 
present in the D20-1mg MIA injected rats (A). In the Guingamp classification, surface 
lesions were present for all groups (1mg and 0.1mg) and at different time points (20 
and 42days) after MIA induction (B). Data are expressed as mean ± SEM n = 10 knee 
joints / group. Differences between groups were analysed using a Kruskal Wallis test 
ZLWK D 'XQQ¶V SRVW KRF DQDO\VLVS  S FRPSDUHG WR '-saline 




4.4.2 Validity testing of the macroscopic scoring 
systems  
Knee samples obtained from an intervention study (chapter 6) were used to 
further validate the Guingamp method of scoring. MIA injected and MNX 
operated rats both exhibit significantly higher macroscopic chondropathy 
scores compared to their corresponding saline injected and sham operated 
controls either by direct or photographic scoring (Fig 4.5A ± D). Positive 
correlations were also observed between direct and photo scoring methods in 
both studies (Fig. 4.5E and F), whereas the modified SFA method showed no 
correlations between direct and photographic methods of scoring (r = 0.3, p = 
0.06). Fig. 4.6 show results from 2 independent observers using the Guingamp 
photographic scoring method (A and B). Both scorers show higher 
macroscopic scores for MNX operated rats compared to sham operated rats, 
individually and when scores were pooled together (C).  
Positive correlations were also observed between both observers (D). Inter-
UDWHU UHOLDELOLW\DQDO\VLV VKRZHGDFRQVHQVXVRIVFRULQJZLWKKLJK&URQEDFK¶V
alpha values for the Guingamp method between direct and photographic 
methods (0.89 ± 0.93) and between 2 independent scorers by photographic 
method (0.73) (Table 4.3), whereas the modified SFA method showed a lower 
&URQEDFK¶V DOSKD YDOXH RI  *XLQJDPS SKRWRJUDSKLF PHWKRG RI VFRULQJ
displayed good repeatability between measurements by the same observer 
XVLQJ WKH VDPH SKRWRJUDSKV &URQEDFK¶V DOSKD  ± 0.96) (Table 4.3). 
Intraobserver agreement comparing photographic Guingamp scoring methods 
displayed excellent ICCs (0.91 ± 0.96), while inter observer agreement 
between observers displayed a fair to good ICC (0.49) (Table 4.3). The 
modified SFA method displayed poor interobserver agreements between direct 
and photographic scoring methods with an ICC value of 0.38.  
As shown by the Bland-Altman plots (Fig. 4.7), there were no systematic 
differences in the direct and photographic scoring methods, between repeated 
scoring and between observers. Positive correlations were observed between 
macroscopic chondropathy scores and other OA histological severity scores for 






Figure 4.5 Direct (A and C) and photographic (B and D) scoring of macroscopic 
chondropathy in MIA injected (A and B) or MNX operated (C and D) rats by one 
observer (LN). Guingamp photo scoring show similar results to direct scoring (A-D) 
and correlates with the direct scoring for both MIA and MNX models of OA (E and F 
respectively). Scatter plots show mean ± SEM of n = 10 rats/group (A-D). Scatter 
SORWV ZLWK UHJUHVVLRQ OLQH VKRZ 6SHDUPDQ¶V FRUUHODWLRQ FRHIILFLHQWV ( DQG )
Differences between groups were analysed using Kruskal Wallis test followed by post 
KRF 'XQQ¶V FRPSDULVRQ  S S S FRPSDUHG ZLWK VDOLQH-







Figure 4.6 Photographic scoring of macroscopic chondropathy in MNX operated 
(A-C) rats.   
Guingamp photo scoring from 2 independent observers show similar results (A and B) 
and are positively correlated (D). Scatter plots show mean ± SEM of n = 10 rats/group 
(A-&6FDWWHUSORWVZLWKUHJUHVVLRQOLQHVKRZ6SHDUPDQ¶VFRUUHODWLRQFRHIILFLHQWV'
Differences between groups were analysed using Kruskal Wallis test followed by post 
KRF 'XQQ¶V FRPSDULVRQ S S S FRPSDUHG ZLWK VKDP-














Scorer2 MNX Photo 
MIA Direct 0.93 NA NA 
MNX Direct NA 0.89 NA 
Scorer1 MNX Photo NA NA 0.73 
MIA Photo2 0.93 NA NA 










Intra observer agreement 
Measure ICC 95%CI Lower 95%CI Upper 
MIA Photo v MIA Photo2 0.91 0.82 0.96 
MNX Photo v MNX Photo2 0.96 0.92 0.98 
Inter observer agreement 
Measure ICC 95%CI Lower 95%CI Upper 
Scorer1 MNX Photo v 
Scorer2 MNX photo 
0.49 -0.23 0.8 
'LIIHUHQFHVEHWZHHQGLUHFWDQGSKRWRJUDSKLFVFRULQJPHWKRGVDQGEHWZHHQWZRLQGHSHQGHQWREVHUYHUVDUHJLYHQDV&URQEDFK¶VDOSha values and ICC (intra-
class correlation coefficients) and 95% confidence intervals. The closer to 1 the CronbacK¶VDOSKDWKHKLJKHUWKHFRQVLVWHQF\RIVFRULQJ7KHUHOLDELOLW\ZDV






Figure 4.7 Bland-Altman plots illustrating agreement between repeated scoring by 
an observer, different methods of scoring and between observers. The 95% limits of 
agreement contain 93% ± 100% (28/30 ± 30/30) of the difference scores (A ± F). 
Mean+2SD (upper limit of agreement), Mean-2SD (lower limit of agreement), Mean 
(bias ± average of the difference values), values outside the limits of agreements are 









Table 4.4 Associations of macroscopic scores with other OA histological 
severity scores and synovitis 
 









-0.01 0.14 0.37* 
Chondrocyte 
morphology 
0.02 0.08 0.29 
Osteochondral 
junction integrity 
-0.003 0.32* 0.34* 
Matrix proteoglycan 
content 
-0.02 0.37* 0.48** 
Synovitis 0.17 0.16 0.51** 
No associations between modified SFA direct scoring and OA histopathology. 
Associations observed for modified SFA photographic scoring and osteochondral 
junction integrity and proteoglycan scores, whereas by Guingamp photographic 






This chapter investigated macroscopic scoring systems for measuring the 
severity of OA pathology in tibiofemoral joints already in the literature to 
identify one that best suits for use in rat models of OA pain. Three (Indian ink, 
SFA and Guingamp) previously reported methods were selected for the study 
based on the first two been developed for use in humans with the Indian ink 
been applied for use in rats and the Guingamp method developed for use in 
rats. Two (SFA and Guingamp methods) out of the three systems were then 
slightly modified to fit the criteria based on the size of the rat knee and the 
chondral compartments (FG, MTP, LTP, MFC, and LFC) available to assess. 
These systems were based on direct visualisation (using a dissecting 
microscope) and on photographs of pathological samples.  
The findings show that the Guingamp classification method is a reliable 
method of grading macroscopic chondropathy and it establishes good 
agreement and validity when compared to Indian ink and the modified SFA 
methods. The Guingamp direct and photographic methods of scoring were 
more sensitive than Indian ink direct and modified SFA direct and 
photographic methods of scoring as it was able to discriminate between normal 
healthy controls and those with OA disease pathology. It was also able to 
detect associations between OA structural change and histological synovitis. 
The Guingamp scoring method, although not directly comparable to man, does 
display good validity following the range of criteria based on truth, 
discrimination and feasibility as described in the OMERACT filter (Boers et 
al., 1998). Truth; if the system measures what it intends to, discrimination; if it 
can distinguish between groups measured and feasibility; if it can be easily 
applied. 
The Guingamp scoring method based on truth showed good face validity. It 
showed higher severity scores for the disease group compared to the normal 
controls that had lower chondropathy scores. Chondropathy is a major 
pathological process in knee OA and loss of cartilage leads to the exposure of 
the subchondral bone (Walsh et al., 2008). Sensory nerves within vessels in the 
subchondral bone are at risk of being exposed and are prone to sensitization by 
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sensitizing factors (Suri et al., 2007). The photographic scoring system 
reported in humans by Walsh et al (Walsh et al., 2008) addresses both extent 
and severity of chondropathy. In contrast, due to the limitation on knee size, 
the photographic chondropathy scoring system method used in this thesis 
reports only on severity of chondropathy. This system although limited still 
measures chondropathy of the whole joint compared to histological systems 
that measure both extent (involvement of cartilage) and severity but only do so 
on one articular surface and not the whole joint (Janusz et al., 2002, Pritzker et 
al., 2006). 
The use of photographs did not adversely affect the performance of the 
Guingamp classification system when compared to the direct scoring method. 
This is consistent with reports that showed that direct examination of 
pathological samples using instruments did not add to the direct scoring 
methods of chondropathy compared to photographic scoring or arthroscopic 
scoring methods with video assessment (Walsh et al., 2008, Oakley et al., 
2005).  
Abrasions on the cartilage surface and presence of fibrotic tissue are seen as 
roughened surfaces which can be highlighted by the use of a dye. Use of Indian 
ink or Evans blue has been reported extensively as tools for macroscopic 
chondropathy grading (Richardson C et al., 2001, Tessier et al., 2003, Janusz et 
al., 2002). Results from these studies report their effectiveness in highlighting 
fibrillations whether minimal or severe and being able to discriminate normal 
controls from disease groups. This was not the case in this study as the use of 
Indian ink did not discriminate between normal controls and disease group. 
This may have been due to the size of the knee joints of animals used, as the 
studies reported use of rabbits and guinea pigs. The data from this chapter 
suggests that using Indian ink is unnecessary and may even reduce the 
performance of the scoring system compared to the modified SFA or 
Guingamp scoring methods that do not use dyes for scoring.  
The original SFA system was developed for assessing articular surface lesions 
at knee arthroscopy studies in humans. Although the other two systems, use of 
Indian ink and Guingamp classification have been reported for use in animals, 
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the SFA system has only been used in humans. If the modified SFA system 
was reported here as being a useful system for scoring chondropathy in 
animals, direct comparisons on pathology would have been facilitated between 
humans and animals but this did not turn out to be the case. 
The modified SFA system was less sensitive to the Guingamp system as it did 
not discriminate macroscopic pathology between the lower dose (0.1mg) MIA 
injected rats compared to saline injected control rats but only in the higher dose 
(1mg MIA) group using the photographic scoring method. Also it was not 
sensitive at all in discriminating macroscopic pathology in any of the groups by 
the direct scoring method. This may have been as a result of the modifications 
made to the SFA system used here. The original SFA method requires 
reporting on an articular diagram the macroscopic changes based on their 
location, depth and size. Furthermore, the original SFA system has 
multiplication factors giving different weights to the different components 
which results in a total score 0-400  (Ayral et al., 1996). In this thesis, the 
modified SFA gave a score of 0-20 and reported grades of the worst lesions 
observed. Modifications were made to this system based on size differences 
between human and rat knee joints. On the other hand, the Guingamp scoring 
system which showed sensitivity in discriminating between OA disease groups 
from normal saline injected or sham operated controls may be forward 
translated for use in man with comparison to the original SFA scoring system. 
The photographic chondropathy scoring method based on the Guingamp 
scoring system was shown to be a reliable way of scoring macroscopic 
chondropathy consistent with reports on good agreements with direct scoring 
method by an observer and between observers based on the original SFA 
scoring system (Walsh et al., 2008). This highlights the usefulness of 
photographic scoring as a research tool because it allows for measurements to 
be carried out on pathological samples that were collected a long time ago and 
comparison studies to be carried out between observers at different time 
periods. Macroscopic chondropathy scoring of OA should not just be limited to 
scoring by photographic method but should also include scoring by direct 
visualisation method as this provides a better judgement of the depth and 
severity of pathological changes to articular surfaces than from the assessment 
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of photographs. Furthermore, there are other aspects of OA pathology 
(softening of the cartilage or yellowish discolouration of the cartilage) that may 
not be captured by photographic scoring, but it is currently uncertain what 
relevance these components may have to patient symptoms or OA 
pathobiology. 
Bland-Altman plots were carried out because the Guingamp method of scoring 
either directly or through photographs or between observers demonstrated high 
ICCs in repeated measurements and also because it was the appropriate 
methodology for this work, based on existing literature on validation 
methodologies (Hanneman, 2008). In order to obtain a good agreement, the 
scores between direct and photographic methods, repeated by an observer and 
between observers should be equal or nearly equal to each other. Bias (mean 
difference) which represents the measurement differences between the scores 
should be ideally or close to zero (Bland and Altman, 1995, Hanneman, 2008). 
Cone or funnel effects at high mean values of the photo or direct scoring were 
not observed, hence the mean and differences between scoring was said to be 
consistent and thus the limits of agreement reported appropriate. 
Compared to the other two systems (Indian ink and modified SFA), the 
Guingamp method of scoring was observed to be associated more with other 
OA structural severity assessments and with synovitis. Macroscopic 
chondropathy scoring is just one of the methods for measuring OA pathology. 
Assessments by radiography, for example of osteophytes (bony out growths) 
give additional information of pathological changes to the cartilage. 
Histological grading is a widely used method for investigating pathological 
change, and it does provide some insights into chemical and cellular changes 
(Appleton et al., 2007, Yorimitsu et al., 2008). On the other hand, this 
assessment of pathological change is observed only on one articular surface 
compared to the whole knee joint. All three (macroscopy, radiography and 
histology) measuring tools portray different but related aspects of the OA 
process and their associations with each other show that these measuring 
systems share common aspects of assessing OA structural severity and might 
increase the validity of an outcome when used together. Despite this, 
macroscopic scoring was reported to be more effective than radiography, 
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computed tomography ± CT and magnetic resonance imaging ± MRI at 
detecting all the lesions, especially mild changes present in mechanically 
induced OA in rabbit knees (Torelli et al., 2004). 
Synovitis is a characteristic feature of human knee OA. Imaging and 
histological studies report on marked synovitis being present in a third of 
people with symptomatic OA (Haywood et al., 2003, Conaghan et al., 2006).  
It was reported that severity of inflammation increased with structural changes 
to articular surfaces independent of patient group (total knee replacement-TKR 
or post mortem-PM) (Walsh et al., 2008). In this study, an association between 
synovitis and macroscopic scoring using the Guingamp method of scoring was 
observed. Synovitis was found to be associated with radiological joint space 
narrowing (JSN), which is normally regarded as an important marker of OA 
progression (Altman et al., 1987). This association between JSN and synovitis 
may suggest that association between OA severity and synovitis may be as a 
result of cartilage pathology (Walsh et al., 2008). This thesis does not have any 
radiological measurements to back up the associations observed between OA 
severity and synovitis. Further work including radiological measurement would 




Macroscopic chondropathy scoring provides a faster way of obtaining 
pathological results on chondropathy in the knee, as this can be undertaken at 
the end of a study and before tissue fixation and processing for 
histopathological assessments.  
The Guingamp classification system has excellent sensitivity and reliability in 
the measurement of macroscopic chondropathy in rat models of painful OA. 
Similarly this system by photographic scoring method was in good agreement 
with scoring by direct visualisation by an observer and between observers. 
Therefore the Guingamp classification system either by direct visualisation or 
through photographs is an effective method for scoring OA pathology in rats 
and can be used for future studies.  
Associations between macroscopic chondropathy scoring and histological 
scoring despite their low values suggest that other important factors that cause 
pathology in OA may be measured by one or the other. Therefore the use of 









CHAPTER 5; THE MONOSODIUM-
IODOACETATE (MIA) MODEL OF OA PAIN; 
COMPARISON BETWEEN TWO MIA DOSES 
AND TIME POINTS 
5.1 INTRODUCTION 
The monosodium iodoacetate (MIA) model was first described for use by 
Kalbhen in hens and rats to chemically induce degenerative arthritis (Kalbhen 
and Blum, 1977) before its widespread use in other species such as Guinea 
pigs, mice, horses etc. (Williams and Brandt, 1984, van der Kraan et al., 1989, 
Janusz et al., 2001, Penraat et al., 2000). This model involves the intra-articular 
injection of monosodium iodoacetate. The MIA model is widely used because 
of its reproducibility and its rapid development of joint pathology. Intra-
articular injection of MIA into the rat tibiofemoral joint space produces 
pathology (cartilage and subchondral bone pathology) with similarities as that 
seen in human OA knees (Guingamp et al., 1997, Guzman et al., 2003). 
Pronounced pain related behaviours (weight bearing and allodynia ± indicating 
reduced paw withdrawal threshold) are also characteristic features of this 
model (Bove et al., 2003, Combe et al., 2004, Sagar et al., 2010, Fernihough et 
al., 2004). The pain behaviours, weight bearing and reduced paw withdrawal 
threshold represent peripheral and central processing in OA (Christiansen and 
Stevens-Lapsley, 2010, Suokas et al., 2012). 
Previously OA was considered to be a strictly peripheral condition but other 
clinical features such as referred pain and sensitivity in areas distant to the joint 
suggests the possibility of altered central processing of nociceptive stimuli 
(Gwilym et al., 2009). Central sensitization occurs during inflammation and 
nerve damage whereby neurons in the superficial and deep regions of the 
dorsal horn of the spinal cord show marked changes of their response 
properties (Schaible, 2007, Sharif Naeini et al., 2005, Pinto et al., 2007). The 
changes seen are: lowered thresholds of nociceptive spinal neurones, increased 
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responses to noxious stimulation of inflamed site or non-inflamed site 
(hyperalgesia), responses to non-noxious stimulation of non-inflamed 
surrounding tissues (allodynia) and expansion of the receptive field (Schaible, 
2007). The pathological models of knee OA including the MIA model are 
essential in understanding the involvement of central mechanisms leading to 
pain responses and the associations between structural features and pain.   
OA structural severity can be evaluated by the macroscopic appearance of 
articular surfaces (Guingamp et al., 1997, Walsh et al., 2008), or microscopic 
changes in tissue sections (Janusz et al., 2002, Mankin et al., 1971, Pritzker et 
al., 2006). The OA Histological Histochemical Grading System (HHGS) 
described by Mankin et al. in 1971 (Mankin et al., 1971) is the most widely 
used grading system for scoring OA pathology. This system developed from 
examining human hip OA has been widely applied directly or with 
modifications to other synovial joints e.g. knee and to a variety of animal 
models (Stoppiello et al., 2014, Murat et al., 2007, Wei et al., 2010). Although 
the HHGS is a widely used system, its reproducibility has been reported to be 
inadequate and its reliability has been questioned (van der Sluijs et al., 1992, 
Ostergaard et al., 1999, Custers et al., 2007). Reports have also shown its 
inability to discriminate between normal and mild to moderate OA pathology 
(Ostergaard et al., 1997, Pearson et al., 2011). 
The OA working group established in 1998 by The Osteoarthritis Research 
Society International (OARSI) created the Osteoarthritis Cartilage 
Histopathology (OACH) grading and staging system with the intention of 
standardizing the assessment of OA histopathology (Pritzker et al., 2006). The 
system was observed to be reliable with Cronbach alpha scores in the range 
0.7-0.8 and reproducible with excellent inter observer agreements (Custers et 
al., 2007). The OACH system has been compared to the HHGS in a surgically 
induced cobalt-chrome implant model of knee OA in goats where it was 
reported to be more reliable than the HHGS (Custers et al., 2007), although 
similar reliabilities between both systems have also been reported (Pearson et 
al., 2011). A disadvantage to the OACH system is that it requires assessing 
multiple features (cartilage surface integrity, chondrocyte morphology, 
proteoglycan loss etc.) for each individual grade and thus the transition 
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between regions of OA structural severity may overlap and therefore makes it 
difficult in assigning a grade (Pritzker et al., 2006, Pearson et al., 2011). In this 
chapter, the OACH system was modified to score only cartilage surface 
integrity. 
The Janusz system of histopathology scoring (Janusz et al., 2002) was 
modified and applied from a scoring system described by Bendele and Hulman 
on spontaneous osteoarthritis in Guinea pigs (Bendele and Hulman, 1991). The 
Janusz system consisted of scoring cartilage pathology alone and did not 
include chondrocyte death and proteoglycan loss as described by Bendele and 
Hulman. This Janusz histopathological scoring system was effective in 
showing joint lesion development following meniscal tear in rats, but its 
reliability or reproducibility, with comparison to the modified OACH or 
OARSI system has not been evaluated.   
Loss of matrix proteoglycan observed as loss of stainable proteoglycan is one 
of the characteristic features of the MIA model (van der Kraan et al., 1989, 
Janusz et al., 2001, Bove et al., 2003). Proteoglycan loss can be scored in the 
cartilage of Safranin-O Fast green, Alcian blue-PAS or Toluidine blue stained 
sections (Pauli et al., 2012, Mokbel et al., 2011, Sun et al., 2012). Safranin-O 
and Alcian blue are cationic dyes that bind specifically to sulphated 
glycosaminoglycans (GAGs) and proteoglycan. A product of the binding of 
Safranin-O is the intense red stain which indicates the presence of proteoglycan 
content. Varying intensity of the red colour is what is scored in histological 
sections assessing cartilage damage. In cartilage, where the levels of GAGs 
have been severely depleted, sensitivity to proteoglycan content is reduced 
(Camplejohn and Allard, 1988). This can occur as a result of disease, fixation 
or wash out during decalcification, especially with prolonged methods e.g. 
ethylenediaminetetraacetic acid (EDTA) (Hyllested et al., 2002, Encfeldt and 
Hjertquist, 1967, Chevrier et al., 2005). In order to reduce variability, another 
proteoglycan stain for example Alcian blue-PAS stain or Toluidine blue stain 
could be used in parallel.   
Structural changes in the OA joint are well characterised but their associations 
with pain behaviour are complex and less understood (Yusuf et al., 2011). This 
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is represented in some patients who complain of pain without structural 
damage while some others that show significant changes in their knee joint do 
not experience any pain. To mimic this, two doses of MIA were used here; a 
lower dose (0.1mg) to represent subclinical pain and the standard dose (1mg) 
to represent clinical pain. 
The hypothesis was that the low dose (0.1mg) MIA would induce OA 
pathology including inflammation but not measurable pain behaviour (weight 
bearing asymmetry and paw withdrawal threshold) while the standard dose 
(1mg) will do both. 
 
5.2 AIMS 
x To characterise the effect of intra-articular injections of a lower (0.1mg) 
and standard (1mg) dose of MIA on pain behaviour and joint structure 
including synovial inflammation. 
x To investigate if OA pathology is homogeneous or heterogeneous 
across the whole knee joint in the MIA model (is it right to score only 
one part of the knee as recommended by the OARSI scoring system)? 
x To validate the histological (Janusz and modified OARSI) scoring 
systems for reproducibility, to determine inter-observer and intra-
observer reliabilities. 
x To compare the sensitivity of the Safranin-O Fast green stain for 
detecting proteoglycan content in the cartilage matrix (comparison to 




5.3 METHODS  
Refer to Chapter 2 for general methodology. Experiments were carried out on 
male Sprague Dawley rats (Charles River, UK) n = 64, weighing 220-370g at 
time of OA induction. Two studies were carried out in this chapter. 
5.3.1 Characteristic features of a low and standard dose 
of MIA injections in naïve animals 
OA induction 
64 male rats (n = 8 or 10 per group) were anaesthetised with isoflurane (2% in 
O2) mixture and received a single intra-articular injection of MIA (0.1mg/50µl 
or 1mg/50µl, based on previous studies (Guingamp et al., 1997, Bove et al., 
2003, Sagar et al., 2010)). Study 1 investigated the effect of intra-articular MIA 
for 20 days post injection (Fig. 5.1) while study 2 went up to 42 days post 
injection (Fig 5.2). 
OA pain behavioural measurements 
The effects of intra-articular injection of MIA or saline on pain behaviour were 
measured as hind limb weight-bearing asymmetry and distal allodynia to 
punctuate stimulation of the hind paw using von Frey filaments (Semmes-
Weinstein monofilaments 1 - 15g). Baseline measurements were obtained 
immediately prior to intra-articular injection (day 0) and from day 3 onwards to 
day 42. In line with the 3Rs (reduction), the 1mg MIA group were sacrificed at 
day 20 as pain behaviour and OA pathology are already established at 2 weeks 
after OA induction (Sagar et al., 2010). Development of allodynia was 
indicated as a decrease in hind paw withdrawal threshold (PWT). Weight 
bearing asymmetry was assessed as a % difference in weight distribution 
between hind limbs (non-arthritic knee ± arthritic knee) / (non-arthritic knee + 






Tissue harvesting and decalcification 
Rats were sacrificed at the end of each study and tissues collected at day 20 
and 42. Fresh synovial and hard joint tissues were collected from ipsilateral 
arthritic (MIA) and non-arthritic (saline) controls. 
Macroscopic scoring of the articular cartilage (Guingamp method) (Guingamp 
et al., 1997) was undertaken on harvested knee joints. 
 
Time course of experiment 1 
 
 
Figure 5.1 Time course of MIA-induced pain behaviour and inflammation. 
Rats were habituated to pain assessment (incapacitance meter and von Frey box) two 
days prior to baseline measurements. MIA was injected intra-articular on day 0. 
Weights, knee diameters and pain behaviour were measured from day 0 (baseline) 









Figure 5.2 Time course of MIA-induced pain behaviour and inflammation. 
Rats were habituated to pain assessment (incapacitance meter and von Frey box) two 
days prior to baseline measurements. MIA was injected intra-articular on day 0. 
Weights, knee diameters and pain behaviour were measured from day 0 (baseline) 
until day 20 (for 0.1mg and 1mg MIA groups) and day 42 (for 0.1mg MIA and saline 






Inflammation was assessed as joint swelling, synovial histological score and 
macrophage infiltration.  
Joint swelling was measured at the same time as behavioural measurements 
using a digital electronic calliper (Mitutoyo, UK), with values representing 
difference in knee diameters (mm) between the arthritic (left) and non-arthritic 
(right) knee joints (Ashraf et al., 2010). 
Synovial sections (5µm), 1 section/rat were stained with haematoxylin and 
eosin (H&E) to assess its lining thickness and cellularity as previously 
described (Mapp et al., 2008, Walsh et al., 1998a). Synovitis scoring was 
performed using a 20× objective lens of a Zeiss Axioscop-50 microscope (Carl 
Zeiss Ltd, Welwyn Garden City, UK).  
Macrophage infiltration was identified by immunoreactivity for CD68 using 
the mouse monoclonal antibody clone ED1 (Dijkstra et al., 1985) and the 
peroxidase-conjugated avidin-biotin-peroxidase complex (ABC) method. 
Macrophage infiltration was quantified using fractional area and was defined as 
the percentage of synovial area that was CD68-positive (Walsh et al., 1998a). 
Macroscopic chondropathy grading of knee joint pathology 
At the end of the experiment at day 20 and day 42, rats were killed by a rising 
concentration of CO2. Tibiofemoral joints of the ipsilateral knees were isolated 
and carefully dissected and disarticulated to assess the severity of damage to 
the chondral surfaces. Macroscopic lesions were graded using the Guingamp 
classification as previously described (Guingamp et al., 1997). Grade 0 = 
normal appearance, 1 = slight yellowish discolouration of the chondral surface, 
2 = little cartilage erosion in load bearing areas, 3 = large erosions extending 
down to the subchondral bone and 4 = large erosions with large areas of 
subchondral bone exposure. Five chondral compartments of the knee: femoral 
groove, medial and lateral femoral condyles and medial and lateral tibia 
plateaus were scored. The 5 compartment scores were combined for a 





Following macroscopic scoring, the joints were fixed in neutral buffered 
formalin for 48h, then decalcified in EDTA for 6 weeks or 10% formic acid-
formalin for 7 days at room temperature and embedded in paraffin. Frontal 
sections following the OARSI  guideline for histological assessment for OA in 
the rat were cut and stained with H&E,  Safranin-O-Fast green or Alcian blue-
PAS (Gerwin et al., 2010). These 5µm cut sections were visualised using a 20x 
objective lens unless stated otherwise. Cartilage chondropathy, chondrocyte 
morphology and proteoglycan content of the cartilage were evaluated as 
previously described using a 4x objective lens (Janusz et al., 2002, Ashraf et 
al., 2011a, Mapp et al., 2010, Kamisan et al., 2013, Pritzker et al., 2006). 
Osteochondral junction integrity was assessed as the number of vascular 
channels present in the articular cartilage per length of tibial plateau (mm) 
(Ashraf et al., 2011a).  
5.3.2 Validation of histopathology scoring systems 
20 sections out of the 240 sections (n = 6 sections/rat) stained with 
haematoxylin and eosin or Safranin-O Fast green were scored for cartilage 
damage (Janusz or modified OARSI methods) (Janusz et al., 2002, Pritzker et 
al., 2006), chondrocyte appearance, vascular channels crossing the 
osteochondral junction (osteochondral junction integrity) and proteoglycan 
content in the cartilage between 4 investigators (LN-scorer1, PG-scorer2, JH-
scorer3, SS-scorer4) to test for reliability of histological scoring.  
Knee sections from another study (chapter 6) scored for cartilage damage using 
the Janusz or modified OARSI methods were evaluated for inter observer 
reliability.  
Statistical analysis 
Synovial inflammation, lining thickness and cellularity were scored as 
previously described, one synovial section per rat and overall grade that best 
represented the section given (Ashraf et al., 2011a). Infiltration by 
macrophages was quantified on 4 fields of view per synovial section per rat 
(Walsh et al., 1998a).  
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Data for each experiment were presented graphically as mean ± SEM and 
analysed using Prism V.6 (GraphPad, San Diego, California, USA). The 
different groups were compared using the non-parametric Kruskal-Wallis test 
IROORZHGE\SRVWKRF'XQQ¶VWHVWIRUHDFKSDUDPHWHU or the Wilcoxon matched-
pairs signed rank test. A two-tailed P value of less than 0.05 was taken as 
significant in all cases. Numerical data were presented as mean (95% CI) or 
median (IQR).  
Internal consistency for histological scoring was determined DV &URQEDFK¶V
alpha and expressed as a number between 0 and 1 (Cronbach, 1951, Tavakol 
and Dennick, 2011). The closer to 1 the CrRQEDFK¶VDOSKDZDVWKHKLJKHUWKH
consistency.  
8QZHLJKWHGDQGZHLJKWHGNDSSDțYDOXHVZHUHFDOFXODWHGIRUDJUHHPHQWȀ
was defined as less than chance agreement if < 0, slight agreement = 0.01-0.20, 
fair agreement = 0.21-0.40, moderate agreement = 0.41-0.60, substantial 
agreement = 0.61-0.80, and almost perfect agreement = 0.81-0.99 (Landis and 
Koch, 1977, Kundel and Polansky, 2003).  
Reliability between histological scoring methods of cartilage damage based on 
the Janusz method (Janusz et al., 2002) or modified OARSI score (Pritzker et 
al., 2006) was reported using a Bland-Altman plot (Bland and Altman, 1986). 
To construct a Bland-Altman plot, the difference between scoring methods 
(Janusz and OARSI) by an observer was plotted on the y-axis against the 
average total between scoring methods on the x-axis. Systematic error in terms 
of bias (mean difference) and random error in terms of precision (Mean±2SD) 









Two studies were carried out in this chapter. Study 1 investigated the effect of 
intra-articular 0.1mg and 1mg of MIA for 20 days, while study 2 went up to 42 
days for only the 0.1mg MIA injected rats. 
5.4.1 Effects of a low 0.1mg and standard 1mg MIA dose 
5.4.1.1 Body weight  
There was a gradual increase in the weights of all the rats irrespective of the 
MIA dose or saline injection administered (Fig. 5.3A and B).  
 
Figure 5.3 Time course of weight gain of rats. 
Gradual increase in weight with intra-articular injection of MIA or saline. Study 1 
shows data for all groups to day 20 while study 2 shows data for 1mg MIA group to 
day 20 and the other groups to day 42. Data are mean ± SEM of weights from 1mg 




Study 1 Study 2 
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5.4.1.2 Intra-articular injection of MIA induces 
changes in pain behaviour; pain phenotypes 
depend on severity of disease 
Intra-articular injection of 1mg of MIA increased pain behaviour; both an 
increase in weight bearing asymmetry (1mg; 189 [118 - 261] v saline; 49.8 [14 
± 85.5] p<0.01) (Fig. 5.4 A and B) and lowered hind paw withdrawal threshold 
(1mg; 187 [160 ± 215] v saline; 282 [265 ± 298] p<0.01) (Fig. 5.5 A and B). 
Similar results were observed in a subsequent study (Fig. 5.4 C and D, Fig 5.5 
C and D). Intra-articular injection of 0.1mg MIA was associated with lowered 
hind paw withdrawal threshold (0.1mg; 187 [115 ± 259] v saline; 282 [265 ± 
298] p<0.05) in the absence of pronounced weight bearing asymmetry (0.1mg; 
52.8 [4.79 ± 101] v saline; 49.8 [14 ± 85.5] ns) (Fig 5.4 A and B, 5.5 A and B). 








Figure 5.4 Effects of MIA on weight bearing asymmetry 
Intra-articular injection of 1mg of MIA induced pain behaviour measured as hind-limb 
weight bearing asymmetry (A&C). B & D indicate area under the curve data for 
weight bearing asymmetry. Intra-articular injection of 0.1mg of MIA resulted in 
minimal weight bearing asymmetry comparable to saline injected control rats (A&C). 
Study 1 shows data for all groups to day 20 while study 2 shows data for 1mg MIA 
group to day 20 and the other groups to day 42. Data are expressed as mean ± SEM, 
1mg MIA (Ŷ), 0.1mg MIA (x) and saline (ż) injected rats (n = 8 or 10/group). 
Differences between groups were analysed using the area under the curve (A and C) 
RYHUWKHWLPHFRXUVHRIWKHVWXG\IROORZHGE\.UXVNDO:DOOLVWHVWZLWKD'XQQ¶VSRVW
hoc analysis (B and D). *p<0.05, **p<0.01 (1mg MIA v saline), ++p<0.01 (1mg MIA 












Figure 5.5 Effects of MIA on paw withdrawal threshold 
Intra-articular injection of 1mg or 0.1mg of MIA resulted in lowered hind paw 
withdrawal threshold indicative of allodynia. ). B & D indicate area under the curve 
data for paw withdrawal thresholds. Study 1 shows data for all groups to day 20 while 
study 2 shows data for 1mg MIA group to day 20 and the other groups to day 42. Data 
are expressed as mean ± SEM, 1mg MIA (Ŷ), 0.1mg MIA (x) and saline (ż) injected 
rats (n = 8 or 10/group). Differences between groups were analysed using the area 
under the curve (A and C) over the time course of the study followed by Kruskal 
:DOOLVWHVWZLWKD'XQQ¶VSRVWKRFDQDO\VLV%DQG'). *p<0.05, **p<0.01 (1mg MIA 










Acute inflammation was observed as joint swelling, synovitis and macrophage 
infiltration into the synovium. Small increases in knee diameter were observed 
at day 1 following intra-articular MIA injection but did not differ from saline 
injected control rats (Fig. 5.6A and B). However at day 3, significant 
differences were observed between MIA and saline injected rats (Fig. 5.6B). 
Joint swelling returned to baseline levels for all rats by 2 weeks (Fig. 5.6A and 
B). Intra-articular injection of MIA was associated with increased synovitis 
detected by histological examination of haematoxylin and eosin stained tissue 
sections (Figs 5.6C and D) and infiltration by macrophages (Fig 5.6E and F) 
into the synovium. Synovitis scores 20 days after intra-articular injection of 
1mg of MIA [2.5 (2 to 3) Fig. 5.6C], [2 (1 to 3) Fig. 5.6D] and 42 days after 
intra-articular injection of 0.1mg of MIA [3 (0 to 3) Fig 5.6D] were 
significantly higher compared to saline injected non-arthritic controls [0 (0 to 
2) p<0.01 Fig. 5.6C], [1 (0 to 1.3) p<0.05, p<0.001 Fig. 5.6D]. Macrophage 
fractional area 20 days after intra-articular injection of 1mg of MIA [16 (11 to 
22) Fig. 5.6E], [13 (7.8 to 17) Fig. 5.6F] was significantly higher compared to 
saline injected [7.1 (2.9 to 11) p<0.05 Fig. 5.6E], [4.1 (1.4 to 6.7) p<0.05 Fig 
5.6F] and 0.1mg MIA injected rats [7.8 (5.1 to 11) p<0.05 Fig 5.6E]. 
Macrophage fractional area 42 days after intra-articular injection of 0.1mg of 
MIA [16 (11 to 22) Fig. 5.6F] was significantly higher compared to saline 















Figure 5.6 Evidence of inflammation 20 and 42 days after OA induction.  
Study 1 shows data for all groups to day 20 while study 2 shows data for 0.1mg and 
1mg MIA groups to day 20 and the saline and 0.1mg groups to day 42. Small changes 
in knee diameter observed after intra-articular injection of MIA or saline (A and B). 
Knee joint diameters for MIA injected rats were significantly different to those of 
saline injected rats (B). Synovitis observed following intra-articular MIA injection 
was significantly higher in the 1mg MIA injected rats at day 20 (C and D) and 0.1mg 
MIA injected rats at day 42 (D) compared to saline injected non-arthritic controls. 
Significantly higher macrophage infiltration into the synovium following 1mg MIA 
injection at day 20 compared to saline injected (E and F) and 0.1mg MIA injected rats 
(E). Macrophage infiltration was also observed to be significantly higher in the 0.1mg 
MIA injected rats at day 42 compared to saline injected rats (F). Data are expressed as 
mean ± SEM or median, 1mg MIA (Ŷ), 0.1mg MIA (x RUǻDQGVDOLQHż) injected 
rats (n = 8 or 10/group). Differences between groups were analysed using the Kruskal 
:DOOLVWHVWZLWKD'XQQ¶VSRVWKRFDQDO\VLVSSS'-1mg 
MIA or D42-0.1mg MIA v saline. +p<0.05 D20-1mg MIA v D20-0.1mg MIA.








D42 - Saline D20 - 1mg MIA 
D20 ± 0.1mg MIA D42 ± 0.1mg MIA 
Synovitis 









D20 ± 0.1mg MIA D42 ± 0.1mg MIA 
D42 - Saline D20 - 1mg MIA 
Synovial macrophage infiltration 
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Figure 5.7 Mild persistent synovitis is a feature both of standard and low dose 
MIA model 
Synovitis characterised as synovial lining thickness/cellularity (A-D) and macrophage 
infiltration (E-H). Extensive synovia proliferation (red arrows) in the day 20-1mg and 
day 42-0.1mg MIA-induced OA rats (C & D) compared with non-arthritic controls 
(A). Photomicrographs show synovial lining (blue arrows) and cellularity as indicated 
by the haematoxylin and eosin stain (A-D). Macrophage infiltration-black dots 
indicate immunoreactivity for CD68, using monoclonal antibody ED1; E-H. 
Photomicrographs show haematoxylin and eosin stained sections of synovium from a 
rat with the median synovitis score and mean macrophage fractional area from each 
group. Scale bar = 50µm. 
   
152 
   
5.4.1.4 Osteochondral pathology 
Intra-articular injection of 0.1mg or 1mg of MIA resulted in structural OA 
phenotypes as indicated by cartilage damage (microscopic and macroscopic), 
abnormal chondrocyte morphology, loss of osteochondral junction integrity 
and matrix proteoglycan loss (Fig. 5.8, Table 5.1 and 5.2). Irrespective of the 
dose of MIA, cartilage damage, abnormal chondrocyte morphology and 
proteoglycan loss were significantly higher in these rats compared to the 
saline-injected non-arthritic controls (Table 5.1; study 1). In study 2, 
irrespective of the dose of MIA or the duration of MIA (20 and 42 days), 
macroscopic chondropathy, cartilage damage and abnormal chondrocyte 
morphology were significantly higher in these rats compared to the saline-
injected non-arthritic controls (Table 5.2). Proteoglycan loss was significantly 
higher only in the day 20 1mg MIA injected rats compared to the saline 
injected rats (Table 5.2). Vascular channels crossing the osteochondral junction 
were not significantly different between the groups at day 20 (Table 5.1; study 
1) but were significantly higher in the day 20 0.1mg and day 20 1mg MIA 
injected rats compared to the day 42 saline injected rats and day 42 0.1mg MIA 
injected rats (Table 5.2; study 2).  
    
 





D42 - Saline D20 - 1mg MIA 
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Figure 5.8 Structural changes in the articular cartilage in the MIA model 
Histological changes of Safranin-O Fast green stained sections showing structural 
pathology presented as cartilage damage, abnormal morphology of chondrocytes and 
proteoglycan loss (A-D). Saline-injected control (A) showing smooth cartilage 
including normal chondrocyte morphology. B & C, 1mg and 0.1mg MIA-treated rats 
showing thinning of cartilage in weight bearing areas (asterisk), complete chondrocyte 
death (hypocellularity) (blue arrow) and chondrocyte cloning (black arrow). 0.1mg rat 
(D) showing cartilage fibrillations (red arrow), hypocellularity (blue arrow) and 
cloning (black arrow). All arthritic groups (B-D) show loss of proteoglycan content as 
seen as reduction in staining intensity (red colour) compared to saline controls (A). 
Photomicrographs (A-D) show tibial plateau from a rat with the median pathology 
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Table 5.1 Pathological features in articular cartilage and subchondral 
bone 20 days after intra-articular injection of MIA (study 1) 
Structural 
changes 
D20-Saline D20-1mg MIA D20-0.1mg MIA 
Cartilage 
damage 
0.38 (0.21 - 1) 2.6 (2.2 ± 4.2)*** 2.1 (1.6 ± 2.8)** 
Chondrocyte 
morphology 




0.5 (0.33 - 0.7) 0.4 (0.4 ± 0.58) 0.5 (0.4 ± 0.83) 
Proteoglycan 
loss 
1.8 (1.4 - 2.5) 2.7 (2.2 - 3.3)** 2.6 (1.9 ± 3.2)* 
 
Histological changes showing structural pathology presented as cartilage damage, 
abnormal morphology of chondrocytes, channels crossing the osteochondral junction 
and proteoglycan loss data. Data are presented as median (IQR), *p<0.05, **p<0.01, 
***p<0.001 (all MIA groups v saline). 
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Table 5.2 Pathological features in articular cartilage and subchondral 









3.5 (1 - 5.3) 10 (8.5 - 
13)*** 
9 (7 - 11)** 8.5 (7.8 -12)** 
Cartilage 
damage 
0.6 (0.18 - 1) 1.8 (1.2 - 4)* 2 (0.83 - 4)** 3 (1.3 - 4)*** 
Chondrocyte 
morphology 
0.67 (0 ± 1.4) 1.8 (1.5 - 
2.3)*** 




0.5 (0.4 - 
0.65) 
1.2 (0.92 - 
1.4)** ++ 
1.5 (1.2 - 
1.7)**** ++++ 
0.51 (0.39 -0.87) 
Proteoglycan 
loss 
2 (1.2 - 2.5) 2.8 (2.2 - 
3.2)** 
2.7 (2 - 3) 2 (1.8 - 2.8) 
 
Histological changes showing structural pathology presented as cartilage damage, 
abnormal morphology of chondrocytes and proteoglycan loss in pictures (Fig.5.8), 
including macroscopic chondropathy and channels crossing the osteochondral junction 
data. Data are presented as median (IQR), *p<0.05, **p<0.01, ***p<0.001 (all MIA 





    
157 
   
5.4.2 Heterogeneity of OA pathology in the MIA model 
Histological scoring of haematoxylin and eosin stained sections for OA 
structural pathology indicates heterogeneity in the MIA model.  
Cartilage damage scored using the Janusz method of scoring was observed to 
be significantly higher in the ipsilateral posterior (IpP) sections of the day 20 
MIA injected rats compared to their corresponding ipsilateral anterior (IpA) 
sections (Fig. 5.9D). Anterior (IpA) cut sections did not show significant 
differences between the day 20 MIA injected rats compared to the day 42 
saline injected rats (Fig. 5.9A), whereas significant differences were observed 
in the ipsilateral posterior (IpP) cut sections of the same groups (Fig. 5.9B). 
When IpA and IpP sections were combined, the total joint scores were 
significantly different for all MIA groups compared to the saline group of 
injected rats (Fig. 5.9C). Although the day 42 0.1mg MIA group posterior 
(IpA) sections were significantly different to the day 42 saline injected (IpA) 
group, unlike the day 20 MIA group, the cartilage damage scores in the day 42 
0.1mg MIA IpP sections were not significantly higher than their corresponding 
IpA sections (Fig. 5.9D).  
Chondrocyte morphology scores for the IpA sections were not significantly 
different to their corresponding IpP sections (Fig 5.10D), but the scores from 
the IpP sections only were observed to be significantly higher in the day 20 
1mg MIA injected rats compared to day 42 saline injected rats (Fig 5.10A and 
B). Significant differences were observed for day 20 0.1mg MIA injected rats 
compared to day 42 saline injected rats in both IpA and IpP cut sections (Fig 
5.10A and B). When IpA and IpP sections were combined, the total joint scores 
for chondrocyte morphology were significantly different for all MIA groups 
compared to the saline group of injected rats (Fig. 5.10C).  
 
    
158 
   
 
 
Figure 5.9 IpA and IpP scores for cartilage damage in the MIA model 
Significantly higher cartilage damage scores for the day 42-0.1mg MIA injected rats 
only compared to saline injected rats using IpA sections (A). Significantly higher 
cartilage damage scores for the day 20-MIA injected rats only compared to saline 
injected rats using IpP sections (B). Significantly higher cartilage damage scores for 
all the MIA injected rats compared to saline injected rats for both IpA and IpP sections 
(C). Significantly higher cartilage damage scores for the IpP-d20-MIA injected rats 
compared to the corresponding IpA sections (D). Data are expressed as mean ± SEM, 
d20-1mg MIA, d20-0.1mg MIA, d42-0.1mgMIA and saline injected rats (n = 
10/group). Differences between groups were analysed using the Kruskal Wallis test 
ZLWKD'XQQ¶VSRVWKRFDQDlysis (A-C) or a Wilcoxon matched-pairs signed rank test 
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Figure 5.10 IpA and IpP scores for chondrocyte morphology in the MIA model 
Significantly higher abnormal chondrocyte appearance scores for the day 20-0.1mg 
MIA injected rats only compared to saline injected rats using IpA sections (A). 
Significantly higher abnormal chondrocyte appearance scores for the day 20-MIA 
injected rats only compared to saline injected rats using IpP sections (B). Significantly 
higher abnormal chondrocyte appearance scores for all the MIA injected rats 
compared to saline injected rats for both IpA and IpP sections (C). Data are expressed 
as mean ± SEM, d20-1mg MIA, d20-0.1mg MIA, d42-0.1mgMIA and saline injected 
rats (n = 10/group). Differences between groups were analysed using the Kruskal 
:DOOLV WHVW ZLWK D 'XQQ¶V SRVW KRF DQDO\VLV $-C). *p<0.05, **p<0.01, ***p<0.001 
MIA v saline (A-C).  
A B 
C D 
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5.4.3 Reliability of histological scoring systems 
Reliability measurements were carried out on histological scoring of cartilage 
damage (Janusz and modified OARSI methods), chondrocyte morphology, 
osteochondral junction integrity and proteoglycan loss in the cartilage between 
four investigators. 20 knee joint sections were scored by one investigator (LN) 
and scoring results compared to the other three investigators (PG, JH and SS). 
Table 5.3 summarises the analysis for inter observer agreement. The 
&URQEDFK¶V DOSKD YDOXHV IRU WKH H[DPLQHG SDUDPHWHUV FDrtilage damage 
(Janusz and modified OARSI methods), chondrocyte morphology, 
osteochondral junction integrity and proteoglycan loss) are within the range of 
0.55- ZLWK WKH PDWFKLQJ XQZHLJKWHG ț YDU\LQJ IURP VOLJKW WR PRGHUDWH
agreement (0.04-DQGWKHZHLJKWHGțYDU\LQJIURPIDir to almost perfect 
agreement (0.24-0.85).  
&KRQGURF\WHPRUSKRORJ\VFRULQJZDVREVHUYHGWRKDYHWKHORZHVW&URQEDFK¶V
alpha value (0.55) while cartilage damage scoring had the highest value (0.99 
respectively) (Table 5.3). Osteochondral junction integrity had the lowest 
XQZHLJKWHGDQGZHLJKWHGțYDOXHVUDQJLQJIURPVOLJKWWRPRGHUDWHDJUHHPHQW
(0.04-ZKLOHFDUWLODJHGDPDJHKDGWKHKLJKHVWXQZHLJKWHGDQGZHLJKWHGț
values ranging from moderate to almost perfect agreement (0.55-0.85) (Table 
5.3).  
Investigating the Janusz and modified OARSI histological scoring methods for 
cartilage damage by one observer (LN) showed statistical significant 
differences between the arthritic groups compared to their normal saline 
injected controls (Fig. 5.12A and B). These two methods were also observed to 
be positively correlated to each other (Fig. 5.12C) and showed no systematic 




Table 5.3 Inter observer agreement between four histological scoring investigators as measured by two different statistical methods  
Reliability (Cronbach's Alpha) v Scorer1 Scorer2 Scorer3 Scorer 4 
Cartilage damage (Janusz) 0.99 0.99 NA 
Cartilage damage (OARSI) NA NA 0.83 
Chondrocyte appearance 0.55 0.81 0.84 
Number of channels crossing the OCJ 0.8 0.79 NA 
Proteoglycan score 0.63 0.84 0.95 
Cohen's unweighted kappa v Scorer1 Scorer2 Scorer3 Scorer 4 
Cartilage damage (Janusz) 0.55 0.46 NA 
Cartilage damage (OARSI) NA NA 0.2 
Chondrocyte appearance 0.21 0.34 0.31 
Number of channels crossing the OCJ 0.04 0.1 NA 





   
Cohen's weighted kappa v Scorer1 Scorer2 Scorer3 Scorer 4 
Cartilage damage (Janusz) 0.85 0.79 NA 
Cartilage damage (OARSI) NA NA 0.5 
Chondrocyte appearance 0.26 0.32 0.5 
Number of channels crossing the OCJ 0.44 0.24 NA 
Proteoglycan score 0.46 0.58 0.74 
 
7KHFORVHUWRWKH&URQEDFK¶VDOSKDWKHKLJKHUWKHFRQVLVWHQF\RIVFRULQJȀZDVGHILQHGDVOHVVWKDQFKDQFHDJUHHPHQWLI 0, slight agreement = 0.01-0.20, 
fair agreement = 0.21-0.40, moderate agreement = 0.41-0.60, substantial agreement = 0.61-0.80, and almost perfect agreement = 0.81-0.99. OCJ ± 





Figure 5.11 Cartilage chondropathy in the MIA model as scored by the Janusz 
and modified OARSI classification methods.  
Janusz method of scoring (A) shows similar results to the OARSI classification 
method (B) and correlates with it (C). D, Bland-Altman plot illustrating agreement 
between the Janusz and OARSI scoring methods by an observer. The 95% limits of 
agreement for the Bland-Altman plot contains 93% (37/40) of the difference scores 
(D). Mean+2SD (upper limit of agreement), Mean-2SD (lower limit of agreement), 
Mean (bias ± average of the difference values), values outside the limits of agreements 
are outliers and values within limits of agreements are individual difference values. 
Scatter plots show mean ± SEM of n = 10 rats/group of their ipsilateral anterior (IpA) 
VHFWLRQV 6FDWWHU SORWV ZLWK UHJUHVVLRQ OLQH VKRZ 6SHDUPDQ¶V FRUUHODWLRQ FRHIILFLHQW
*p<0.05, **p<0.01 MIA-PBS or MIA-M911 versus saline-PBS controls. M911 ± anti-






5.4.4 Comparison between Safranin-O and Alcian blue in 
the detection of matrix proteoglycan 
Knee joint sections stained with Safranin-O Fast green or Alcian blue-PAS 
were scored in order to investigate the sensitivity of these stains to detect 
proteoglycan content in the cartilage matrix. Proteoglycan loss was scored as 
the loss of red staining or its intensity (Safranin-O) or loss of blue staining or 
its intensity (Alcian blue-PAS). A high proteoglycan score equals a high 
proteoglycan loss or loss of staining intensity. Loss of Safranin-O was 
significantly higher in the MIA (0.1mg and 1mg) injected rats compared to the 
saline injected non-arthritic controls as observed in the Safranin-O Fast green 
stained sections (Fig. 5.13A). Loss of Alcian blue was significantly higher in 
the 1mg MIA injected rats only compared to the 0.1mg MIA and saline 
injected rats as observed in the Alcian blue-PAS stained sections (Fig. 5.13B). 
Comparing both staining methods showed that there was significantly higher 
loss of Safranin-O in the Safranin-O Fast green stained sections for all groups 
of rats compared to the loss of Alcian blue in the Alcian blue-PAS stained 




Figure 5.12 Proteoglycan content in the cartilage matrix of the MIA model, 
comparing the Safranin-O Fast green stain to the Alcian blue-PAS stain 
Significantly higher proteoglycan loss (score) for the day 20 MIA (0.1mg and 1mg) 
injected rats compared to day 20 saline injected rats using Safranin-O Fast green stain 
(A). 1mg MIA injected rats had a significantly higher loss of proteoglycan compared 
to the 0.1mg MIA and saline injected rats using Alcian blue-PAS stain (B). 
Significantly higher proteoglycan loss for the Safranin-O Fast green stained sections 
compared to the Alcian blue-PAS stained sections (C). Data are expressed as mean ± 
SEM (n = 8/group). Differences between groups were analysed using the Kruskal 
Wallis test witKD'XQQ¶VSRVWKRFDQDO\VLV$DQG%RUD:LOFR[RQPDWFKHG-pairs 
signed rank test (C). *p<0.05, **p<0.01, *** or ****p<0.001 MIA v saline (A and B). 








The MIA model displays characteristic features of symptomatic knee OA as 
indicated by pain related behaviours (increased weight bearing asymmetry and 
reduced hind paw withdrawal threshold), inflammation and joint (macroscopic 
and microscopic) pathology (Liu et al., 2011, Mapp et al., 2013, Ashraf et al., 
2014, Guingamp et al., 1997). 
Intra-articular injection of the cellular glycolytic inhibitor MIA brings about 
pathology by inhibiting the enzyme glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) which is responsible for the breakdown of glucose to 
release energy. This results in lowering chondrocyte metabolism and 
eventually leads to chondrocyte cell death (Kalbhen, 1987, van der Kraan et 
al., 1989).  Pathological changes to the knee joint begin to occur as a result of 
progressive loss of chondrocytes (hypocellularity). This includes fibrillations 
and thinning or loss of the cartilage matrix.  
In this chapter, two doses (0.1mg and 1mg) and two time points (day 20 and 
42) were examined. The 0.1mg MIA injected rats were sacrificed at either day 
20 or day 42 but the 1mg MIA injected rats were all sacrificed at day 20. The 
reason for this is because the 1mg dose is a widely explored dose, with 
published reports of pain behaviour and structural pathology from 2 weeks 
post OA induction. One of the criteria for this thesis was to carry out 
experiments on a reduced number of rats, while limiting the pain, suffering and 
distress caused to the rats hence the shorter time point (day 20) for the 1mg 
MIA dose. 
5.5.1 Symptomatic features of OA in the MIA model 
Chondropathy is a hallmark of human OA (Walsh et al., 2008). In this study it 
was observed that both the lower dose (0.1mg) and standard dose (1mg) of 
MIA showed alterations in pathology which were significantly different to the 
saline injected non-arthritic rats (Guingamp et al., 1997, Guzman et al., 2003). 
Cartilage pathology measured by macroscopic scoring or on histological 
sections did not significantly differ between doses (0.1mg or 1mg) or between 
duration of OA disease (day 20 and 42). This lack of difference may have been 
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because this model is a rapidly progressive model and pathology is already 
established by day 20 (Sagar et al., 2010, Bove et al., 2009). Likewise changes 
to chondrocyte morphology which is a major feature of this model did not 
significantly differ between doses or duration of disease. On the other hand the 
osteochondral junction integrity measured as the number of vessels crossing 
the osteochondral junction into the calcified cartilage / mm length of cartilage 
was significantly lower (i.e. the lower the integrity, the more channels crossing 
the osteochondral junction and vice versa) in the day 20-MIA injected rats 
compared to the day 42-0.1mg MIA and day 42-saline injected non-arthritic 
rats in study 2. In study 1 the osteochondral junction integrity was not 
significantly different between the groups (01.mg, 1mg and saline) at day 20 
i.e. each group of rats had a similar density of vascular channels crossing the 
osteochondral junction.  
The adult healthy cartilage is known to be avascular (Takebe et al., 2014, 
Hunter et al., 2009), but in OA, vascular growth by angiogenesis has been 
reported to occur at the osteochondral junction and hence the cartilage is no 
longer avascular (Walsh et al., 2007, Suri et al., 2007). The findings from the 
current studies are in line with published work by Mapp et al 2013 which 
showed a reduction in the number of vascular channels crossing the 
osteochondral junction (i.e. higher osteochondral junction integrity) with time 
in the MIA model (Mapp et al., 2013). Increased densities of vascular channels 
crossing the osteochondral junction may suggest new vessel growth with 
subchondral bone remodelling. Increased vascular channels may be a source of 
pain in OA with reports of sensory nerves growing alongside blood vessels in 
vascular channels associated with angiogenesis (Walsh et al., 2010). It has 
been reported that  angiogenesis may contribute to pain in OA (Ashraf et al., 
2011a). The bisphosphonate Zoledronate was reported to reduce pain in both 
the MIA and medial meniscal tear (MMT) models of OA and one of the 
potential mechanisms might be through improving subchondral bone integrity 
as Zoledrenate was observed to  partially restore bone mineral density and 
improve subchondral bone remodelling (Strassle et al., 2010, Yu et al., 2012). 
Inflammation in the synovium is a feature of human knee OA (Wenham and 
Conaghan, 2010, Scanzello and Goldring, 2012). Inflammation in the MIA 
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model includes mild joint swelling which is seen in the early phase of the 
model, synovial thickening and infiltration into the synovium by immune cells 
such as macrophages (Bove et al., 2003, Clements et al., 2009). In this study, 
intra-articular MIA injection either 0.1mg or 1mg did induce an increase in 
joint swelling which subsided within 7-14 days. Extensive synovia 
proliferation and increased thickening of the lining layer in both the day 20-
1mg and day 42 0.1mg MIA dose were observed. A similar result was 
observed for macrophage infiltration into the synovium. These results are in-
line with data in the literature that showed persistent synovial inflammation in 
rats injected with 1mg MIA at day 21 (Clements et al., 2009). Synovitis 
persisting where joint swelling subsides may suggest a move from acute 
inflammation to chronic inflammation in the standard 1mg dose and the 
increase in duration for the low dose (d42-0.1mg) making it more persistent. It 
might also suggest site specificity or localisation of synovitis. Synovitis 
located at joint margins was reported to subside within 7-14 days post 1mg 
MIA injection (Bove et al., 2003), this corresponds to reduced joint swelling. 
In this chapter, synovitis was scored at the infrapatellar fat pad and at this 
location, synovitis was found to still be present at 20 days post MIA injection. 
Peripheral sensitization is a process that can occur as a result of increased 
activity from peripheral nociceptors by inflammation or joint pathology (Neogi 
et al., 2013). Increased input from peripheral nociceptors may in turn 
contribute to central sensitization (Woolf, 2011). Central sensitization 
increases pain hypersensitivity in inflamed tissue, produces hypersensitivity in 
non-inflamed tissue (spread of pain) and sustains pain sensitivity after 
initiating injury is long gone (Latremoliere and Woolf, 2009, Woolf, 2011).  
Weight bearing asymmetry, an indicator of standing pain is brought about by 
the tendency to lean away or put less weight on the affected joint in OA 
(Christiansen and Stevens-Lapsley, 2010). This phenomenon does occur in 
animals with unilateral joint injury and can be measured (Bove et al., 2003). 
Weight bearing asymmetry is associated with peripheral and central 
sensitization (Graven-Nielsen and Arendt-Nielsen, 2002). On the other hand, 
mechanical thresholds which indicate widespread pain for example in the 
affected and non-affected limb (Arendt-Nielsen et al., 2010) can also be 
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measured in animals (Sagar et al., 2010) and suggests a contribution of central 
sensitization (Suokas et al., 2012, Graven-Nielsen and Arendt-Nielsen, 2002). 
Intra-articular injection of MIA into the knee joint led to a dose dependent 
increase in pain behaviour as observed as a change in hind limb weight bearing 
asymmetry. This change in weight bearing asymmetry was only observed 
following intra-articular injection of 1mg of MIA. This is similar to already 
published data which have used this dose or higher to represent late severe OA 
(Kelly et al., 2013b, Combe et al., 2004, Liu et al., 2011). On the other hand 
the 0.1mg (lower) MIA dose showed minimal changes in weight bearing 
asymmetry comparable to the saline injected non-arthritic control rats. A 
similar result of 0.3mg dose not altering weight bearing asymmetry was 
reported by Sagar et al, (Sagar et al., 2010), although this was not the case 
reported by another publication using the 0.1mg dose (Bove et al., 2003). The 
reason for the low dose (0.1mg) MIA not showing any weight bearing 
asymmetry until the end of the study (day 42) even though they were seen to 
present with joint pathology is not clear. Joint pathology may contribute to 
peripheral sensitization which in turn drives weight bearing asymmetry. Intra-
articular injection of nerve growth factor (NGF) was reported to augment pain 
behaviour in OA knees (Ashraf et al., 2014). Structural changes to the joint or 
on-going pain may be the cause of OA sensitivity to NGF. Further work will 
be required to investigate if NGF would augment weight bearing asymmetry in 
the low (0.1mg) dose MIA rats and if this sensitivity to NGF is as a result of 
structural pathology.  
Intra-articular injection of MIA led to a reduction in paw withdrawal threshold 
in rats treated with either the 0.1mg or 1mg dose compared to the 
corresponding saline injected non-arthritic rats. These data are in line with 
already published data which used the 1mg dose or higher (Combe et al., 2004, 
Burston et al., 2013, Sagar et al., 2015). Another study reports on a reduction 
in mechanical threshold for a 0.125mg MIA dose (Im et al., 2010). These 
reductions in thresholds by the MIA injected rats may have been as a result of 
inputs from inflammation (neurogenic inflammation ± see Chapter 1) leading 
to central sensitization. It can also be as a result of the MIA model reported to 
be partly neuropathic i.e. presenting with a neuropathic component 
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(Ivanavicius et al., 2007). Reports comparing the MIA model with other 
neuropathic pain models showed that OA pain pathways do overlap in some 
ways with neuropathic pain mechanisms and that MIA injected rats were seen 
to respond to chronic and neuropathic pain treatments (Fernihough et al., 2004, 
Ivanavicius et al., 2007, Vonsy et al., 2009). The present study highlights that 
reduced paw withdrawal thresholds may not be restricted to end stage OA in 
the higher MIA dose but may also be seen in the lower MIA dose.  
5.5.2 Heterogeneity of OA pathology in the MIA model 
OA is a heterogeneous disease characterised by multi-tissue failure in synovial 
joints. This includes the cartilage, bone, synovium, muscle etc. (Driban et al., 
2010). The MIA model is also heterogeneous in this aspect as it exhibits failure 
in different tissues similar to that seen in human knee OA (Little and Zaki, 
2012). Although the MIA model can be said to be homogeneous in terms of 
cartilage pathology as it shows chrondropathy on both the lateral and medial 
tibial plateau (Barve et al., 2007), when assessing chondropathy, it is wrong to 
generalise the pathology seen in a part of the joint to the whole knee joint. The 
recommendations by the OARSI histopathology initiative for histological 
assessments of OA in the rat (Gerwin et al., 2010) suggests the method of 
frontal sectioning. Here the rat knee joint is split in a frontal plane into two 
equal anterior and posterior halves. From this, 3 sections per part (anterior or 
posterior) are cut at 200µm intervals and stained for histopathological 
assessments.   
In this study it was observed that sections from one compartment of the joint 
alone were not enough to discriminate the diseased groups (MIA-injected rats) 
from the normal controls (saline-injected rats). For example for chondropathy 
in the day 20 rats, it was observed that sections from the posterior part of the 
knee was found to show significant differences between OA and normal 
controls rather than sections from the anterior part of the knee, and 
chondropathy was significantly higher in the posterior knees rather than the 
anterior knees. Combining both parts (anterior and posterior sections) of the 
knee together to give a total joint score increased the sensitivity to detect 
chondropathy and thus the discrimination between disease groups and normal 
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controls increased. In cases like this it would be unwise to score chondropathy 
on one part of the knee only. This is in contrast to the OARSI recommendation 
for histopathology in the rat (Gerwin et al., 2010) which suggest assessing 
pathology in only one part of the knee, although the recommendation was 
based on the surgically induced MMT model. One of the reasons why 
chondropathy was observed more in the posterior part of the knee to the 
anterior part may be because rats like human tend to weight bear more on the 
posterior part than the anterior part. The day 42 0.1mg MIA injected rats 
however had equal chondropathy scores for both anterior and posterior knees. 
This may have been due to the duration of OA development in the MIA model 
as the day 20 0.1mg and 1mg MIA injected rats showed significantly higher 
chondropathy in the posterior part but not the anterior, thus it can be said that 
chondropathy initially arises in the posterior part of the knee before it spreads 
to the anterior part of the knee.  
A similar situation was observed for the measurement of chondrocyte 
appearance. Significant differences for all MIA groups compared to the saline 
control group were observed when joint scores from both anterior and 
posterior parts were combined. Therefore when carrying out histological 
assessments on rats, this should be taken into consideration so as to obtain true 
results.  
5.5.3 Reliability of histological scoring systems 
This study assessed the reliability of the Janusz (Janusz et al., 2002) and 
modified OARSI scoring systems on rat knees (Pritzker et al., 2006). The 
Janusz system was reported for use in the surgical meniscal tear rat model and 
the OARSI system have been used in a few animal models including the MIA 
model (Sagar et al., 2010) and in human samples (Pearson et al., 2011). One of 
the reasons for developing the OARSI score was to create a standard scoring 
system that would enable comparability of results between or across studies, 
when used independently or in parallel with other systems (Aigner et al., 
2010). In this case the modified OARSI system was used in parallel to the 
Janusz system for scoring cartilage chondropathy. Both systems were able to 
discriminate between OA groups from normal controls. Also the Janusz system 
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showed a positive correlation to the modified OARSI system. Results from the 
Bland-Altman plot comparing the Janusz system to the modified OARSI 
system show good agreement (Bland and Altman, 1986, Hanneman, 2008). 
The modified OARSI and Janusz systems including histological scoring for 
chondrocyte appearance, osteochondral junction integrity and loss of matrix 
proteoglycan in the cartilage were evaluated between 4 investigators to 
examine the reliability and reproducibility of histological scoring systems for 
pathological assessments. Reliability and reproducibility were assessed using 
the reliability DQDO\VLV DQG UHSRUWHG DV &URQEDFK¶V DOSKD YDOXHV DQG WKH
&RKHQ¶V NDSSD VWDWLVWLF 7KH &URQEDFK¶V DOSKD ZKLFK PHDVXUHV LQWHUQDO
consistency pertaining to how items within a test measure the same concept or 
construct can be rated on a scale from 0 to 1, with 1 being near perfect 
consistency and 0 been poor or no consistency (Spiliotopoulou, 2009, Tavakol 
and Dennick, 2011). The higher the correlation between two items been 
PHDVXUHGWKHJUHDWHUWKH&URQEDFK¶VDOSKDYDOXH7KHUHZDVDJRRGUHOLDELOLW\
for histological scoring between observers (0.5-0.99), with cartilage 
chodropathy scoring having the higKHVW&URQEDFK¶VDOSKDDQGDEQRUPDO
chondrocyte morphology scoring having the least (0.5). The reason for this 
may be because cartilage scoring may be easier to score than chondrocyte 
morphology. There is a clear cut for scoring fibrillations in the cartilage. 
Whereas for chondrocyte morphology assessment, the change from normal 
(score 0) to hypercellularity (score 1) and the early stages of cloning (score 2) 
may be hard to judge unlike normal (score 0), the late stages of cloning (score 
2) and cell death or hypocellularity (score 3) (see Chapter 2). The cartilage 
scoring system for example the OARSI system was developed in a way that it 
could be applied more consistently to less experienced investigators than the 
HHGS (Pritzker et al., 2006, Rutgers et al., 2010, Custers et al., 2007, Mankin 
et al., 1971). The chondrocyte morphology scoring system is a subset score of 
the HHGS (Mankin et al., 1971). Furthermore, the scale of the cartilage 
scoring system having more items (0-5 with 1-3 cartilage involvement for 
Janusz method of scoring and 0-6 with 1-4 involvement for the modified 
OARSI method of scoring) than the chondrocyte morphology scoring system 






consistency as the values analysed may be dependent on factors such as e.g. 
scale length (the number of items in the scale) (Helms et al., 2006). It has been 
shown that reliability increases with scale length (Cronbach, 1951, Voss et al., 
2000) 7KHUHIRUH UHVXOWV VKRXOG QRW EH HQWLUHO\ EDVHG RQ &URQEDFK¶V DOSKD
values. In this case, reliability was also measured using the &RKHQ¶V NDSSD
statistic. 
Some observer agreements for rating scoring methods between investigators 
may be observed as good but this can EHGXHWRFKDQFH7KH&RKHQ¶NDSSDț
was developed as a measure of agreement that corrected or adjusted for chance 
(Cohen, 1960, Kundel and Polansky, 2003). 7KHțYDOXHVIRU WKHKLVWRORJLFDO
assessments between the 4 investigators were in the range of slight to moderate 
DJUHHPHQW Ȁ FDQ EH FDOFXODWHG EHWZHHQ LQYHVWLJDWRUV ZKR UHSRUW UHVXOWV RQ
multiple categoULHVWKLVLVFDOOHGWKHZHLJKWHGț,t takes into account the actual 
closeness of measurement between investigators and how close the differences 
EHWZHHQ PHDVXUHPHQWV DUH 7KH ZHLJKWHG ț LV DOZD\V JUHDWHU WKDQ WKH
XQZHLJKWHGțZKHQXVHG IRUPXOWLSOHFDWHJRries but the same when used for 
RQO\WZRFDWHJRULHV7KHZHLJKWHGțLVFRPPRQO\XVHGWKDQWKHțDVLWUHIOHFWV
the actual agreement better (Cicchetti, 1981, Kundel and Polansky, 2003). The 
ZHLJKWHGțYDOXHVIRUWKHKLVWRORJLFDODVVHVVPHQWVEHWZHHQWKHLQYHVWLJDWRUV
were in the range of fair to almost perfect agreement.  
,Q ERWK XQZHLJKWHG DQG ZHLJKWHG ț Falculations, the scoring of cartilage 
chondropathy by Janusz or OARSI methods of scoring were observed to have 
higher agreement and the osteochondral junction integrity scoring having the 
least agreement. This may have to do with the cartilage damage being easier to 
score as mentioned above.  
5.5.4 Sensitivity of histological stains in the detection of 
matrix proteoglycan 
The Safranin O-Fast green stain is a widely used stain for assessing loss of 
proteoglycan in the cartilage of OA animals and in the HHGS in humans 
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(Gerwin et al., 2010, Mankin et al., 1971). Unlike the Toluidine blue stain 
which is also widely used, the Safranin O-Fast green stain has been reported as 
not being a sensitive indicator of proteoglycan content in the cartilage in which 
GAGs have been depleted (Camplejohn and Allard, 1988). Thus it was 
suggested that for simple histological scoring of proteoglycan content the 
Toluidine blue stain should be used (Kraus et al., 2010). The Alcian blue-PAS 
stain like the toluidine blue stain provides more intense staining as it has a 
higher affinity for sulphur in the cartilage compared to Safranin-O 
(Camplejohn and Allard, 1988, Scott, 1973). It was observed that Safranin-O 
Fast green stained sections were less sensitive in detecting proteoglycan 
content in the cartilage compared to the Alcian blue-PAS stained sections. This 
may be as a result of this stain being less sensitive as reported above or it being 
more sensitive in the detection of proteoglycan loss in the cartilage due to 
disease or wash-out during fixation or decalcification (Hyllested et al., 2002, 
Encfeldt and Hjertquist, 1967, Chevrier et al., 2005). The Safranin-O Fast 
green stained sections were able to discriminate better between OA disease 
groups and normal saline controls. The MIA (0.1mg and 1mg) injected rats 
were observed to have significantly higher proteoglycan loss scores compared 
to the saline injected rats than the Alcian blue-PAS stained sections which 
showed significantly higher proteoglycan loss in the 1mg MIA injected group 
only. It can also be argued that the 0.1mg MIA injected rats showed less 
proteoglycan loss as it may be a milder model and may show progressive loss 
of proteoglycan with time (d20-0.1mg MIA injected rats). In this case, further 
work would have to be done to investigate this, to examine the loss of 
proteoglycan in the 0.1mg MIA model using the Alcian blue-PAS stain and 




The MIA model displayed characteristic features of human knee OA observed 
as pain behaviour, inflammation and joint pathology. Inflammation and joint 
pathology did not differ between doses (0.1mg and 1mg MIA) and between 
duration (day 20 and 42) thus indicating that the low dose MIA model may not 
be a slow progressive model. Further work may be required to investigate 
inflammation and structural pathology at earlier time points (day 3, 7 and 14).  
Reduced hind paw withdrawal thresholds indicating allodynia in the absence of 
pronounced weight bearing asymmetry may suggest that mechanisms other 
than ongoing nociceptive and peripheral input mediate distal allodynia in the 
lower dose (0.1mg) MIA model. These results show that central augmentation 
of pain is not restricted to late severe OA (higher MIA doses) following MIA 
injection in rats.  
The MIA model was observed to show heterogeneity in terms of joint 
pathology, with pathology present in the posterior part of the knee at 3 weeks 
of arthritis induction but later spreads to the anterior part with time. Therefore 
pathology seen in a part of the joint should not be generalised to the whole 
knee joint in this model.  
Histological scoring systems are important for assessing of OA pathology. The 
cartilage scoring systems by Janusz or modified OARSI scoring displayed 
good agreements between each other and between the 4 investigators. 
Although one was not better than the other, the OARSI system should be 
applied over the Janusz system in scoring OA pathology as it is increasingly 
widely used and was created specifically for use in OA in order to inform a 
standardized practice. 
For the purpose of the detection of proteoglycan loss for OA pathology, the 
Safranin-O Fast green stain is the better choice. It is important that a stain 
which can detect proteoglycan loss efficiently is used, as proteoglycan content 
is considered one of the major characteristics of cartilage integrity in healthy, 
repaired or tissue-engineered cartilage (Rutgers et al., 2010).     
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CHAPTER 6; CONTRIBUTION OF NGF IN 
OA PAIN: TARGETING THE NGF-TRKA 
PATHWAY IN TWO RAT MODELS OF OA 
6.1 INTRODUCTION  
For more than half a century, the neurotrophin nerve growth factor (NGF)-ȕ
has been known to be responsible for the axonal growth and survival of 
sensory nerves (Levi-Montalcini and Hamburger, 1951). In the adult, NGF 
sensitises peripheral nociceptors and might contribute to the development of 
central sensitisation. NGF effects on sensitisation and nerve growth are 
predominantly mediated by binding to its high affinity receptor Tropomyosin 
receptor kinase A (TrkA) (Woolf, 1996). TrkA is a member of a family of 
receptors with tyrosine kinase activity, including also TrkB and TrkC. NGF 
can also bind, with lower affinity, to the p75 receptor although the biological 
relevance of these interactions remains uncertain. 
In recent years, NGF has been widely reported to play a role in many acute and 
chronic pain states, especially those associated with inflammation including 
rheumatoid arthritis and spondyloarthritis (Watson et al., 2008, McMahon, 
1996, Barthel et al., 2009). Increased endogenous NGF levels in the synovial 
fluid of people with chronic arthritis (Aloe et al., 1992), expression of NGF 
within the inflamed synovium (Manni et al., 2003) and subchondral bone 
(Walsh et al., 2010) are all evidence of NGF involvement in OA. In patients 
matched for severity of chondropathy, synovitis and NGF immunoreactivity 
was higher in patients who sought joint replacement surgery for symptomatic 
knee OA than in patients who had not reported symptoms, further indicating 
that NGF may mediate a contribution of inflammation to OA pain (Stoppiello 
et al., 2014). As well as sensitising nociceptors, NGF mediated growth of 
sensory nerve terminals into articular cartilage and into the inner regions of 
knee menisci might be a potential source of arthritis pain (Ashraf and Walsh, 
2008, Suri et al., 2007, Ashraf et al., 2011b). NGF itself can stimulate new 
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blood vessel growth (angiogenesis), a characteristic of chronic inflammation 
(Mapp and Walsh, 2012). NGF might also upregulate and increase the release 
of inflammatory mediators into the joint thereby augmenting inflammation and 
further exacerbating pain (âWHPSHOMDQG)HUMDQ, Linker et al., 2009). 
Sequestering NGF reduces pain in several experimental models (Iwakura et al., 
2010, McNamee et al., 2010) and NGF blockade reduces OA pain and 
improves function in randomised clinical trials (Lane et al., 2010, Sanga et al., 
2013, Tiseo et al., 2014). Furthermore, NGF blockade was associated with 
greater clinical benefit than observed in active treatment control groups using 
non-steroidal anti-inflammatory drugs (NSAIDS) or opiates (Verburg, 2012). 
Together these data support targeting of NGF pathways for the relief of OA 
pain. Randomised controlled trials of NGF blockers, although demonstrating 
analgesic efficacy, were once put on hold by the Federal Drug Administration 
due to evidence of an increased risk of rapidly progressive OA (RPOA-
osteonecrosis) leading to joint replacement surgery in some treated participants 
(Hochberg et al., 2012). RPOA was observed in patients receiving either of 2 
different NGF blockers, suggesting a class effect, and post hoc analyses have 
suggested that this increased risk might be associated with concurrent NSAID 
use, whereas it was not associated with potency of analgesia (Schnitzer et al., 
2014). 
Blocking TrkA should prevent NGF-mediated sensitisation, while permitting 
other, less well understood effects of p75 or Trk receptors (B & C), some of 
which may be beneficial or may potentiate the occurrence of adverse effects if 
blocked simultaneously (Winston et al., 2003). Evidence of hyperphagia 
observed in mice may be as a result of BDNF-TrkB blocking (Unger et al., 
2007). Small molecular, orally active Trk inhibitors may also be more 
acceptable and cost effective than monoclonal antibodies (Opar, 2010, Ghilardi 
et al., 2010). However selectivity of drugs for TrkA over related tyrosine 
kinase receptors has proved difficult to achieve. AR786 is a novel orally active 
inhibitor of TrkA kinase activity, with >1000 fold greater potency for TrkA 




Blockade of NGF signalling may reduce OA pain by reducing sensitisation, 
nerve growth and inflammation, but is not anticipated to be anti-nociceptive 
per se (Ma and Woolf, 1997). Traditional analgesic agents, such as opiates, 
also block normal, protective, nociceptive signalling, and display a rapid onset 
of action, but treatment discontinuation leads to an equally rapid increase in 
pain. Peripheral sensitisation is mediated, in part, by altered gene expression 
(Nicol and Vasko, 2007), and analgesic benefits from inhibiting NGF 
signalling may be expected to be of slower onset and sustained following 
treatment withdrawal. Preventive analgesia, for example by treating during 
critical phases during the development of OA or sensitisation, may permit 
treatment discontinuation with sustained pain reduction.  
Subchondral bone remodelling has been implicated to play an important role in 
OA pain and pathology from clinical and preclinical studies (Kwan Tat et al., 
2010, Ogino et al., 2009). Bone remodelling is controlled by the activity of 
osteoclasts (bone resorption cells) and osteoblasts (bone formation cells) with 
pathological bone resorption caused by increased osteoclast activity. NGF has 
been reported to be involved in inducing RANKL-independent 
osteoclastogenesis and may contribute to normal and pathological subchondral 
bone remodelling (Hemingway et al., 2011). 
The hypothesis was that the NGF-TrkA pathway mediates pain behaviour, 





Figure 6.1 NGF-TrkA complex formed by binding of NGF to the TrkA receptor. 
Downstream signalling of the formation of this complex may alter nociception, 
inflammation and structural pathology thereby moderating pain.  
 
6.2 AIMS  
x To explore the contribution of the NGF-TrkA pathway to pain 
behaviour, synovitis and joint pathology in the MIA and MNX rat 
models of OA. 
x To evaluate duration of sustained analgesia following discontinuation 







Refer to Chapter 2 for general methodology. Experiments were carried out on 
male Sprague Dawley rats (Charles River, UK) n=100, weighing 200-300g at 
time of OA induction. 
OA induction 
Rats were anaesthetised briefly with isoflurane (2% in O2) and received a 
single intra-articular injection of MIA (1mg/50µl; Sigma U.K; n = 20) in 
sterile 0.9% normal saline through the infrapatellar ligament of the knee or 
underwent transection of the medial meniscus (n = 50). Non osteoarthritic 
(saline; n =10 or SHAM; n = 20) rats were used as controls. MNX induction 
was carried out by Paul Mapp. 
Behavioural measurements of OA pain 
Pain behaviour was measured as hind limb weight-bearing asymmetry and 
distal allodynia to punctuate stimulation of the hind paw indicated by reduced 
hind paw withdrawal thresholds. Baseline measurements were obtained 
immediately prior to intra-articular injection or surgery (day 0) and every 2 to 
4 days from day 3 onwards for both therapeutic and preventive studies. Weight 
bearing asymmetry was assessed as a % difference in weight distribution 
between hind limbs (non-arthritic knee ± arthritic knee) / (non-arthritic knee + 
arthritic knee) x100 using an incapacitance meter (Linton Instruments, U.K). 
Hind paw withdrawal threshold was assessed using a series of von Frey 
monofilaments (Semmes-Weinstein monofilaments 1 - 15g) and recorded as 
the lowest weight of monofilament that elicited a withdrawal of the hind paw. 
TrkA inhibitor (AR786) drug therapy 
AR786 (kindly provided by Array Biopharma, Boulder, CO) was administered 
in a therapeutic or preventive protocol as previously described (Ghilardi et al., 
2010, Ghilardi et al., 2011).  
To evaluate the effects of therapeutic treatment of AR786 in the MIA and 
MNX models of OA, treatment with AR786 (30mg/kg, p.o., bid) or 5% 
Gelucire 50/13 vehicle (Gattefosse, Cedex, France) was administered twice 
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daily for 7 days from 2 weeks after OA induction (after OA was established). 
Rats were stratified into groups of n = 10 at day 10 (to ensure balanced weight 
bearing behaviour between groups prior to drug administration) by a researcher 
not otherwise involved in the study. Rats received either AR786 (MIA or 
MNX + drug) or vehicle (MIA or MNX + vehicle; saline or SHAM + vehicle).  
To evaluate the effects of a preventive treatment and treatment withdrawal of 
AR786 in the MNX model of OA, AR786 (30mg/kg, p.o., bid) or vehicle (5% 
Gelucire) was administered 1 h prior to and 8 h following OA induction, and 
thereafter until the end of the study (day 28 after OA induction). AR786 
treatment was discontinued and replaced with vehicle in some rats 2 weeks 
after continuous treatment. Rats were stratified into treatment groups each 
comprising 10 rats, 10 days after OA induction (i.e. 4 days before treatment 
discontinuation on day 14). Stratification was according to weight bearing 
asymmetry by a researcher not otherwise involved in the study. Rats received 
either AR786 (MNX + drug; MNX + drug-discontinued) or vehicle (MNX + 




Figure 6.2 Time course of experiment investigating the effect of a therapeutic 
administration of the TrkA inhibitor AR786 in the MIA and MNX models of OA.  
Rats were habituated to pain assessment (incapacitance meter and von Frey box) 
before baseline measurements were obtained. OA (intra-articular MIA injection or 
MNX surgery) was induced on day 0. Two weeks (day 14) following OA induction, 
AR786 was administered by oral gavage twice daily for 7 days (day 20). Rats were 
handled and scruffed daily prior to oral gavage. Macroscopic scoring and tissue (joint) 
harvesting were carried out on day 21. Weights, knee diameters, weight bearing and 




Figure 6.3 Time course of experiment investigating the effect of preventive 
administration of the TrkA inhibitor AR786 in the MNX model.  
AR786 was administered by oral gavage twice daily prior to (day -1), during and after 
OA induction until the end of the study (day 27). Rats were habituated to pain 
assessment (incapacitance meter and von Frey box) before baseline measurements 
were obtained. OA (MNX surgery) was induced on day 0. Macroscopic scoring and 
tissue (joint) harvesting were carried out on day 28. Weights, knee diameters, weight 
bearing and von Frey measurements were carried out at various time points.  
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Anti-NGF (muMab911 or M911) drug therapy 
Monoclonal antibody (M911) (Hongo et al., 2000) kindly provided by 
Rinat/Pfizer, San Francisco, CA was studied in both therapeutic and preventive 
protocols on pain behaviour, synovitis and osteoclast numbers in the MIA 
model by Luting Xu and Paul Mapp. Knee joint tissues from this study were 
then examined by me to investigate the effect of this antibody on 
histopathology.  
For the therapeutic protocol, rats received a weekly dose of M911 (s.c. 
10mg/kg) or PBS vehicle on day 14 and 21 after model induction; [M911 
(MIA or saline) or PBS (MIA or saline)] or a weekly dose of M911 (s.c. 
10ml/kg) or PBS from the day of model induction for the preventive protocol; 
[M911 (MIA or saline) or PBS vehicle (MIA or saline)].  
Inflammation 
Inflammation was assessed as joint swelling, synovial histological score and 
macrophage infiltration.  
Joint swelling was measured at the same time as behavioural measurements 
using digital electronic callipers (Mitutoyo, UK), with values representing 
difference in knee diameters (mm) between the arthritic (left) and non-arthritic 
(right) knee joints. 
Synovium with patella from each knee was harvested at the end of each study, 
HPEHGGHG LQ 2&7 DQG VQDS IUR]HQ RYHU PHOWLQJ LVRSHQWDQH ȝP WKLFN
synovial sections were cut using a motorized cryostat, mounted on glass slides, 
and briefly air dried before staining. Synovitis grade was assessed on 
haematoxylin and eosin-stained sections according to lining thickness and 
cellularity on a scale from 0 to 3. Synovitis scoring was performed using a 20× 
objective lens of a Zeiss Axioscop-50 microscope (Carl Zeiss Ltd, Welwyn 
Garden City, UK).  
Macrophage infiltration was identified by immunoreactivity for CD68 using 
the mouse monoclonal antibody clone ED1, and the peroxidase-conjugated 
avidin-biotin-peroxidase complex (ABC) method. Macrophage infiltration was 
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quantified using a 20× objective lens of a Zeiss Axioscop-50 microscope (Carl 
Zeiss Ltd, Welwyn Garden City, UK). Macrophage infiltration was quantified 
using fractional area and defined as the percentage of synovial area that was 
CD68-positive. 
Macroscopic chondropathy grading of knee joint pathology 
At the end of each study, rats were killed either by an overdose in CO2 
(therapeutic study ± day 21) or an overdose of pentobarbital (i.p.) (preventive 
study ± day 28). Macroscopic chondropathy scoring of knee joints was based 
on the Guingamp classification (Guingamp et al., 1997). Macroscopic lesions 
were graded as: 0 = normal appearance; 1 = slight yellowish discoloration of 
the chondral surface; 2 = little cartilage erosions in load-bearing areas; 3 = 
large erosions extending down to the subchondral bone; and 4 = large erosions 
with large areas of subchondral bone exposure. Each of the chondral 
compartments of the knee (the medial and lateral femoral condyles, the medial 
and lateral tibia plateaux, and the femoral groove) was graded. The 5 
compartment scores were summated (giving a maximum possible score of 20 
per knee). 
Osteoclast numbers 
Frontal sections (5µm) were stained for tartrate resistant acid phosphatase 
(TRAP) positive osteoclasts. 6 sections / rat (2 sections at 50µm intervals) 
from the anterior half of the knee joint were firstly dewaxed in xylene, 
rehydrated in serial alcohol and distilled water, and finally recalcified in a 
solution containing 1mM CaCl2 and 1mM MgCl2 in PBS before TRAP were 
stained using the commercially available kits (Sigma-Aldrich, UK). The 
number of TRAP positive osteoclasts were counted within the subchondral 
bone area comprising the area between the cartilage/bone junction and the 
growth plate as previously described (Parfitt et al., 1987, Dempster et al., 
2013). 
Histopathology 
At the end of the M911 study, rats were overdosed with pentobarbital (i.p.). 
Tibiofemoral joints were removed and post-fixed in neutral buffered formalin 
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(containing 4% formaldehyde), decalcified in ethylenediaminotetraacetaic acid 
(EDTA). Frontal tissue sections following the Osteoarthritis Research Society 
International (OARSI) guideline for histological assessment for OA in the rat 
ZHUHFXWDWȝPDQGVWDLQHGIRUHYDOXDWLRQV (Gerwin et al., 2010). 
Articular cartilage surface integrity was scored using the modified OARSI 
cartilage histopathology assessment system (Pritzker et al., 2006). Cartilage 
surface integrity and chondrocyte appearance were evaluated using H&E 
stained sections, and proteoglycan loss was determined using sections stained 
with Safranin-O Fast green, all of which followed the modified OARSI scoring 
and were scored on 3 sections / rat. Cartilage histopathology assessment 
system was scored on a scale from 0 (normal) to 6 (deformation), and a total 
joint damage score (range 0-24) was calculated as cartilage surface integrity x 
% of cartilage involved; 0 (no involvement) to 4 (>50% cartilage involvement) 
as previously described (Pritzker et al., 2006). Chondrocyte appearance was 
graded from 0 (normal appearance and density), to 3 (chondrocyte 
hypocellularity). Proteoglycan loss was evaluated on a scale from 0 (normal 
proteoglycan staining) to 4 (complete loss of proteoglycan staining) on 
Safranin-O Fast green stained sections (Mankin et al., 1971). 
Statistical analysis 
Synovial inflammation, lining thickness and cellularity were scored as 
previously described, one synovial section per animal and overall grade that 
best represented the section given (Ashraf et al., 2011a). Infiltration by 
macrophages was quantified on 4 fields of view per synovial section per 
animal (Walsh et al., 1998a).  
Statistical analysis was performed using Prism V.6 (Graph Pad, San Diego, 
California, USA). All data were analysed using Kruskal Wallis test followed 
by post hoc DXQQ¶V FRPSDULVRQ *UDSKV DUH presented as mean ± SEM or 
median. Data in text were presented as mean (95% CI) or median (IQR).  A 




6.4.1 Effects of AR786 in the MIA and MNX models of OA 
pain 
6.4.1.1 Body weight 
There was a gradual increase in the weight of all the rats irrespective of model 
induction or treatment administered (Fig. 6.4 A-C). The MNX vehicle-treated 
rats had lower weights from the start of the study and thereafter to the end of 
the study, but this was not significantly different to the rats in the other groups 






Figure 6.4 Time course of weight gain of rats.  
There was a gradual increase in weight in all groups of rats over the course of the 
study. Oral administration of either AR786 (30mg/kg p.o. bid) or vehicle (5% 
Gelucire 50/13) control given continuously (A and B) or discontinued (C) from day 
14 (dotted line) did not alter weight gain. Line graphs show mean ± SEM over time 
of n = 10 rats/group. Saline- or sham-operated vehicle-treated non-arthritic controls 






6.4.1.2 Pain behaviour 
Intra-articular injection of MIA, or MNX surgery, was each followed by 
increased weight bearing asymmetry from 3 days after arthritis induction, 
compared with non-arthritic saline-injected or sham operated controls (Figs. 
6.5 A-B and 6.6 A). Hind paw withdrawal thresholds ipsilateral to the arthritic 
knee were reduced (greater sensitivity) by 3 days after arthritis induction in the 
MIA group and 7-10 days in the MNX group compared with non-arthritic 
controls (saline; Fig. 6.5 C and sham; Figs. 6.5 D and 6.6 B). Pain behaviour 
was sustained in arthritic rats through to study termination at 21 or 28 days 
after arthritis induction (Figs. 6.5 and 6.6).  
Effects of TrkA inhibitor on established OA pain behaviour. 
Rats received TrkA inhibitor (AR786; 30mg/kg, p.o., bid) from 2 weeks after 
OA induction (at a time corresponding to fully established OA joint pathology 
and pain behaviour both in MIA- and MNX-induced models) and continued 
for 7 days. Weight bearing asymmetry was significantly reduced following 3 
days oral administration of AR786 in rats with MIA-induced OA [4.3 (-1.9 to 
10) %] and following 5 days treatment in MNX-induced OA [9.2 (5.1 to 13) 
%]), compared to vehicle-treated arthritic rats at the same time points (MIA 
[21 (14 to 29) % p<0.05, Fig. 6.5A] and MNX [27 (24 - 30) % p<0.05 Fig. 
6.5B]). Hind paw withdrawal thresholds were also significantly increased (less 
sensitive) following 5 days treatment with AR786 in rats with MIA-induced 
OA [11 (7 to 15) g] or MNX-induced OA [13 (10 to 15) g]) compared to 
vehicle treated arthritic rats (MIA [2.7 (1.2 to 4.2) g p<0.01 Fig. 6.5C] and 
MNX [6.9 (4.3 to 9.5) g p<0.05] Fig. 6.5D). After 7 days treatment with 
AR786, weight bearing and hind paw withdrawal thresholds in arthritic rats 
were comparable to those in non-arthritic controls, irrespective of the mode of 












Figure 6.5 Effects of therapeutic AR786 on pain behaviour in the MIA and MNX 
models of OA 
MIA injection or MNX surgery was associated with increased pain behaviour (weight 
bearing asymmetry and lowered hind paw withdrawal thresholds) which was 
sustained until the end of the study (day 21) (A-D). Administration of AR786 
(30mg/kg twice daily) (dotted line) completely abolished pain behaviour by day 17 (3 
days after start of treatment) in the MIA-injected rats (A & C). Pain behaviour was 
attenuated by day 19 (5 days after start of treatment) and completely abolished to 
control levels by day 21 (7 days after start of treatment) in the MNX-operated rats (B 
& D). Data indicate mean ± SEM for n = 10 rats per group. Differences between 
JURXSV ZHUH DQDO\VHG XVLQJ .UXVNDO :DOOLV WHVW IROORZHG E\ SRVW KRF 'XQQ¶V
comparison between groups. #p<0.05 MIA or MNX vehicle treated versus MIA- or 
MNX-drug treated, ++p<0.01 MIA- or MNX-drug treated versus saline- or sham-
operated vehicle non-arthritic controls, and ***p<0.001 MIA- or MNX-vehicle versus 




Effects of TrkA inhibition on the development of OA pain behaviour 
Rats received TrkA inhibitor (AR786; 30mg/kg, p.o., bid) one day prior to, 
during and after OA induction by MNX for 28 days. Treatment with AR786 
was withdrawn in one group of rats (n = 10) two weeks after arthritis induction 
and replaced with vehicle treatment. Weight bearing asymmetry did not 
manifest in MNX-operated rats which received AR786 throughout the study 
(day 28; [4 (-0.1 to 8.1) %] compared to vehicle-treated, MNX-operated rats 
[24 (21 to 28) %, p<0.001, Fig. 6.6A]). Likewise hind paw withdrawal 
thresholds were not altered compared to baseline in arthritic rats that received 
AR786 throughout the study (day 28; [12 (9.9 to 14) g]) compared to vehicle-
treated MNX-operated rats which had significantly lowered thresholds [5.8 
(4.2 to 7.4) g, p<0.01, Fig. 6.6B]. Following withdrawal of AR786 treatment 
14 days after arthritis induction, weight bearing asymmetry remained 
attenuated compared to arthritic rats that had never received the drug (Fig. 
6.6A). Over time, weight bearing asymmetry gradually increased, but remained 
significantly different to vehicle-treated control arthritic rats until 4 days 
before study termination 10 days after treatment withdrawal. Arthritic rats that 
had their treatment withdrawn did not show a statistical significant difference 
in weight bearing asymmetry compared to arthritic rats that had continued 
treatment through to the end of the study (Fig. 6.6A). By contrast, hind paw 
withdrawal thresholds rapidly decreased (increased sensitivity) following 
withdrawal of AR786 treatment, and 5 days after treatment withdrawal, 
thresholds were comparable to those in rats with MNX-induced OA that never 
received the drug (Fig. 6.6B). The rapid decrease in paw withdrawal threshold 
in the arthritic rats that had their treatment withdrawn was significantly 
different to arthritic rats with continued treatment at the end of the study (day 







Figure 6.6 Effect of preventive AR786 on pain behaviour in the MNX model of 
OA 
MNX surgery was carried out on day 0. Oral administration of either AR786 
(30mg/kg twice daily) or vehicle (5% Gelucire) control was given from a day before 
OA induction (day -1). AR786 treatment was discontinued in some rats (n = 10) and 
replaced with vehicle treatment (dotted line) 14 days after OA induction. MNX 
surgery was followed by an increase in pain behaviour (weight bearing asymmetry 
and lowered hind paw withdrawal thresholds - A and B) which was sustained until the 
end of the study (day 28) in rats that were treated with vehicle. Administration of 





behaviour (A and B). By day 24, 10 days after discontinuation of AR786 treatment in 
MNX-operated rats, weight bearing asymmetry was significantly greater than in 
sham-operated rats, but did not reach the levels observed in MNX-operated, vehicle-
treated rats and did not differ significantly from rats that continued to receive AR786 
through to the end of the study (day 28) (A). Paw withdrawal thresholds were reduced 
at day19, 5 days after treatment discontinuation in MNX-operated rats that had 
received AR786 treatment until day 14. By this time, paw withdrawal thresholds in 
MNX-operated rats did not differ significantly between those in which AR786 had 
been discontinued compared with those that had never received AR786 (MNX-
operated, vehicle-treated rats). Reduced paw withdrawal threshold was significantly 
different to sham-operated, vehicle-treated rats by day 21, 7 days after treatment 
discontinuation and to MNX-operated rats that continued to receive AR786 by day 28, 
14 days after treatment discontinuation (B). Data are mean ± SEM of n = 10 rats per 
group. #p<0.05 MNX vehicle treated versus MNX-drug continued, ++p<0.01 MNX-
drug discontinued versus sham-operated vehicle control, %%p<0.01 MNX vehicle 
treated versus MNX-drug discontinued, ***p<0.001 MNX vehicle treated versus 




6.4.1.3 Inflammation  
Small increases in knee diameter were observed from 3 days following intra-
articular injection of MIA, but did not differ from saline-injected control rats 
(Fig. 6.7A). MNX or SHAM surgery each resulted in increased knee diameter 
that persisted in MNX-operated rats, in which knee diameters were 
significantly greater than sham operated controls from 14 days after surgery 
(Fig. 6.7B). Intra-articular injection of MIA was followed by increased 
synovitis detected by histological examination of haematoxylin and eosin 
stained tissue sections (Figs 6.7C and 6.8B) and infiltration by macrophages 
(Fig 6.7E) into the synovium. Likewise after MNX surgery, there was an 
increase in synovitis (Figs 6.7D and 6.8E). Synovitis scores 21 days after intra-
articular injection of MIA [2 (2 to 3)] were significantly increased compared to 
saline-injected, non-arthritic controls [1 (0 to 1.5) p<0.01] (Figs. 6.7C and 
6.8A - B). Likewise after MNX surgery, synovitis scores were significantly 
increased compared to sham-operated rats [2 (2 to 3) v 0 (0 to 1) p<0.01] (Fig. 
6.7D and 8.6D - E). Macrophage fractional area after intra-articular MIA [19 
(10 to 29) %] were significantly increased compared to saline injected, non-
arthritic controls [5.9 (4.2 to 7.5) %, p<0.05, Fig 6.7E].  
Effects of TrkA inhibition on OA knee inflammation 
Joint swelling, synovial histology and macrophage fractional area were 
examined to determine whether observed effects of TrkA inhibition on pain 
behaviour may be mediated or moderated by effects on inflammation. 
Administration of AR786 had no significant effect on joint swelling in either 
the therapeutic or preventive studies (Fig. 6.7A and B), nor on macrophage 
fractional area in the therapeutic study (Fig. 6.7E). Administration of AR786 
from 14 days after intra-articular injection of MIA resulted in a significant 
reduction in synovitis score 7 days later [1 (0 to 2.3)], compared to vehicle-
treated, MIA-injected rats [2 (2 to 3), p<0.05, Fig. 6.7C]. However, no 
significant reductions in synovitis scores were observed at 4 weeks following 













Figure 6.7 Effect of AR786 on MIA- or MNX-induced inflammation 
Small changes in knee joint diameter were observed after intra-articular injection of 
MIA or saline (A), or after MNX- or sham surgery (B). Either AR786 (30mg/kg twice 
daily) or vehicle (5% Gelucire 50/13) control was administered orally from day 14 
(dotted line). Knee joint diameters did not differ significantly between MIA- or saline-
injected knees, nor between MIA-injected rats treated with either AR786 or Gelucire 
vehicle (A). MNX-operated knees displayed increased diameters compared with 
sham-operated knees from 14 days after surgery, when rats were treated with Gelucire 
vehicle, but not with AR786 (B). Synovitis was reduced in MIA-injected rat knees 
following day 14 treatment for 7 days with oral AR786 compared to Gelucire vehicle 
treated controls (C). Synovitis appeared similar after MNX surgery in rats treated 
either with AR786 or vehicle (D). Macrophage fractional area was increased in MIA-
injected rats but not significantly reduced by the 7 day AR786 treatment (E). Knee 
diameters are given as differences between injected/operated and contralateral knees. 
Data are mean ± SEM of n = 10 rats/group (A, B and E) or individual knees and 
median (C - D). *p<0.05 MIA- or MNX- vehicle versus saline or SHAM-operated 
controls respectively (A, B and E). #p<0.05 MIA vehicle treated versus MIA-drug 
treated and **p<0.01 MIA vehicle treated versus saline vehicle controls (C). 
**p<0.01, ***p<0.001 MNX-all groups versus sham-operated vehicle controls (D).  
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Figure 6.8 Synovitis in the MIA and MNX models of OA 
Synovia collected 21 days after saline injection and 7 days oral treatment with 
Gelucire vehicle (A) or 28 days after sham surgery and 28 days oral treatment with 
Gelucire vehicle (D) display normal microscopic appearances.  Both OA models 
displayed microscopic evidence of synovitis. MIA-injection (B), or MNX surgery (E) 
resulted in mild synovitis, characterised by increased thickness of the lining layer 
(blue arrows), and increased sublining cellularity. Synovitis was reduced in MIA-
injected rat knees following treatment for 7 days with oral AR786 (C) compared to 
Gelucire vehicle treated controls (B). Synovitis appeared similar after MNX surgery 
in rats treated either with AR786 (F) or vehicle (E). Photomicrographs show 
haematoxylin and eosin stained sections of synovium from a rat with the median 
synovitis score from each group. Scale bar = 200µm. 
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6.4.1.4 Macroscopic pathology  
Intra-articular injection of MIA or MNX surgery was each followed by 
increased cartilage damage as indicated by increased macroscopic 
chondropathy scores (Guingamp scoring method). Macroscopic chondropathy 
scores 21 days after arthritis induction were significantly higher in vehicle-
treated arthritic rats induced by MIA [10 (7.4 to 13)] or MNX [10 (8.6 to 12)], 
compared to non-arthritic control rats (saline-injected [1 (0.1 to 1.9) p<0.001] 
and sham-operated [1.5 (0.7 to 2.3) p<0.01] respectively) (Figs. 6.9A and B). 
Likewise, macroscopic chondropathy scores, 28 days after arthritis induction 
were significantly higher in vehicle-treated arthritic rats induced by MNX [7.1 
(6.2 to 8)] compared to non-arthritic sham-vehicle treated control rats [1.3 (0.5 
to 2.1) p<0.05] (Fig. 6.9C). MIA-induced OA was characterised by widespread 
macroscopic pathology (Figs. 6.9A and 6.11B), whereas chondropathy in 
MNX-induced OA was predominantly localised to the medial tibiofemoral 
joint (Figs. 6.9B - C and 6.10E). 
Administration of AR786 had no significant effect on macroscopic 
chondropathy in either OA model, whether administered in treatment or 
preventive protocols (Fig.  6.9).  




Figure 6.9 Macroscopic chondropathy scoring in the MIA and MNX models of 
OA.  
Both OA models displayed macroscopic evidence of chondropathy (A ± C), 21 days 
(A, B) or 28 days (C) after arthritis induction. Administration of AR786 had no 
significant effect on macroscopic evidence of chondropathy in either treatment (A, B) 
or preventive (C) protocols. Scatter plots show mean ± SEM of n = 10 rats/group. 
*p<0.05, **p<0.01, ***p<0.001 compared with saline-injected or SHAM-operated 









Figure 6.10 Macroscopic appearances of chondropathy in the MIA and MNX 
models of OA 
Tibial plateaux from 21 days after saline-injection (A) or sham-operation (D) show 
normal appearances with no evidence of cartilage erosion. Tibial plateaux from rats 21 
days after MIA-injection (B and C) or MNX (E and F), and following 7 days 
treatment with Gelucire vehicle (B and E) or AR786 (C and F) display erosions of the 
articular cartilage in the weight bearing areas (black arrows), some of which extend to 
the underlying subchondral bone. Osteophytosis (red arrows) is also apparent in the 
medial tibial plateau of the MNX-operated rats (E and F). Photomicrographs (A-F) 
show medial and lateral tibial plateaux from a rat with the median chondropathy score 
from each group. 
Lateral Medial 
Saline-vehicle MIA-vehicle MIA-AR786 
SHAM-vehicle MNX-vehicle MNX-AR786 
A B C 
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6.4.1.5 Numbers of TRAP positive osteoclasts  
The numbers of tartrate-resistant acid phosphatase (TRAP) positive 
multinucleated osteoclasts in the subchondral bone of the tibial plateau were 
increased following either intra-articular injection of MIA or MNX surgery. 
TRAP positive multinucleated osteoclasts numbers in the subchondral bone 21 
days after arthritis induction were significantly higher in MIA [68 (59 to 76)] 
and MNX [32 (26 to 38)] rats compared to non-arthritic control rats (saline-
injected [46 (43 to 50) p<0.001] or sham-operated [23 (19 to 26) p<0.05] 
respectively) (Fig. 6.11). Administration of AR786 from 14 days after OA 
induction by intra-articular injection of MIA resulted in significant reductions 
in the numbers of TRAP positive multinucleated osteoclasts 7 days later [51 
(46 to 56)], compared to vehicle-treated, MIA-injected rats [68 (59 to 76), 
p<0.05, Fig. 6.11A]. However, no significant reductions in numbers of TRAP 
positive osteoclasts were observed in the MNX-drug treated rats (Fig. 6.11B).  




Figure 6.11 TRAP positive multinucleated osteoclasts in MIA and MNX models 
of OA 
Numbers of TRAP positive multinucleated osteoclasts were increased in the joint 
samples of MIA and MNX-vehicle treated rats at day 21. Numbers of TRAP positive 
multinucleated osteoclasts were significantly reduced by AR786 therapeutic treatment 
in MIA-injected rats (A) but not MNX-operated rats (B). Scatter plots show mean ± 
SEM of n = 10 rats/group on six sections per rat from the anterior half of the knee 
joint. ***p<0.001 MIA vehicle versus saline-vehicle control, %%%%p<0.001 MIA-
vehicle versus naïve-drug treated (MIA-CONTRA) and ##p<0.01 MIA-vehicle versus 
MIA-drug treated (A). *p<0.05 MNX-vehicle or drug treated versus sham-operated 
vehicle (B). Ipsilateral (IPSI - arthritic knee), contralateral (CONTRA ± non-arthritic 
knee). 
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Figure 6.12 TRAP positive multinucleated osteoclasts in the MIA and MNX 
models of OA  
Medial tibial plateaux 21 days after saline-injection (A) or sham-operation (D) show 
minimal numbers of multinucleated osteoclasts (red arrows) in the subchondral bone. 
Both OA models displayed increased numbers of multinucleated osteoclasts (red 
arrpws), MIA-injection (B), or MNX surgery (E). Numbers of TRAP positive 
multinucleated osteoclasts were reduced in MIA-injected rat knees following 
treatment for 7 days with oral AR786 (C) compared to Gelucire vehicle treated 
controls (B). Numbers of TRAP positive multinucleated osteoclasts were similar after 
MNX surgery in rats treated either with AR786 (F) or vehicle (E). Photomicrographs 
show TRAP stained sections of the tibial plateau from a rat with the median osteoclast 
count from each group. Scale bar = 200µm.  
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6.4.2 Therapeutic and preventive administration of a 
monoclonal NGF antibody M911 in the MIA 
model  
Knee joint samples from the muMab911 study were kindly provided by Luting 
Xu to allow me to further explore possible effects of blocking the NGF-TrkA 
pathway on joint pathology in the MIA model. Pain data are not shown, but the 
compound had a significant inhibitory effect on pain behaviour in both 
therapeutic and preventive protocols. 
6.4.2.1 Structural (microscopic) pathology 
Intra-articular injection of MIA was associated with alterations to the articular 
cartilage of the knee joint after 28 days, measured as cartilage damage score in 
the tibial plateau compared to saline-injected rats (Fig 6.13A and B). There 
was also a significant decrease in matrix proteoglycan in the MIA-injected rats 
compared to saline controls (Fig 6.13E and F), and abnormal chondrocyte 
morphology in MIA-injected rats compared to saline-injected rats (Fig 6.13C 
and D). M911 (s.c. 10mg/kg) did not significantly alter histopathological 
changes to the cartilage in any of the treatment protocols: 14 days after arthritis 
induction (therapeutic treatment; Fig 6.13A, C and E) or weekly administration 
before and after arthritis induction (preventive treatment; Fig 6.13B, D and F). 
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Figure 6.13 Microscopic pathology in the MIA model of OA  
The MIA model displayed histologic evidence of pathology measured as cartilage 
chondropathy (A and B), abnormal chondrocyte morphology (C and D) and 
proteoglycan loss (E and F), 28 days after arthritis induction. Administration of M911 
had no significant effect on microscopic pathology in either treatment (A, C and E) or 
preventive (B, D and F) protocols. Scatter plots show mean ± SEM of n = 7-10 
rats/group. *p<0.05, **p<0.01, ***p<0.001 MIA-PBS or MIA-M911 compared with 
saline-injected PBS vehicle controls. 
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Figure 6.14 Microscopic appearances of pathology in the MIA model of OA 
Knee joints collected 28 days after saline injection and 2 weeks of weekly 
subcutaneous injection with PBS vehicle (A) or 4 weeks of weekly subcutaneous 
injection with PBS vehicle (D) display normal microscopic appearances. The MIA 
model displayed microscopic evidence of structural pathology in both studies (B, C, E 
and F). MIA-injection resulted in cartilage fibrillations (E), erosions (B and F), 
subchondral bone breakdown (F) and abnormal morphology of chondrocytes (B, C, E 
and F). Structural pathology appeared reduced or mild in the MIA-injected rat knees 
following 2 weeks of weekly subcutaneous treatment with M911 (C) but this was not 
significant compared to PBS vehicle treated controls (B). Photomicrographs show 
haematoxylin and eosin stained sections of the medial tibial plateau from a rat with 
the median cartilage chondropathy (OARSI) score from each group. Scale bar = 
200µm. 
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6.5 DISCUSSION 
The effect of a novel selective TrkA inhibitor, AR786 and an anti-NGF 
antibody M911 was investigated in two rat models of OA.  It was found that 
pain behaviour associated with OA was inhibited by AR786 using both 
preventive and therapeutic protocols. AR786 also reduced OA induced 
synovitis and TRAP positive multinucleated osteoclast numbers in the MIA 
model, whereas no significant effect on chondropathy was detected in both 
MIA and MNX models. M911 administration in both preventive and 
therapeutic protocols did not significantly affect structural pathology assessed 
by histology. These data suggest the potential of a small molecule, orally 
available, selective TrkA inhibitor for the treatment of OA pain.  
Intra-articular injection of MIA, or MNX surgery, led to pathological features 
of OA (chondropathy and mild synovitis), and increased pain behaviours, as 
previously reported (Ashraf et al., 2014, Sagar et al., 2013). Weight bearing 
asymmetry, comparable to standing pain in people with OA (Christiansen and 
Stevens-Lapsley, 2010) might result from a combination of nociception, 
peripheral and central sensitisation (Suokas et al., 2012). Reductions in hind 
paw withdrawal thresholds to punctate mechanical stimulation are indicative of 
allodynia, and are associated with the development of central sensitisation in 
rats with OA (Sagar et al., 2010). Central sensitisation may augment joint pain, 
and contribute to more widespread pain sensitivity in people with OA (Suokas 
et al., 2012). These data support a sequential progression from peripheral to 
central nociceptive mechanisms during the induction of OA in rats, with early 
weight bearing asymmetry followed by the establishment of distal allodynia. 
Sequential development of augmented pain processing during OA 
development is further indicated by electrophysiological, cellular and 
molecular studies in rat models of OA (Sagar et al., 2011, Burston et al., 2013). 
By 14 days after OA induction, either by MIA or MNX, an OA phenotype is 
established which resembles that seen in humans, including chondropathy, 
synovitis, weight bearing asymmetry and reduced mechanical pain thresholds 
at sites distant from the affected joint (Mapp et al., 2013). These characteristics 
change little during the following 35 days in the absence of therapeutic 
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intervention. Minor differences in pain phenotypes reported between MIA and 
MNX OA models may reflect heterogeneity also observed between different 
people with OA. Reductions in hind paw withdrawal threshold in MIA-
induced OA were more pronounced than in MNX-induced OA, as previously 
reported (Mapp et al., 2013), consistent with a greater contribution from 
central pain processing (Ivanavicius et al., 2007, Orita et al., 2011). 
Consistency of TrkA inhibitor analgesic effects between models suggests that 
findings may be relevant to OA in general, rather than being specific to the 
mode of OA induction.  
Oral administration of the TrkA inhibitor AR786 abolished pain behaviour in 
both MIA and MNX models in preventive and therapeutic studies. These 
findings extend previous reports of analgesic effects of Trk inhibitors in non-
malignant skeletal and bone cancer pain (Ghilardi et al., 2010, Ghilardi et al., 
2011), to indicate that analgesic effects of Trk inhibition may be mediated 
specifically by TrkA. NGF blockade using a TrkA-immunoglobulin G (TrkA-
IgG) fusion protein also reduced pain behaviour in rodent OA (McNamee et 
al., 2010). Analgesic efficacy of NGF blockade using monoclonal antibodies in 
clinical trials confirms the importance of NGF to OA pain. These findings 
indicate a role also for the high affinity NGF receptor, TrkA, and demonstrate 
the potential for a small molecule selective inhibitor of TrkA as a novel 
therapeutic strategy in OA. NGF is released during inflammation, and 
increased expression of NGF within the synovium (Stoppiello et al., 2014) or 
subchondral bone (Walsh et al., 2010) may mediate OA pain by binding to 
TrkA on adjacent unmyelinated and thinly myelinated sensory neurones. NGF 
binding to TrkA initiates phosphorylation and increased sensitivity of the 
calcium channel TRPV1, increased expression of neuropeptides substance P, 
and calcitonin gene-related peptide (CGRP) and of brain derived neurotrophic 
factor (BDNF) (Pezet and McMahon, 2006, Basbaum et al., 2009).  Increased 
neuropeptide release into the joint can facilitate neurogenic inflammation and 
angiogenesis, and further sensitise articular nociceptors (Mapp et al., 2012, 
Bullock et al., 2014). Release of BDNF within the spinal cord may contribute 
to central sensitisation (Lu et al., 2009). Rats with OA are particularly sensitive 
to the effects of NGF on pain behaviour, and display increased TrkA 
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expression in DRGs not only ipsilateral, but also contralateral to the arthritic 
joint (Ashraf et al., 2014).  
AR786 displays low CNS penetration, with plasma : CSF ratios approximately 
10:1 (Andrews, 2014). However, TrkA inhibition attenuated distal allodynia to 
punctuate stimulation, a behavioural correlate of abnormal central pain 
processing. NGF may induce central sensitisation indirectly by increasing 
BDNF expression in primary afferent neurons (Apfel et al., 1996). 
Furthermore, synovitis may be a stimulus to the generation of central 
sensitisation during arthritis (Ashraf et al., 2014). Reductions in distal 
allodynia relapsed more quickly after treatment withdrawal than did weight 
bearing asymmetry, suggesting that TrkA inhibition has a more sustained 
effect on peripheral pain processing, than on central sensitisation. Referred 
pain (distal allodynia) results from both central and peripheral input (Suokas et 
al., 2012). It is likely, therefore that reduction of distal allodynia following 
TrkA inhibition results from blocking peripheral actions of NGF.   
It was observed that rats with OA that received 14 days pre-emptive treatment 
continued to display improved weight bearing asymmetry for at least 10 days 
after treatment withdrawal. These sustained analgesic effects are consistent 
with a reduction in peripheral sensitisation that requires further sustained 
stimulus from the arthritic joint in order to relapse. This raises the potential 
that TrkA inhibition might prevent the transition to a sensitised state if 
administered for short periods during critical phases of OA development, or 
during active phases of disease. This contrasts, for example, with NSAIDs 
such as indomethacin, which, while reducing weight bearing asymmetry in 
MNX-induced OA, requires continued treatment for maintenance of effect, 
with a relapse of weight bearing asymmetry to levels that are comparable to 
those seen in arthritic rats that have never received indomethacin only 3 days 
after treatment withdrawal (Ashraf et al., 2014, Sagar et al., 2011).  
On the other hand, the discontinued NSAID nimesulide being able to show a 
sustained effect in attenuating allodynia (but not weight bearing asymmetry) 
ZKHUH WKH 7UN$ LQKLELWRU GLGQ¶W IXUWKHU H[SDQGV RQ WKH IDFW WKDW 7UN$
inhibition has a more sustained effect on peripheral pain processing, than on 
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central sensitisation and that other mechanisms which may or may not be 
involving the NGF-TrkA pathway are at work here (Sagar et al., 2011). For 
example other central mechanisms of pain i.e. inputs from the spinal cord, such 
as increased expression of cyclooxygenases (COX) maybe involved as spinal 
COX-2 expression has been known to be increased and plays a crucial role in 
pain (Prochazkova et al., 2009, Seybold et al., 2003).  
Synovitis is a characteristic feature of human knee OA that is associated with 
pain (Hill et al., 2007). Inflammation itself might mediate pain through the 
generation of factors that activate or sensitise joint nociceptors, including NGF 
(Fischer et al., 2010). Furthermore, synovitis might contribute to progressive 
cartilage damage (Scanzello and Goldring, 2012, Hill et al., 2007, Loeuille et 
al., 2005). TrkA activation increases inflammatory neuropeptide release from 
sensory nerves, including substance P and calcitonin gene-related peptide, 
these may mediate neurogenic inflammation (Kidd and Urban, 2001). 
Furthermore, TrkA might be expressed by mast cells (Nilsson et al., 1997), 
synovial fibroblasts (Manni et al., 2003), macrophages (Barouch et al., 2001) 
and chondrocytes (Pecchi et al., 2014), and inflammatory cell activation by 
NGF leads to the upregulation and release of histamine, bradykinin or 
prostaglandins, which might further activate or sensitise joint nociceptors 
(âWHPSHOMDQG)HUMDQ, Linker et al., 2009). AR786 reduced synovitis in 
rats with MIA-induced OA, but did not significantly reduce either knee 
swelling or synovitis in rats with MNX-induced OA. Different effects of 
AR786 on synovitis between the 2 models may reflect different mechanisms of 
inflammation, or a more intense (and less responsive) synovitis in the MNX 
model (Mapp et al., 2013).   
Chondropathy is a hallmark of human OA (Walsh et al., 2008), and cartilage 
changes have been associated with pain severity (Torres et al., 2006). Clinical 
trials of NGF-blocking antibodies were once put on hold by the Federal Drug 
Administration due to the rare occurrence of RPOA in patients receiving these 
agents (Schnitzer et al., 2014). Small reductions in macroscopic chondropathy 
scores observed following treatment with AR786 did not reach statistical 
significance and are unlikely to have made any major contribution to the 
observed reductions in pain behaviour. Likewise the minimal reductions in 
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microscopic chondropathy scores with therapeutic administrations of M911 
also not reaching significance may not have contributed to the analgesic effect 
of this compound (pain data are not shown). In both AR786 and M911 studies, 
there was no evidence of OA exacerbation following treatment, but the 
occurrence of rare effects seen in predisposed individuals to NGF blockade 
cannot be excluded. It is possible that RPOA associated with NGF-blockade 
using monoclonal antibodies is due to effects of NGF that are not mediated by 
TrkA, or occur only in association with concomitant cyclooxygenase inhibition 
or other predisposing factors (Schnitzer et al., 2014). These studies were not 
designed to investigate rare adverse events as they were limited by small n 
numbers and the experiments were carried out on a species that share a 
relatively homogenous genetic background and dosing regimens have been 
undertaken for a short period of time and without concomitant medications. 
Therefore, more extensive toxicological studies would need to be undertaken 
with anti-NGF antibodies and TrkA inhibitors to investigate effects of NGF-
TrkA blockade on structural pathology and contribution of these effects to rare 
adverse events. 
Subchondral bone remodelling plays an important role in OA pain and 
pathology. Bone remodelling may occur before cartilage degeneration in OA, 
at which stage potential pain mediators (cyclooxygenase 2, substance P, TNF-
ĮPD\EHGHWHFWHGLQWKHVXEFKRQGUDOERQH(Kwan Tat et al., 2010, Ogino et 
al., 2009). Reports from the Boston Osteoarthritis Knee study reported that 
bone marrow lesions, detected by MRI, were strongly associated with OA knee 
pain and recent clinical trials using the bisphosphonate zoledranate confirms 
this association (Felson et al., 2001, Laslett et al., 2012). The outgrowth of 
sensory nerves following blood vessel growth within the subchondral bone 
may be a cause of pain in OA as these nerves are usually prone to sensitisation 
and have been reported to express the TrkA receptor (Suri et al., 2007, 
Castañeda-Corral et al., 2011). Bone remodelling is controlled by the activity 
of osteoclasts (bone resorption cells) and osteoblasts (bone formation cells). 
Osteoclastogenesis, development of osteoclasts is regulated by the 
osteoprotegerin (OPG)/receptor activator of NF-ț%5$1.UHFHSWRUDFWLYDWRU
of NF-ț% OLJDQG 5$1./ V\VWHP $VVRFLDWLRQV EHWZHHQ SDLQ DQG ERQH
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marrow lesions and the analgesic effects of zoledronic acid may suggest effects 
mediated by osteoclast activity in the subchondral bone. AR786 reduced 
numbers of TRAP positive multinucleated osteoclasts in the subchondral bone 
of rats with MIA-induced OA but did not significantly reduce numbers of 
TRAP positive multinucleated osteoclasts in rats with MNX-induced OA. The 
effects of AR786 in reducing pain behaviour and osteoclast numbers in the 
MIA model is similar to reports on the RANKL inhibitor, osteoprotegerin Fc 
(OPG-FC) in inhibiting pain behaviour by targeting osteoclasts (Sagar et al., 
2014). This suggests involvement of NGF-TrkA pathway not just in mediating 
nociception and inflammation but also in mediating pathology by activating 
function of cells (osteoclast) that contribute to structural pathology.  
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6.6 CONCLUSIONS 
Inhibition of NGF activity by blocking TrkA reduced pain behaviour in two rat 
models of OA. Analgesic mechanisms of TrkA inhibition might include 
reductions in synovitis, osteoclast activity as well as reducing nociceptor 
sensitisation.  
Reductions in pain behaviour were observed both using preventive and 
treatment protocols, and were sustained for up to 10 days despite treatment 
discontinuation. Clinical trials of NGF blockade have demonstrated potential 
for blocking the NGF-TrkA pathway for the relief of OA pain.  
Further research should address possible differences between NGF-blockade 
and selective TrkA inhibition, and the potential for sustained benefit from 
discontinuous treatment, in order to help realise the potential of NGF-TrkA 
pathway inhibition for OA pain relief.  
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CHAPTER 7; GENERAL DISCUSSION 
7.1 MAIN STUDY FINDINGS 
Using animal models of arthritis, these data show that the NGF-TrkA pathway 
may play a role in mediating inflammation, osteochondral pathology and pain 
behaviour. These data also show validated methods for assessing joint 
pathology in these rat models. 
The carrageenan model of inflammatory arthritis exhibited pain behaviour and 
acute inflammation observed as joint swelling, synovitis and macrophage 
infiltration into the synovium. The macrophage infiltration observed consisted 
of all activated macrophages displaying features of both M1 and M2 subtypes.  
The MIA and MNX models of OA exhibited inflammation (joint swelling, 
synovitis and macrophage infiltration) and pain behaviour. The MIA and MNX 
models displayed structural pathology both macroscopically and 
microscopically. The pain phenotypes (weight bearing asymmetry and hind 
paw withdrawal threshold) observed in the MIA model were dependent on the 
MIA dose. The 0.1mg MIA injected rats displayed reduced hind paw 
withdrawal threshold but not weight bearing asymmetry whereas the 1mg MIA 
injected rats displayed both.   
The Guingamp method of macroscopic scoring permitted discrimination 
between OA disease group (MIA and MNX) and normal controls (saline and 
sham). This method of scoring had a higher reliability and reproducibility than 
other macroscopic scoring methods (Indian ink and modified SFA).  
The Janusz and modified OARSI histopathology scoring systems for cartilage 
damage were reliable and reproducible with similar variability and had strong 
correlations to each other. For histopathological assessment in the MIA model 
at earlier time points, the total joint score (anterior and posterior part) gave 
sufficient power to enable discrimination between the diseased group and the 
non-arthritic saline-injected controls. This finding is original as it contradicts 
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what was published for OARSI histopathological assessments in the rat 
(Gerwin et al., 2010), which encourages assessing only one part of the joint. 
Following preventive or therapeutic treatment with the tropomyosin receptor 
kinase (Trk) A inhibitor, AR786, pain behaviour was inhibited in both MIA 
and MNX models, while inflammation was attenuated only in the MIA model. 
Analgesia was sustained for up to 10 days in the MNX model following 
AR786 treatment discontinuation. AR786 administration reduced the numbers 
of tartrate resistant acid phosphatase (TRAP) positive multinucleated 
osteoclasts in the MIA model, although it did not significantly alter 
macroscopic measures of structural pathology in either models of OA. These 
findings are novel as this thesis first reports the use of the TrkA inhibitor 
AR786 in reducing OA associated pain behaviour in the MIA and MNX 
models of OA. It also reports on the sustained analgesic effect of this 
compound in the MNX model. Preventive and therapeutic treatment with the 
anti±NGF monoclonal antibody M911 also did not alter changes to cartilage 
pathology. 
Collectively these findings support the hypothesis that pain behaviour and 
structural pathology are features of OA models that are mediated by NGF and 
TrkA. NGF may mediate OA pain by altering joint function and structure, 
including neuronal sensitisation, inflammation and subchondral osteoclast 
activation. Therefore inhibition of the NGF-TrkA signalling has therapeutic 
potential in ameliorating structural pathology and associated pain in OA. 
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7.2 NGF; A MEDIATOR OF INFLAMMATION, 
OSTEOCHONDRAL PATHOLOGY AND PAIN 
IN OSTEOARTHRITIS 
To date there are no effective structure modifying treatments, and available 
analgesic treatments are limited in efficacy and have associated adverse side 
effects (Matthews and Hunter, 2011, Goldring and Berenbaum, 2015). These 
two areas of unmet clinical need (structural joint degeneration and pain) co-
exist but may not necessarily coincide as treatments that attenuate pain are 
rarely able to alter structural pathology and in some cases may exacerbate joint 
pathology (Reijman et al., 2005, Brown et al., 2012). On the other hand, 
structure modifying treatments (e.g. doxycycline) often fail to provide effective 
pain relief (Brandt et al., 2005, Nuesch et al., 2009). Given the complexity of 
OA, a single therapy may not be effective and therefore future research 
requires addressing both symptoms and structural changes (Mobasheri, 2013, 
Pulsatelli et al., 2013, Thakur et al., 2014).  
The findings from this thesis show the symptomatic features of OA 
(inflammation, osteochondral pathology and pain behaviour), evidence of 
NGF-TrkA involvement in contributing to these features and the potential of 
targeting the TrkA receptor. 
7.2.1 Inflammation 
In this thesis, inflammation was observed as joint swelling, synovitis and 
infiltration into the synovium by inflammatory macrophages. 
Intra-DUWLFXODULQMHFWLRQRIȜFDUUDJHHQDQKDVEHHQVKRZQSUHYLRXVO\WRLQGXFH
acute inflammation (Walsh et al., 1998a, Valenti et al., 2012), similarly in this 
thesis, intra-articular injection of 2% carrageenan induced acute inflammation 
(joint swelling and synovitis). With this model, joint swelling begins within 
minutes of injection and therefore permits an accurate definition of the time of 
onset of acute inflammation. Intra-articular injection of 1mg of MIA or MNX 
surgery have also been shown to induce synovitis (Mapp et al., 2013), 
similarly in this thesis, intra-articular injection of 1mg of MIA or MNX 
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surgery induced inflammation. Oral administration of AR786 was observed to 
reduce synovitis in the MIA model, the mechanism of this inhibition is not 
entirely clear but it highlights the possible involvement of the NGF-TrkA in 
mediating inflammation. Increased expression of NGF has been reported in 
human OA synovium (Stoppiello et al., 2014) produced by synovial fibroblasts 
or macrophages. Synovial cells express TrkA and are therefore sensitive to 
NGF. NGF can also stimulate the proliferation of the synoviocytes 
(Raychaudhuri and Raychaudhuri, 2009). 
Synovitis is reported to contribute to OA pain in both preclinical and clinical 
studies (Orita et al., 2012, Hunter et al., 2013). Inflammatory cells are also 
reported to contribute to OA (de Lange-Brokaar et al., 2012). For example, 
activated macrophages were detected in OA patients and were associated with 
clinical OA symptoms (Byers Kraus et al., 2013, Daghestani et al., 2015).  
In this thesis it was demonstrated that macrophages of the M1 and M2 
subtypes were present in the carrageenan model of inflammatory arthritis. ED 
macrophage markers were used to stain for all activated phagocytic 
macrophages (ED1 ± CD68), macrophages involved in tissue healing (ED2 ± 
CD163) and chronic inflammatory macrophages (ED3 ± CD169). Likewise in 
the MIA model of OA, macrophages expressing ED1 were present in the 
synovium. As reported in other studies, macrophages that express these 
markers were observed in the joint of intra-articular injected carrageenan and 
antigen induced arthritis rats (Walsh et al., 1998a, Dijkstra et al., 1987). 
AR786 was observed to have no significant effect in reducing ED1 expressing 
macrophages although it significantly reduced synovitis score. This would 
suggest that NGF-TrkA may contribute to the regulation of inflammatory 
mediators that contribute to the inflammatory process or other inflammatory 
cells. NGF was reported to play a role in the stimulation of inflammatory 
cytokines (IL-1, -2, -6, -8 and TNF) and leukocyte activation or migration 
(Seidel et al., 2010). TrkA is expressed by most immune cells  (B and T 
lymphocytes, mast cells, monocytes, neutrophils, basophils and eosinophils) 
thus allowing NGF to modulate cell differentiation and regulate the immune 
response (Aloe et al., 2012, Bracci-Laudiero, 2010, Prencipe et al., 2014). 
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7.2.2 Osteochondral pathology 
Characteristic features of structural pathology in OA can be observed 
macroscopically and by histology on joint tissue sections. The features 
observed in humans are cartilage fibrillations and eventual loss of cartilage, 
loss of proteoglycan, loss of osteochondral junction integrity (increased 
breaching of the osteochondral junction by vascular channels), subchondral 
bone remodelling (Walsh et al., 2008, Stoppiello et al., 2014). In rat models of 
OA, structural changes in the joint consists of cartilage fibrillations, abnormal 
morphology of chondrocytes, proteoglycan loss, loss of osteochondral junction 
integrity, subchondral bone remodelling and increased numbers of activated 
osteoclasts in the subchondral bone (Mapp et al., 2013, Ashraf et al., 2011a, 
Sagar et al., 2014, Yu et al., 2013). Similarly in this thesis the MIA and MNX 
models also demonstrated the above features of OA structural pathology. In 
this respect the MIA and MNX models used in this thesis were shown to 
effectively mimic the human condition.  
Although the TrkA inhibitor did not significantly reduce macroscopic 
chondropathy changes in the MIA model, it does not discount that there might 
be a small biologic effect on chondropathy. Irrespective of the lack of effect in 
altering chondropathy, it was observed to reduce the numbers of TRAP 
positive osteoclasts in the MIA model. NGF was reported to play a role in 
inducing RANKL-independent osteoclastogenesis (Hemingway et al., 2011). 
NGF induced both osteoclast differentiation and activation. These NGF-
induced cells were positive for TRAP and capable of bone resorption 
(Hemingway et al., 2011). Other reports point to the involvement of osteoclasts 
in chondropathy and pain as their inhibition prevented cartilage pathology and 
pain behaviour in the MIA model (Strassle et al., 2010, Sagar et al., 2014). The 
results in this thesis support the involvement of NGF-TrkA in regulating 
osteoclast function and points to important effects on OA pathology.  
7.2.3 Pain 
Chronic pain represents a major public health burden with evident 
socioeconomic impact on its sufferers, for example, in people with OA.  
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OA pain can be either localised and/or referred. Localised pain may be 
associated with peripheral sensitization while referred pain may be associated 
with both peripheral and central sensitization (Suokas et al., 2012, Hucho and 
Levine, 2007). Central sensitization is implicated in advanced OA as 
evidenced by the presence of persistent pain even after knee replacement 
surgery and spread of pain beyond the affected joint (Lundblad et al., 2008, 
Lluch et al., 2014). Pain behaviours in this thesis, weight bearing asymmetry 
(pain on loading) and lowered paw withdrawal threshold at remote sites 
broadly represent peripheral and central sensitization in OA (Sagar et al., 2010, 
Ashraf et al., 2014).  
One of the main findings from this thesis was that reduced paw withdrawal 
thresholds was not restricted to the higher 1mg MIA dose but was present in 
the low 0.1mg MIA dose. Indeed, hind paw withdrawal thresholds were 
lowered following both the 0.1mg dose of MIA and the 1mg dose of MIA, in 
the absence of weight bearing asymmetry in the 0.1mg dose. This might offer a 
model of a different pain phenotype which suggests that there may be different 
subgroups of people in OA which present with central pain only, and the 
separation of these subgroups of people would allow for the development of 
targeted treatments for OA pain.  
Recent clinical studies suggest that NGF may represent a good target for the 
development of innovative analgesic treatments. Evidence from both clinical 
and preclinical research indicates that NGF is an important mediator of 
inflammatory nociceptive and neuropathic pain (Watson et al., 2008, Seidel et 
al., 2010, Seidel et al., 2013, Ashraf et al., 2014). NGF signals through TrkA 
or p75, and although p75 can interact with TrkA, most of NGF-induced 
sensitisation is reported to occur through TrkA (Eibl et al., 2012, Watson et al., 
2008).  
To confirm the role of the NGF-TrkA in mediating pain, the TrkA inhibitor 
AR786 was used. It was observed that AR876 attenuated already established 
pain behaviour when administered therapeutically and prevented the 
development of pain behaviour when given as a pre-emptive treatment in OA 
models. These results observed in this thesis are in line with already published 
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work that report that inhibition of NGF function reduces hyperalgesia and pain 
behaviour in models of acute local inflammation, chronic inflammatory 
arthritis and OA (McNamee et al., 2010, Seidel et al., 2010, Seidel et al., 
2013). Other studies report the attenuation of non-malignant skeletal or bone 
cancer pain with inhibition of TrkA function (Ghilardi et al., 2010, Ghilardi et 
al., 2011), although the Trk inhibitor used in both studies blocks the other two 
Trk (TrkB, C) receptors in addition to TrkA. In this thesis, there is evidence for 
TrkA involvement in mediating OA pain as the inhibitor used here was 
selective for TrkA. Also in the above studies, they report that early or 
sustained administration but not late or acute administration was effective in 
inhibiting pain behaviour, while in this thesis late or acute administration was 
just as effective as the early or sustained administration of AR786. Thus 
implying that this inhibitor would be beneficial for use in both early and late 
OA pain states. 
AR786 reduced synovitis and numbers of TRAP positive osteoclast, which 
indicates this therapeutic approach may reduce the mechanisms underlying the 
pain behaviour in these models. It is likely that synovitis contributes to pain 
through the synthesis and release of factors (neuropeptides; substance P, 
CGRP, other inflammatory mediators; ILs, TNF, histamine, bradykinin, 
prostaglandins and NGF) that activate or sensitise joint nociceptors (Fischer et 
al., 2010, Kidd and Urban, 2001). TrkA activation is reported to contribute to 
increased neuropeptide release (Mantyh et al., 2011). Osteoclasts might 
contribute to pain by creating an acidic environment in the subchondral bone 
(Jimenez-Andrade et al., 2010) and the release of proteases such as cathepsin 
K (Teitelbaum, 2007). The released protons (H+) can directly activate and 
sensitise sensory neurones thus increasing pain signalling (Jimenez-Andrade et 
al., 2010). Osteoclasts are able to cut channels through the osteochondral 
junction (Mapp and Walsh, 2012), and loss of osteochondral junction integrity 
may expose sensory nerves in the subchondral bone to sensitising factors from 
the cartilage and synovium (Mapp and Walsh, 2012). 
NGF-blocking antibodies sequester NGF and prevent it binding to its 
receptors, therefore it is not known if NGF contributes to pain through p75 or 
only through TrkA, although NGF binding to p75 has been reported to cause 
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pain (Watanabe et al., 2008). The p75 receptor was associated with 
inflammatory pain in the CFA model. The findings in this thesis suggest that 
the majority of the pain behaviour exhibited by the OA models is dependent on 
NGF binding to TrkA, and not through the p75 receptor as AR786 specifically 
blocks TrkA. Nevertheless, NGF binding to p75 modulates or increases 
binding of NGF to TrkA (Toni et al., 2014, Lachance et al., 1997) and 
blocking NGF binding to p75 on sympathetic neurones transiently reduces 
TrkA activation (Lachance et al., 1997). Therefore NGF-p75 signalling may be 
influenced by AR786 and contribute to the effect reported herein. TrkA is 
expressed by DRGs in the spinal cord and there is increased expression with 
intra-articular NGF injection (Ashraf et al., 2014). Although the compound 
used here does not cross the blood brain barrier (Andrews, 2014), the effect of 
this compound in reducing central sensitization might be through effect of 
blocking TrkA expressed on DRGs thus preventing or dampening the 
ascending of sensory input to the brain. 
7.2.4 Targeting NGF or TrkA for OA 
Despite the successes of molecules targeting TrkA for controlling pain in 
animal models, there are still no clinical trials for it. As mAbs carry the risk of 
immune reactions such as acute anaphylaxis, serum sickness and the 
generation of antibodies against the therapeutic agent, the use of Trk inhibitors 
may be a better choice. Adverse events such as peripheral oedema, arthralgia, 
pain in extremity and neurosensory symptoms were reported with anti-NGF 
mAbs in clinical trials (Pokrovnichka, 2012). On the other hand, if drug 
development were to begin for Trk inhibitors, investigators will need to take 
into account the lack of selectivity of pan Trk inhibitors. Blocking of other Trk 
receptors may result in adverse effects (Winston et al., 2003). These include 
hyperphagia, obesity and ataxia (in greater doses) which have been reported to 
be attributed to inhibition of BDNF/TrkB signalling (Unger et al., 2007).   
In this thesis the importance of the selective targeting of TrkA is highlighted 
from evidence of its involvement in contributing to nociception, inflammation 
and pathology. 
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7.3 LIMITATIONS OF CURRENT RESEARCH 
The results presented in this thesis support the evidence of symptomatic 
features of arthritis in animal models and the involvement of the NGF-TrkA in 
contributing to these features. These conclusions are limited by a number of 
factors and are outlined for each chapter below; 
Firstly one of the main limitations is the use of animal models. Rat OA models 
used in this thesis and elsewhere display similar histological and pain 
behavioural characteristics to those observed in chronic human OA (Sagar et 
al., 2013). The consistent analgesic effects of AR786 between models suggest 
that findings from this thesis might be relevant to OA in general, rather than 
being specific to the mode of OA induction. However, caution must be 
exercised before generalising from laboratory findings to human OA. Rat 
models develop rapidly and pain mechanisms might differ in early compared 
to long established OA. The efficacy of drugs may not directly reflect that 
observed in humans due to the rapidity of disease progression or the 
low/minute concentrations of drug treatment administered in clinical trials 
following toxicological studies (Lampropoulou-Adamidou et al., 2014). OA 
animal models are for the most part driven by mechanical factors than in the 
naturally occurring OA in humans, therefore some factors that contribute to 
human OA may not be affected in certain animals. Treatment may be effective 
in animals because they are initiated at or close to the time of injury in contrast 
to human clinical trials (Martel-Pelletier and Pelletier, 2013). However, 
preclinical research plays a major role in understanding the mechanisms of 
disease and the identification of potential treatment targets. 
CHAPTER 3 
The present study reports on characteristic features of acute inflammation to 
include acute joint swelling and acute synovitis. It does not however report on 
infiltration by neutrophils which are the cardinal cells of acute inflammation 
but rather reports on macrophage infiltration, the signature cells of chronic 
inflammation. However, this thesis reports that macrophages are involved and 
present in the early stages of inflammation in the carrageenan model. 
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The study is also limited to acute inflammation and is important for 
therapeutics targeting acute inflammation but not persistent or chronic 
inflammation. Mechanisms underlying the shift from acute to persistent 
chronic inflammation in humans is not entirely clear and in OA, and patients 
may present with both acute and chronic inflammation (Bonnet and Walsh, 
2005).  
Rats used in this chapter did not have equal body weights at the time of 
arthritis induction. The carrageenan injected rats had higher body weights than 
the naïve rats. This might have occurred as a result of the random selection of 
rats for induction not based on body weights but on baseline behaviour (weight 
bearing asymmetry) by an independent researcher. 
CHAPTER 4 
The disadvantage of the macroscopic chondropathy scoring (either by direct 
scoring or photographic scoring) like histological scoring is that the scoring 
methods did not include the patella. Patellofemoral OA is a known source of 
pain and disability. During tissue harvesting, the patella was always removed 
in attachment to the synovium as this aids for histological assessment of 
synovitis. Radiography, although not carried out in this thesis may be another 
method of investigating associations between patellofemoral OA and 
histological synovitis.  
Another limitation to this study was that reliability tests were carried out 
between observers with different levels of experience. Therefore, reliability 
and validity estimates may have limited generalizability and that inter-observer 
variation may be less with more experienced operators. 
Synovitis was associated with radiological joint space narrowing (JSN), which 
is normally regarded as an important marker of OA structural severity (Altman 
et al., 1987). This association between JSN and synovitis may suggest that 
association between OA severity and synovitis may be as a result of cartilage 
pathology (Walsh et al., 2008). This thesis does not have any radiological 
measurements to back up the associations observed between OA severity and 
synovitis. 
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CHAPTER 5 
The study from this chapter showed that central sensitization represented by a 
reduction in hind paw withdrawal threshold indicative of allodynia was 
observed also in the low 0.1mg MIA dose which may represent early mild OA. 
This conclusion was based just on the pain behaviour data only and did not 
include data from other factors involved in central sensitization i.e. spinal glia 
cells (astrocytes, microglia).  
This chapter consisted of two studies; study 1 had 3 groups of rats (0.1mg, 
1mg  and saline) all stopped at day 20, while in the second study, there were 4 
groups (day 42 ± saline, day 42 ± 0.1mg MIA, day 20 ± 0.1mg MIA and day 
20 ± 1mg MIA). The lack of the day 20 ± saline and the day 42 ± 1mg MIA 
might be limitations to the current study as direct comparisons for time in the 
saline and 1mg MIA rats could not be made. Specifically, the effect of time on 
the number of vascular channels crossing the osteochondral junction in the 
saline group. Was the reduction in vascular densities observed in both the day 
42 saline and day 42 - 0.1mg MIA injected rats really due to ageing?  
CHAPTER 6 
The experiments with AR786 did not investigate microscopic pathology 
(histopathology). Effect of drug not significantly altering pathology was 
entirely based on macroscopic grading. This explores the outer appearance of 
the knee joint but not the underlying appearance i.e. looking down the 
microscope with pathology highlighted or intensified by histological stains. 
Due to this, other effects of the compound for example on subchondral bone 
remodelling which is known to play an important role in OA pain and 
pathology were not investigated. On the other hand, the experiment with M911 
did not investigate macroscopic pathology but only microscopic pathology. 
Investigating the effect of both compounds on microscopic and macroscopic 
pathology could further increase the understanding of the contributions of 
NGF-TrkA to OA joint pathology. 
NGF is responsible for sensory nerve growth, and pain in OA is mediated by 
sensory nerves. NGF produced by vascular cells may contribute to the growth 
     
233 
   
of fine, unmyelinated sensory nerves along newly formed vessels (Walsh et al., 
2010, Nico et al., 2008). Exposure of these vessels in the subchondral bone to 
sensitizing factors or their ingrowth into the cartilage or meniscus may be a 
potential source of pain (Mapp and Walsh, 2012, Suri et al., 2007, Ashraf et 
al., 2011b). This thesis did not investigate sensory nerve growth in the OA 
models and thus effect of AR786 on nerve growth was not explored.  
Despite the above limitations, the work presented in this thesis supports the 
view that blocking the TrkA receptor may be beneficial in relieving structural 
pathology and pain in OA. The above limitations therefore form a basis for 
future work that should help in further investigating the mechanisms of 
structural pathology and associated pain in OA. 
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7.4 DIRECTIONS FOR FUTURE RESEARCH 
This thesis provides a platform for further research into the mechanisms of 
structural pathology and associated pain in OA. 
The presence of joint swelling, synovitis and macrophage infiltration 
confirmed the induction of acute inflammation in the carrageenan model of 
monoarthritis. It also confirmed the presence of different subtypes of 
macrophages in acute inflammation. Further work should determine whether 
this distribution of macrophage subtypes resembles that in chronic 
inflammation in the OA synovium using the MIA and MNX models, and their 
associations to synovitis and pain behaviour in the models. Equally, further 
work should test the specificity of the ED macrophage markers in labelling 
their specific macrophage subsets by either using double immunofluorescence 
to co-localise the markers on macrophages.  
Synovitis is associated with radiological joint space narrowing (JSN), which is 
normally regarded as an important marker of OA progression (Altman et al., 
1987). This association between JSN and synovitis may suggest that 
association between OA severity and synovitis may be as a result of cartilage 
pathology (Walsh et al., 2008). This thesis does not have any radiological 
measurements to back up the associations observed between OA severity and 
synovitis. Further work including radiological measurement should address 
association between OA severity and synovitis.  
Central sensitization represented by a reduction in hind paw withdrawal 
threshold indicative of allodynia was observed also in the low 0.1mg MIA 
dose which represent early mild OA. This conclusion was based just on the 
pain behaviour data only. Future work to back up these results would require 
research into investigating cells in the spinal cord e.g. astrocytes, microglia and 
neurones which have been reported to show increased excitability of spinal 
neurones and are associated with pain behaviour (allodynia) showing central 
sensitization in the 1mg MIA dose (Sagar et al., 2010, Kelly et al., 2013b, 
Sagar et al., 2011). Furthermore another pain behaviour measurement for 
example, gait analysis system (CatWalk) can be used to test the sensitivity of 
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the incapacitance meter in detecting weight bearing asymmetry in the 0.1mg 
MIA model. 
Reductions in distal allodynia relapsed more quickly after treatment 
withdrawal than did weight bearing asymmetry, suggesting that TrkA 
inhibition has a more sustained effect on peripheral pain processing, than on 
central sensitisation. Further research should determine whether low 
concentrations of AR786 in CSF could alter central pain processing in the 
brain.   
Reports on the discontinued NSAID nimesulide being able to show a sustained 
effect in attenuating allodynia (but not weight bearing asymmetry) where the 
7UN$ LQKLELWRU GLGQ¶W IXUWKHU H[SDQGV RQ WKH above statement that TrkA 
inhibition has a more sustained effect on peripheral pain processing, than on 
central sensitisation and that other mechanisms which may or may not be 
involving the NGF-TrkA pathway are at work here (Sagar et al., 2011). For 
example other central mechanisms of pain such as, increased expression of 
cyclooxygenases (COX) maybe involved as spinal COX-2 expression is 
increased and plays a crucial role in pain (Prochazkova et al., 2009, Seybold et 
al., 2003). Further work would be required to investigate if TrkA inhibition has 
an effect in altering central processing which would include 
electrophysiological, cellular and molecular studies. 
AR786 reduced synovitis in rats with MIA-induced OA, but did not 
significantly reduce either knee swelling or synovitis in rats with MNX-
induced OA. Different effects of AR786 on synovitis between the 2 models 
may reflect different mechanisms of inflammation, or a more intense (and less 
responsive) synovitis in the MNX model (Mapp et al., 2013).  Further research 
should determine whether anti-inflammatory effects of AR786 are mediated by 
direct actions on inflammatory cells or by reducing neurogenic inflammation 
(effect on SP and CGRP synthesis and release), and whether AR786-sensitive 
inflammation is generalizable to arthritis in man. 
NGF plays a role in inducing RANKL-independent osteoclastogenesis 
(Hemingway et al., 2011). Further research should investigate if effect of 
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AR786 on osteoclast numbers would reduce their effects in contributing to 
joint pathology and pain.  
Reductions in pain behaviour were observed both using preventive and 
treatment protocols with AR786, and were sustained for up to 10 days despite 
treatment discontinuation. Clinical trials of NGF blockade have demonstrated 
potential for blocking the NGF-TrkA pathway for the relief of OA pain. 
Further research should address possible differences between NGF-blockade 
and selective TrkA inhibition, and the potential for sustained benefit from 
discontinuous treatment, in order to help realise the potential of NGF-TrkA 
pathway inhibition for OA pain relief. 
 A study using the pan Trk inhibitor reported the attenuation of sarcoma 
induced nerve sprouting and neuroma formation and bone cancer pain in the 
mouse (Ghilardi et al., 2010). The role of NGF is to facilitate nerve growth. 
Further work should investigate the effect of AR786 on sensory nerve growth 
in the OA models and also explore whether inhibiting nerve growth would 
have an effect on joint pain.   
Reports of RPOA (osteonecrosis) with anti-NGF treatments encourage more 
research for better NGF blockers. On the other hand, given the many 
unresolved issues around anti-NGF mAbs, their further research is 
discouraged. The occurrence of RPOA was mostly in association with NSAIDs 
(Brown et al., 2012). Future studies should investigate the effect of TrkA 
inhibitors in addition to NSAIDS on joint pathology in OA. 
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7.5 CONCLUSION 
In OA, there is progressive joint degeneration with eventual loss of joint 
function accompanied by associated pain. The symptoms of OA are well 
characterised and although the pathophysiology underlying the symptoms are 
extensively studied, it is still an area that presents a significant challenge to OA 
researchers. The lack of disease modifying OA drugs results in the treatment of 
pain to relieve OA symptoms. A better understating of the mechanisms by 
which structural pathology results in pain is encouraged for the development of 
new targeted therapies.  
The results presented in this thesis using models of OA support the hypothesis 
that pain behaviour and structural pathology are features of OA models that are 
mediated by NGF and TrkA. NGF-TrkA signalling contributes to 
inflammation, osteoclast activation and associated pain. TrkA inhibition 
therefore holds therapeutic potential for OA treatment.  
The occurrence of RPOA with Tanezumab encourages alternative targeting of 
NGF-TrkA signalling for OA pain relief (Brown et al., 2012). The issues of the 
occurrence of the unexpected adverse effects for example with blocking NGF 
make known the significant gaps in our current understanding of the broader 
roles of NGF in the pathogenesis of OA pathology and pain.  
Bridging the gap in our knowledge of OA and OA associated pain requires that 
clinical research in OA patients is complemented by preclinical research in 
disease-specific OA models. Clinical studies provide useful information on 
associations between clinical symptoms (i.e., pain) and particular tissue 
pathologies, genetic differences (e.g., single nucleotide polymorphisms - 
SNPs), psychosocial determinants, etc. In contrast preclinical studies provide 
information on causal relationships between specific molecular, cellular or 
pathological events and OA pain using therapeutic or prophylactic 
interventions in the absence of such interventions for OA patients (Malfait et 
al., 2013). The proper design, execution and reporting of results from 
preclinical animal research help to make data from these studies more 
reproducible and translatable to clinical research. Despite this, preclinical 
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studies can only guide, rather than accurately predict results of research in 
man.  
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APPENDICES 
Materials and Reagents  
Acetic acid                  VWR Ltd. Lutterworth, UK  
Acetone                  VWR Ltd. Lutterworth, UK  
Accu-Edge disposable microtome blades                   University of Nottingham stores 
Albumin, Bovine (A-4503)                Sigma Aldrich, Poole, UK  
Alcian blue (A5268)                 Sigma Aldrich, Poole, UK  
Ammonium Chloride                 VWR Ltd. Lutterworth, UK  
Axio Vision Imaging system                Carl Zeiss Ltd. Welwyn Garden City, UK 
Axiocam                  Carl Zeiss Ltd. Welwyn Garden City, UK 
Beta-D-glucose (G5250)                 Sigma Aldrich, Poole, UK  
Cork Blocks 20mm x 3mm (E7.15/CD)               Raymond Lamb, Eastbourne, UK  
Coverslips 22mm x 64mm                VWR Ltd. Lutterworth, UK  
DePeX TM                          VWR Ltd. Lutterworth, UK  
Diaminobenzidine (D5637)    Sigma Aldrich, Poole, UK  
Diammonium Nickle II Sulphate (A1827)   Sigma Aldrich, Poole, UK  
Disodium phosphate heptahydrate (S9390)  Sigma Aldrich, Poole, UK 
EDTA Disodium Salt (E5134)     University of Nottingham stores 
Electronic Calliper     Miyutoyo UK Ltd. Andover, UK  
Eosin (1%)      Raymond Lamb, Eastbourne, UK  
Ethanol absolute (32221)     Sigma Aldrich, Poole, UK  
Fast Green (F-7258)     Sigma Aldrich, Poole, UK  
Formalin Neutral buffered pH 7.0                                VWR Ltd. Lutterworth, UK  
Formic Acid (399388)    Sigma Aldrich, Poole, UK  
Glucose Oxidase Aspergillus Niger (G2133)  Sigma Aldrich, Poole, UK  
Harris Haematoxylin     Raymond Lamb, Eastbourne, UK 
Haematoxylin (H3136)     Sigma Aldrich, Poole, UK  
Horse Serum (H1270)     Sigma Aldrich, Poole, UK  
Hydrochloric Acid     VWR Ltd. Lutterworth, UK  
Hydrogen peroxide (H1009)    Sigma Aldrich, Poole, UK  
Incapacitance Meter    Linton Instruments, Norfolk, UK  
Iron (III) Chloride (157740)    Sigma Aldrich, Poole, UK   
Isopentane     VWR Ltd. Lutterworth, UK  
KS300 image analysis software   Imaging Associates Ltd. Thame, UK 
Lambda Carrageenan (C-3889)    Sigma Aldrich, Poole, UK   
Sprague Dawley rats    Charles River, Kent, UK 
Mayers Haematoxylin     Raymond Lamb, Eastbourne, UK 
Methanol      Sigma Aldrich, Poole, UK 
Novasapa cold steriliser     Pfizer Animal Health, Surrey, UK 
Paraformaldehyde (P6148)    Sigma Aldrich, Poole, UK 
Periodic acid      Sigma Aldrich, Poole, UK 
Phosphate Buffered Saline pH 7.4 (43711)   VWR Ltd. Lutterworth, UK 
Polysine TM Microscope adhesion slides (10219280) Fischer Scientific Ltd. Loughborough, 
UK 
Polyvinylpyrrolidone (PVP40T)    Sigma Aldrich, Poole, UK 
Safranin-O (S-2255)     Sigma Aldrich, Poole, UK 
Schiff reagent (1090330500)    VWR Ltd. Lutterworth, UK 
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Shandon Pathcentre Tissue Processor             Shandon Thermo Scientific, Leicester, UK 
SLS Slides Immunofl Wht 3 Well 10mm°  
(MIC3410)                                                                  Scientific Laboratory Supplies Ltd. 
Nottingham, UK 
Sodium acetate trihydrate (236500)              Sigma Aldrich, Poole, UK 
Sodium Chloride (S-3014)                            Sigma Aldrich, Poole, UK 
Sodium Chloride Solution, 0.9% (S8776)             Sigma Aldrich, Poole, UK 
Sodium iodoacetate (I9148)              Sigma Aldrich, Poole, UK 
Sony DSC-s85 CyberShot digital camera             Carl Zeiss Ltd. Welwyn Garden City, UK 
Sterile Op-Cover                     Kruuse Ltd. Sherburn in Elmet, North Yorkshire 
Sterile scalpel blades no.11                Swann-Morton Sheffield, UK  
Surgical Instruments                Interfocus Ltd. Cambridge, UK 
Syringe insulin-0.5ml 29G (6134897)              VWR Ltd. Lutterworth, UK 
Tissue Tek® embedding centre                Sakura Finetek Europe, The Netherlands 
Tissue Tek OCT® mounting medium               Raymond Lamb, Eastbourne, UK 
TRAP Kit                                                                     Sigma Aldrich, Poole, UK 
Tris base (T1509)                 Sigma Aldrich, Poole, UK 
Vectastain® Elite ABC Kit (PK6100)      Vector Laboratories Ltd. Peterborough, UK 
Vetasept Povidone-Iodine Scrub   Animalcare Ltd. Dunnington, York 
Xylene       Sigma Aldrich, Poole, UK 
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Buffers and solutions used for immunohistochemistry 


















Decalcification fluid dH2O 
Tris (trizma) base 
EDTA (10% w/v) 

























Horse Blocking Buffer BSA (5%) 











Hydrogen Peroxide in 
Methanol 
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PBS (10 x concentrated at 0.1 
M) 

















Sodium Acetate (0.1M) Sodium acetate trihydrate 





Sodium Acetate (0.2M) Sodium acetate trihydrate 



































TRAP kit Acetate solution 
Citrate solution  
Fast Garnet GBC Base solution  
Naphthol AS-BI Phosphoric acid 


















Description Specificity Other names Clone Isotype Product type Code Company Reference Dilution 
Mouse Anti-rat 
CD68 
CD68 ED1, macrosialin ED1 IgG1 Monoclonal MCA341GA Serotec Ltd. 
Oxford, UK 





CD163 ED2 ED2 IgG1 Monoclonal MCA342GA Serotec Ltd. 
Oxford, UK 





CD169 ED3 ED3 IgG2a Monoclonal MCA343GA Serotec Ltd. 
Oxford, UK 







Description Antigen Donor Label Code Company Dilution 
Anti-Mouse 
IgG 
Affinity 
Purified, 
Rat 
Absorbed 
Mouse 
IgG 
Horse Biotinylated BA-
2001 
Vector 
Laboratories 
Ltd. 
Peterborough, 
UK 
1:100 
 
